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Abstract 
Background 
Cardiovascular risk prediction is problematic in adolescents with obesity. Pulse wave 
velocity (PWV) can contemporaneously capture arterial stiffening in obesity. Stress 
has been implicated in the aetiology of obesity and cardiovascular risk. This thesis 
examines these relationships within a community sample of obese adolescents 
recruited to an obesity intervention (the HELP trial). 
Methods 
Two systematic reviews were performed for: i) associations between PWV and 
obesity; ii) associations between stress, obesity and metabolic risk. In the HELP trial 
PWV, adiposity measures, blood pressure, cardiovascular blood testing, stress 
measures (salivary cortisol, A-FILE questionnaire) were measured longitudinally. 
Baseline and longitudinal analyses investigated associations between adiposity, 
blood pressure, and blood markers with stress and PWV.  
Results 
Systematic reviews found: i)moderate evidence for increased arterial stiffening in 
obese children, especially in central arteries; ii)mixed findings for associations 
between stress, obesity and cardiovascular risk. 174 adolescents were recruited to 
the HELP study. Baseline findings: i)PWV was associated with adiposity; ii)PWV was 
not associated with BP or blood tests; iii) severe obesity groups had greater average 
PWV however overlap between groups was large; iv)stress measures were not 
associated with adiposity, blood pressure or blood tests; v)stress exposure was 
associated with risk of binge eating. Longitudinal findings: i)PWV in the group did not 
change; ii)multi-level models showed no association between stress measures, 
adiposity or blood pressure over time; iii)blood pressure and adiposity were 
associated over time.  
Conclusions 
 4 
Greater adiposity was associated with greater arterial stiffness. Partitioning by 
obesity severity was unreliable. Lack of associations between BP, blood testing and 
arterial stiffness questions their reliability for predicting cardiovascular risk in obese 
adolescents. Increases in adiposity and blood pressure were linked. The thesis did 
not demonstrate associations between stress and adiposity, blood pressure or PWV. 
Reducing BMI in adolescents with obesity may be an effective way to reduce 
cardiovascular risk. 
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Impact Statement 
 
Potential benefits of the research presented in this thesis are as follows: 
 
1. Direct clinical care. This thesis showed that above all, BMIz, i.e. degree of obesity 
in adolescents appears to be most associated with arterial stiffening. In clinical 
contexts, in particular obesity services, the findings of this thesis can benefit 
approaches to assessment and advice by directing emphasis on overall BMI/BMIz 
rather than blood risk parameters and acanthosis nigricans. In particular the 
emotional impact of discussing acanthosis nigricans with young people should take 
precedence over perceived risk. Potential use of PWV in clinical settings to identify 
those young people more at risk may be more of use than blood testing. 
2. Public health. The research presented in this thesis adds to the evidence that 
there is potential cardiovascular risk for young people with obesity, with future 
health, well-being and financial implications for this current generation of 
adolescents. This research should be used to maintain and further the argument for 
public health approaches and investment into prevention and reduction of obesity in 
children and adolescents. 
3. Further research. Using PWV as a modality should take places as this thesis has 
shown it is a practical research tool. Further discussion of future possible research is 
presented in detail in the discussion of the thesis. 
4. A number of papers have been published from this thesis which are a key part of 
its impact. 
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Research questions 
 
In a group of adolescents with obesity: 
 
1. How is degree of adiposity associated with pulse wave velocity as a proxy of 
arterial stiffening at a cross-sectional and longitudinal level? 
2. How is blood pressure associated with pulse wave velocity as a proxy of 
arterial stiffening at a cross-sectional and longitudinal level? 
3. How are other conventional measures of cardio-metabolic risk such as 
conventional blood markers (e.g. cholesterol) and acanthosis nigricans 
associated with pulse wave velocity as a proxy of arterial stiffening at a cross-
sectional and longitudinal level? 
4. How are measures of stress associated with degree of adiposity at a cross-
sectional and longitudinal level? 
5. How are measures of stress associated with blood pressure at a cross-
sectional and longitudinal level? 
6. How are measures of stress associated with pulse wave velocity at a cross-
sectional and longitudinal level? 
 
Research questions 1-3 are collectively addressed in chapters 1, 3,4 and 6 (with 
chapter 4 and 6 presenting cross-sectional and longitudinal data respectively). 
Research questions 4-6 are collectively addressed in chapters 2,3,5 and 6 (with 
chapter 4 and 6 presenting cross-sectional and longitudinal data respectively). 
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All research questions are addressed in the discussion chapter 7. 
 
 
 
 
 
Table of commonly used abbreviations within the thesis. 
ACTH adrenocorticotropic hormone 
AI Augmentation index 
ALT Alanine aminotransferase 
AN Acanthosis nigricans 
AUC Area under the curve 
BMI Body mass index (Kg/m2) 
BMI z BMI z-score for age and sex 
BP Blood pressure 
C-dayAUC 
Total day cortisol from awakening to evening, area under the 
curve (See figure 3.1) 
C-evening Cortisol evening sample  (See figure 3.1) 
C-ratio Ratio of evening cortisol / wakening cortisol  (See figure 3.1) 
C-wake Cortisol on wakening sample  (See figure 3.1) 
CAR Cortisol awakening response 
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CAR-AUC 
Cortisol awakening response, area under curve  (See figure 
3.1) 
CAR-rate Cortisol awakening response, rate of change  (See figure 3.1) 
CRF-GOSH Clinical research facility at Great Ormond Street Hospital 
DAWBA Development and wellbeing assessment 
DBP Diastolic blood pressure 
Diastolic z Systolic blood pressure z-score for age and sex. 
DM Diabetes mellitus 
FMI Fat mass index (Kg/m2) 
HbA1c Percentage glycosylated Haemoglobin (units %) 
HDL High density lipoprotein 
HDL/C ratio HDL/total cholesterol ratio 
HELP 
Health eating and lifestyle program (original trial from which 
thesis comes from) 
HOMA-IR Homeostatic model assessment-Insulin resistance. 
HPA Axis Hypothalamic-pituitary-adrenal axis 
IMD Index of multiple deprivation 
IOTF International obesity Task Force 
LDL Low density lipoprotein 
MetS Metabolic syndrome 
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PWV Pulse wave velocity (units m/s) 
RSE Rosenberg's self esteem score 
SAD Sagittal-abdominal diameter (cm) 
SBP Systolic blood pressure 
Systolic z Systolic blood pressure z-score for age and sex. 
SD standard deviation 
t Time (various time points, e.g. t0 = time 0) 
TBFM Truncal body fat mass 
UFC Urinary free cortisol 
Waist z Waist circumference z-score for age and sex. 
WBTM Whole body fat mass 
WHO World Health Organisation 
WMD Weighted mean difference (in meta-analysis) 
z Z-score 
 
 
 
 
 
 
 
 24 
 
 
 
 
 
Chapter 1: Evidence for a long-term cardiovascular risk 
associated with obesity in adolescence. 
1.1 Introduction 
As a clinician who has worked with adolescents with obesity in a weight 
management service, the validity of perceived risk associated with degree of 
overweight and associated cardio-metabolic co-morbidities has long interested me. 
Within such clinical settings, it is standard practice to partition by degree of obesity, 
and use adult-based cardio-metabolic markers to conceptualize risk for later 
cardiovascular disease, and moreover to communicate these findings to counsel 
young people and their families.1 Yet when working in these settings, I often 
wondered about the validity of this well-established practice in terms of scientific 
evidence, particularly where they were used to support interventions. In 2010 I was 
employed as the medical research fellow for a randomized controlled trial of a 
weight management intervention for adolescents with obesity at the UCL Institute of 
Child Health (The HELP trial which is now published).2 The study itself is described in 
more detail in chapter 3, however the study also provided me with the opportunity 
to explore evidence for potential long-term cardiovascular risk in an obese group of 
adolescents with cross-sectional and longitudinal methods, which is a key focus of 
this thesis. 
In this first chapter, I will address the background to research questions 1-3 (namely 
1) how degree of adiposity is associated with pulse wave velocity as a proxy of 
arterial stiffening at a cross-sectional and longitudinal level; 2) how blood pressure is 
associated with pulse wave velocity as a proxy of arterial stiffening at a cross-
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sectional and longitudinal level; and 3) how other conventional measures of cardio-
metabolic risk such as blood testing and acanthosis nigricans are associated with 
pulse wave velocity as a proxy of arterial stiffening at a cross-sectional and 
longitudinal level). I will firstly examine what is currently known about the 
relationship between obesity in young people and long-term cardiovascular risk, and 
outline important key concepts and definitions necessary to explore this 
relationship, and then present a systematic review of the literature on pulse wave 
analysis. Finally I will outline the relevance of information presented in this chapter 
as the basis for the research questions 1-3 studied in this thesis. 
1.2 Obesity definitions 
The term overweight strictly refers to an excess of body fat rather than body weight 
per se. By convention, international definitions of overweight and obesity in both 
children and adults use the body mass index (BMI), a function of weight (in kg) 
divided the square of height (in m). Obesity, and severe obesity, are increasing 
grades of overweight. In adults an individual is described as having overweight when 
their BMI is equal to or exceeds 25Kg/m2 and obesity when their BMI is equal to or 
exceeds 30 kg/m2; with severe (or “morbid”) obesity greater than 40. These cut-offs 
have been validated to long-term outcome data in adults, correlated with mortality 
risk. Whitlock et al published data on relative risks of death in 35-79 year olds 
related to their BMI.3 This demonstrated that there was an increase in risk of death 
in adults with a BMI over 25, with each increase of 5 kg/m2 over 25 shown to 
increase mortality by 30%. Adults with a BMI in the range of 30–35 were shown to 
have their lives shortened on average by 2–4 years, while those at 40–45 are 
reduced by 8–10 years. 
Definitions of overweight and obesity are complicated in children because of a 
paucity of similar longitudinal data to validate them. Moreover, the normal 
distribution of BMI varies by age and sex throughout childhood and using the same 
cut-offs for all ages and sexes would therefore be inappropriate. Definitions of 
obesity in childhood have utilized the convention in child health of applying 
extremes of normal distributions of the BMI distribution.4 However there is variation 
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clinically and in research over which cut-offs are used internationally – with cut-offs 
including above the 95th centile,5 and the International Obesity Task Force (IOTF) cut-
offs based on combining international data sets of BMI distributions.6 Obesity degree 
itself has been categorised into severity levels using >2.5 standard deviations of BMI7 
and also >3.5 SD.1 It is important to note that because definitions of obesity in 
childhood utilize extremes of the normal population, by definition such cut-offs will 
include a large number of children who are potentially healthy. Thus, in effect the 
higher the cut-off centile for BMI is placed, the more specific it will become at 
picking up children with higher body fat.  
The number of children and young people reaching cut-offs used to define obesity 
has increased dramatically in the last 30 years internationally in both high and low 
income countries.8-12 In England, the national child measurement program measures 
all school age children at school reception (aged 4/5) and school year 6 (aged 10/11 
years) and categorizes children by BMI centile.13 The 2011/12 results (which 
incorporated over 1 million children; with 93% of eligible children included) showed 
that 13.1% of reception children had overweight (>85th centile) and 9.5% had obesity 
(>95th centile), with 22.6% of this age group of children with either overweight or 
obesity. Proportions of obesity across the United Kingdom vary by region, with 
London carrying the greatest burden,14 the region that the data used in this thesis 
were drawn from. In London, around 11% of children entering reception year at 
school have obesity, and by the age of 10-11 (the age just before the lowest age of 
subjects in this thesis) 25% of black children will have obesity, 22% of south Asian 
children and just under 20% of white children.14 Obesity is also more common in 
boys than girls in London at age 10-11 at 24% versus 19%.14 Obesity is greater in 
regions of London with the highest degrees of deprivation.14 
1.3 Measures and proxies for body fat in children 
BMI is a pragmatic, inexpensive proxy of stratifying children and adolescents by 
degree of body fat, and as described above carries the drawback of not being able to 
directly measure body fat. Wells has demonstrated the normal variation of fat mass 
in healthy children by using Dual-energy X-ray absorptiometry (DEXA), underwater 
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weighing, deuterium dilution, bioelectrical impedance analysis, and 
anthropometry.15 Theoretically, centile charts could be developed for fat content 
using these methods but so far these do not exist, and moreover given the 
complexities and expense of measuring using these techniques, its use would be 
limited. Other, easier methods for trying to measure body fat more accurately in 
clinical and research contexts, which can be used directly on young people (and are 
used in this thesis – see chapter 3), are measuring waist circumference, which offers 
the advantage of attempting to measure and stratify central adiposity which is 
associated with cardio-metabolic risk (see below) and also measuring bio-
impedance. I will outline these here, and the background to them as they are used in 
this thesis as measures of fat. 
 
Waist circumference 
 
Waist circumference is most commonly measured using a non-flexible measuring 
tape midway between the 10th rib and iliac crest, and centiles have been developed 
to standardize measurements for each age and sex.16 Another method of measuring 
intra-abdominal fat is to measure Anterior-posterior sagittal abdominal dimension 
(SAD) using a Holtain-Kahn abdominal caliper with young people in a supine 
position.17 This method has been shown to correlate better than waist 
circumference in adults for cardio-vascular risk factors such as lipids, although it 
does not have standardized measures/centiles unlike waist circumference.18. 
 
Bio-impedance (bio-electrical impedance) 
 
This method models the body of an individual as a cylindrical conductor, and uses 
bio-electrical impedance measures to derive total free fat mass (FFM). This method 
is readily available using commercially available equipment, and in this thesis the 
Tanita BC 418MA (Tanita, UK) is used. The reason this particular equipment was used 
in the thesis is because it has been validated against the more complex four 
component model described above, in a published study which also provided a more 
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precise formula for free fat mass for adolescents using height and impedance 
measured using this model of Tanita (the use of this in this thesis is described in 
more detail in chapter 3).19  
 
 
1.4 relationship between obesity and long term cardiovascular risk 
As described above, Whitlock et al’s study provided evidence of risk of death 
predicted by increasing BMI in adults.3 However, error bars were wide, and there is 
therefore variation in risk within individuals at the same BMI. Variation may be due 
to presence or not of obesity-associated cardio-metabolic risk factors: namely 
hypertension, central adiposity, dyslipidaemia and insulin resistance. From the 
MUNSTER study, Schulte et al demonstrated that whilst mortality increased with 
increasing BMI in adults in this study, the increases in mortality could, in analyses, be 
explained by the presence of additional cardio-metabolic risk factors such as 
hypertension and dyslipidaemia.20 The importance of the clustering of risk factors 
within individuals with obesity has led to the concept of both the “metabolic 
syndrome” (MetS)21 22 and “metabolically healthy obese adults”.23 However, whilst 
risk in “metabolically healthy obese adults” may be lower than in obese individuals 
with co-existing cardio-metabolic risk factors, in a systematic review including 10 
studies, Kramer et al showed that in obese adults without co-existing cardio-
metabolic factors (so called “metabolically healthy obese adults), the relative risk for 
cardiovascular events was still greater compared to metabolically healthy normal 
weight adults (RR 1.24 (1.02 -1.55)) – thus being obese alone still carries 
cardiovascular risk.24   
 
There is now a well-established evidence for the interaction between individual 
cardio-metabolic risk factors and long-term cardiovascular risk in obese adults, in 
particular location of adiposity (central versus more peripherally placed adiposity), 
hypertension, dyslipidaemia and insulin resistance: 
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 Location of adiposity : Padwal et al showed that those with central adiposity 
using weight circumference and DEXA had greater risk of death from 
cardiovascular events compared to those with alternate distributions. 25 
 
 Hypertension: A recent Cochrane review showed that drops in weight from 
weight reducing diets led to reductions in systolic and diastolic blood 
pressure.26 Data from the Framington study showed that a 6.8 kg loss of 
weight in obese participants led to a 22-26% relative risk reduction of 
developing hypertension over time.27  
 
 Dyslipidaemia : Higher levels of total cholesterol,  triglycerides and lower 
levels of HDL (higher levels being cardio-protective) have been demonstrated 
in adults with obesity; and all of these risk factors are associated with 
coronary artery disease.28 
 
 Insulin resistance and diabetes has been shown to be more common in adults 
with obesity,29 especially those with central obesity,30 and carries increased 
risk for cardiovascular disease.31 
1.5 Metabolic syndrome in children and conventional markers of 
cardiovascular risk in children and adolescents with obesity. 
With the emerging increase internationally of obesity in children and young people, 
definitions of MetS in children and adolescents have been developed (table 1.1), 
with an increased incidence of children and adolescents meeting these criteria with 
increasing levels of obesity.1 32 Such definitions however have been the subject of 
debate, principally because of an observed temporal instability of definitions 
through growth and development, particularly during puberty, limiting their 
contemporaneous use to predict future cardiovascular risk (see below).2 In their 
large, school-based study of over 1000 adolescents over 3 years, Goodman and 
colleagues found that around half of adolescents meeting the AHA and IDF 
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definitions of MetS at entry to the study no longer fitted such definitions at exit at 3 
years.2 As well as the challenge of predicting which adolescents will continue to have 
the MetS into their adulthood, this instability also calls into question the basis of 
pharmacological treatments in this age group, treatments which themselves carry 
cost and potential side effects.  
 
In the United Kingdom, consensus guidelines for assessing cardiovascular risk have 
been published in the format of the Obesity Services for Children and Adolescents 
(OSCA) guidelines.1 These guidelines provide specific guidance on absolute values to 
define abnormalities of important cardio-metabolic co-morbidities in children and 
young people with obesity. These are summarized in table 1.2. These guidelines are 
important for the thesis, as they will be used as the definitions for cardio-metabolic 
risk in the thesis and various cut-offs (as outlined further in chapter 3). 
 
Table 1.1: Summary of current guidelines for the MetS in children and adolescents. 
Parameters Modified ATP III IDF (10-16 years) NHANES III 
Waist 
circumference 
Not required ≥ 90th percentile 
(but ethnic 
specific) 
≥ 90th percentile 
Number of 
abnormalities 
required 
≥ 3 ≥2 ALL 
Triglycerides 
 
> 95th percentile ≥1.7 mmol/L ≥ 1.24 mmol/L 
HDL < 5th percentile < 1.03 mmol/L < 1.03 mmol/L 
BP Either systolic or Either systolic or Both ≥90th 
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Parameters Modified ATP III IDF (10-16 years) NHANES III 
diastolic raised diastolic raised percentile 
Systolic > 95th percentile > 95th percentile  
Diastolic > 95th percentile ≥85 mm Hg 
Glucose Impaired measured 
glucose tolerance 
≥ 5.6 mmol fasting ≥ 6.1 mmol/L 
fasting 
 
Key: ATP = Adult treatment panel; IDF = International Diabetes Federation; NHANES 
= National Health and Nutrition Examination Survey 
 
Table 1.2 : Summary of OSCA guideline1 definitions of cardio-metabolic risk factor 
co-morbidities associated with obesity. 
Risk factor Definition 
Extreme obesity >3.5 BMI z score for age and sex 
Hypertension Systolic or diastolic blood pressure >98th 
centile for age and sex (equivalent to > 2.06 
z-score_ 
Impaired fasting glucose 6.1-6.9 mmol/L 
Abnormal HOMA-IR  
(calculated by insulin * glucose/22.5) 
> 4.4,  
Insulin resistance / raised insulin. Dependent upon pubertal staging :  
>10 mU/L pre/early puberty,  
>30 mU/L mid puberty, mU/L 
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Risk factor Definition 
>20 late and complete puberty 
Low LDL <0.9 mmol 
Raised triglycerides   >1.47 mmol/L 
Raised cholesterol >5.2 mmol/L 
“Abnormal HDL/C ratio”  > 4.3. 
 
 
A final subject in this section that I am also interested in, as a marker for cardio-
metabolic risk in children and young people with obesity, is the relevance of 
Acanthosis nigricans (AN). AN is a dark, velvety skin pigmentation associated with 
obesity33 and frequently encountered in clinical practice in young people with 
obesity. Correctly interpreting its relevance and communicating this to patients and 
families is important. Studies have identified AN in adolescence as a marker for type 
2 Diabetes Mellitus (DM)34 35 and insulin resistance (IR)36-39 yet it is unclear whether 
AN in adolescent obesity is associated with increased cardiovascular risk separately 
to risk for diabetes. The OSCA guidelines recommend using it as a marker of co-
morbid risk in obesity. There is evidence that there may be emotional impact from 
acanthosis nigricans. Huang el al recently reported in one study that depression was 
greater in adolescents with obesity and AN compared to those with obesity alone.40 
and Pirgon et al have also shown that adolescent girls with obesity and acanthosis 
have lower self esteem scores compared to those with obesity without AN, and 
healthy weight controls.41 It is my own clinical experience that AN causes stress for 
young people. Both their own, and their family’s knowledge of it is also anecdotally 
low in my experience, and young people and their families have frequently thought 
it to be removable with cleaning. As I will discuss below, I was interested in 
investigating the longer-term cardiovascular relevance of acanthosis nigricans and 
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whether it added anything more helpful than degree of obesity alone, within an 
obese group.  
1.6 Current longitudinal evidence for long-term cardiovascular risk, 
obesity and cardio-metabolic risk factors in children and adolescents 
with obesity. 
The evidence presented above for the implications of cardio-metabolic risk factors 
either individually, or in clusters in adults with obesity does not necessarily translate 
in helping understand long term cardiovascular risk in children and adolescents with 
obesity – firstly because they have not been validated in the long term in children 
and young people; but also because, as discussed above, they are temporally 
unstable. A key reason for the paucity of long-term evidence for outcomes of both 
obesity alone, and obesity with cardio-metabolic risk factors such as hypertension 
and dyslipidaemia in children and adolescents is because the obesity epidemic in 
children and adolescents is recent. 
There are however some longitudinal studies to provide information which have 
tracked children and adolescents into adulthood to see what differences are evident 
in later adulthood, though there are currently limits as to how late these studies can 
follow-up for. Juonala et al followed 6328 subjects from childhood to adulthood 
(mean follow up of 23 years later).42 They reported that children with obesity at 
entry into the study who continued to be obese versus healthy weight children who 
continued to be healthy weight adults, had relative risks for type 2 diabetes of 5.4, 
hypertension of 2.1 and raised triglycerides of 3, and increased intima media 
thickness in the carotid arteries of 1.7. The risk of these factors in children with 
obesity who became healthy weight children in adulthood was the same as those 
who developed obesity. Thus one answer to understanding risk is to track the 
associations of cardiovascular outcomes with persistence of obesity in childhood into 
adulthood, where we have more data. Twig et al followed older adolescents, which 
allowed for follow up at older ages than younger children.43 They followed 2.3 
million adolescents from a mean age of 17.5 into adult life and looked at risk of 
death from cardiovascular causes. The hazard ratio for death from coronary artery 
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disease in later life in obese (greater than the 95th centile) versus healthy weight 
adolescents was 2.6 (1.7-4.1) and 2.6 (1.7-4.1) for stroke. Baker et al followed 
children and adolescents (range 7-13 years) into adult life (greater than 25 years) 
and found a linear association between BMI and coronary artery disease related 
events and death.44 They also found that the association was stronger, the older the 
participant was at entry into their study. 
1.7 Evidence for arterial stiffening in childhood and adolescence as a 
contemporaneous indication of future cardio-vascular risk. 
Given the current limitations of long-term follow-up studies, an alternative approach 
to predicting long-term cardiovascular risk is to look for contemporaneous evidence 
of pathological changes known to be involved with cardiovascular disease. It has 
been known for some time that pathological arterial processes, in particular 
atherosclerosis, begin in childhood and adolescence. For example, Berenson et al 
reported in the 1990s on 204 autopsies in a group being followed up as part of a 
longitudinal cardiovascular risk study, in which they found raised fibrous plaque 
lesions present in the aorta in 20% of the 2-15 age group, and that the amount of 
atherosclerotic changes was associated with pre-morbid body mass index, blood 
pressure and lipid concentrations.45 Similar findings were also found by McGill et al 
on a large number of autopsies in young people.46 
Although a degree of stiffness in an artery is necessary and helpful so as to transmit 
blood during diastole; elasticity is also important so that arteries are compliant and 
can receive blood from the upstream artery, or in the aorta directly from the left 
ventricle.47 Increased stiffening, especially over age, represents pathological changes 
related to cardiovascular disease.48 Arterial stiffening is thought to be primarily 
related to changes in the elastin function and organization in the extra-cellular, 
media component of an artery and atherosclerosis, a process where the internal 
component of arteries are altered deleteriously involves the intima of artery (see 
figure 1.1).48 However atherosclerosis and stiffening tend to co-exist with the same 
risk factors over time, the areas affected are in very close proximity, and the process 
of stiffening is thought to have a damaging effect on the atherosclerotic process. 
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Thus arterial stiffening and atherosclerosis are better viewed as processes which are 
inter-related, although the complex relationship between each other is still not fully 
understood.48 Indeed, adult studies of pulse wave velocity, a measure of arterial 
stiffening (see below), has been shown to be associated with degree of arterial 
plaques in coronary arteries in adults, the hallmark of athersclerosis.49 Measurement 
of arterial stiffness is now recognized as a way of studying cardiovascular risk in 
people with obesity with established scientific guidance.50 51  
A number of reasons have been cited for potential explanations for increased 
arterial stiffness in obesity such as associated insulin resistance,52 53 dyslipidaemia54 
and hypertension.53 54 The importance of hypertension in this process, especially in 
the context of obesity will be discussed at various points throughout the thesis. 
 
 
 
 
Figure 1.1 : The anatomy of an artery:  
An artery comprises 3 main regions: the intima which is most internal and is in proximity to 
blood contents, the media which contains mostly elastin, collagen and smooth muscle; and 
the adventitia.55 It is the media which is thought to be the most involved in arterial stiffening 
due to changes in elastin and collagen structure and function and the intima which is 
associated with atherosclerotic changes. However in reality, given their proximity, the two 
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processes are thought to be inter-related.48 
 
Whilst working with a group of adolescents with obesity in the HELP program I was 
interested in understanding arterial stiffening within this group and how it 
interacted with co-existing cardio-metabolic risk factors. There are a number of 
modalities available to study early evidence of atherosclerosis in children and young 
people which have been applied in obesity; in particular carotid intimal-media 
thickness, measurement of carotid artery calcification and proxies of arterial 
stiffening using pulse waves. It is beyond the scope of this thesis to explore all of 
these modalities, however the reader is directed to two important consensus 
guidelines on the topic led by Urbina et al50and Laurent et al.51  Whilst working as 
the fellow for the HELP trial, I had the opportunity to access equipment and training 
to measure and examine pulse waves (Sphygmocor, AtCor Medical, Sydney 
Australia) – see below); and this offered a non-invasive and relatively swift method 
for me to study arterial stiffness in the group of adolescents with obesity studied in 
the HELP  trial. I will therefore now specifically discuss arterial stiffness and how this 
can be measured by analysis of pulse waves in more detail.   
 
1.8 Pulse wave analysis: pulse wave velocity and augmentation index. 
Pulse wave velocity 
 
Pulse wave velocity (PWV) is a technique of measuring arterial stiffening between 
two regions. The concept of PWV was first defined in the 19th century, independently 
by Moens and Korteweg (later defined as the Moens-Korteweg equation), which 
defines PWV based on Newtonian mechanics using the Young’s elastic modulus 
applied to an artery (E), arterial thickness (h), radius (r) and blood density (ρ)56: 
 
PWV = √ E . h 
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            2 r ρ 
  
 
It can be seen from this equation that as a measure, PWV is indirectly proportional 
to the distensibility of the artery (given it is a function of the square of the inverse of 
the radius), which explains why a more positive value of PWV implies a stiffer 
artery.57 58 In practical terms, the measurement of pulse wave velocity has been 
developed most effectively and conveniently by measuring the delay in transit of the 
pulse wave at two sites, and the distance between the two sites, with PWV being 
calculated as a function of the distance divided by the time delay in meters/second; 
with validated algorithms used to detect the foot of waves at different sites (see 1. 
2). PWV can be measured between short segments, as has been done using MRI and 
USS, but more commonly has been used for longer segments between two 
peripheral arterial sites using tonometry (e.g. carotid:radial) due to the more 
straightforward nature of peripheral measures in ambulatory research settings.57  
 
The recent recognition of the value of PWV has been its evident usefulness as a 
predictor of cardiovascular outcomes in adults.  Beyond research showing PWV 
measures correlate with more direct measures of arterial plaques mentioned 
above,49 two important, recent systematic reviews have been published on adult 
outcomes which have demonstrated the importance of PWV in the prediction of 
cardiovascular outcomes. Ben-Sholomo et al meta-analysed 16 studies, pooling a 
total of 17,635 participants and looked at the predictive value of aortic PWV (aPWV) 
for cardiovascular disease. After adjusting for age and sex, they found that a 1 
standard deviation increase in log aPWV was associated with a 1.5 hazard ratio of 
coronary artery disease and 1.45 for cardiovascular disease. Even after controlling 
for contemporary conventional risk factors such as lipids and blood pressure, aPWV 
remained an independent risk predictor for coronary artery disease, stroke and 
cardiovascular disease events (eg MI). Vlachopoulos et al published a meta-analysis 
of 17 longitudinal studies measuring aPWV, pooling 15,877 participants. They 
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reported that the relative risk of cardiovascular events increases linearly by tertile of 
PWV. Relative risk for cardiovascular event mortality was 2.2 for higher versus lower 
aortic PWV groups. They reported that an increase in aortic PWV by 1 standard 
deviation resulted in a 47% increase in total cardiovascular events and 47% increase 
in cardiovascular mortality (after adjustment for age, sex and conventional risk 
factors). PWV in adults therefore appears to be a reliable predictor of cardiovascular 
events and mortality, separate to the measures of cardio-metabolic risk such as 
lipids and blood pressure discussed above. 
 
Arterial stiffening is a process which increases with age, and in children, cross 
sectional data have been published for PWV in healthy children which have show a 
steady rise with age.59 The normative changes in PWV in children and adolescents is 
discussed in more detail in section 1.9.4. 
Augmentation index 
 
Another way of using pulse waves to study arterial stiffness is to use the peripheral 
pulse to generate a picture of the central arterial waveform, and then use its 
structure to assess systemic arterial stiffness. This is done most commonly by using 
tonometry at the radial pulse to measure pressure waveforms at the radial pulse 
which are then subjected to a validated transfer function which generates a 
representation of the arterial waveform. The arterial wave form can then be used to 
derive the augmentation index (AI).60 
 
The aortic waveform is made up of two component waves – the forward and 
reflective waves.47 The first, the forward wave, is generated by the pressure caused 
by ventricular ejection; the second due to the elastic properties of the whole distal 
arterial tree (from aorta to arterioles), called the reflective wave.60 These feature as 
two noticeable points during the waveform – but differ based on age. In young 
adults, the first wave component and the reflective wave look distinct (see figure 
1.3), with the peak of the reflective wave occurring after the peak of systole; 
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however as individuals age and arterial stiffness increases, the waveform changes 
shape and the wave starts to look more homogenous with the inflection of the 
reflective wave occurring before peak systolic pressure. As a result, the difference 
between the inflection point of the reflective wave and peak systolic pressure of the 
wave increases as a proportion of the total wave pressure (systole minus diastole).60 
The augmentation index is calculated by the ratio of the peak systolic pressure – the 
pressure at inflection, divided by the total aortic amplitude (which is the difference 
between peak systolic pressure and peak diastolic pressure) as a percentage. As 
arterial stiffness in the arteries increases, the inflection and systolic difference will 
become larger compared to the systolic-diastolic pressure, thus the augmentation 
index increases proportionally to arterial stiffness. 61 This is illustrated in figure 1.3.  
The augmentaion index has been demonstrated to be reproducible,62 and has been 
shown in adults to be associated with future cardiac disease and events.63 However, 
the value as a predictor for cardiovascular disease in adults has not been consistent. 
64 65   Because the aortic pulse pressure wave is generated from the radial pulse, it is 
not as direct a measure of arterial stiffness as pulse wave velocity is.  
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Figure 1.2 Measurement of PWV 
 Pulse wave velocity (PWV) is measured by measuring pulse wave forms at two arterial sites, 
and then calculated by dividing the distance between the two measuring sites (L) by the 
difference in wave commencement delay  (in seconds) between the two waveforms at the 
two different sites, resulting in a velocity in metres/second. The technologies which have 
been developed to measure PWV have developed specific algorithms to detect the start of 
wave forms.57 
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Figure 1.3 : Measurement of Augmentation Index 
The Augmentation index is calculated after the aortic wave is generated from algorithms 
using the radial pulse wave. The  aortic wave comprises two distinct components: the initial 
wave from ventricular ejection during systole, and the reflective wave which is due to 
systemic pressure. In younger people the reflective wave occurs after peak systolic pressure, 
whereas in older adults it occurs before. The augmentation index is the ratio of the difference 
in the pressure between the start of the reflective wave and systolic pressure to the total 
pulse amplitude (systolic – diastolic pressure) expressed as a percentage. Augmentation 
index increases with age, and with arterial stiffening.  
 
 
 
1.9 Pulse wave analysis and Augmentation index systematic review 
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Upon initial exploration of the literature on the effects of obesity on PWV and 
augmentation index in children and adolescents, findings appeared to vary between 
individual studies. A systematic synthesis of the evidence in this area had never been 
performed before, and systematic review techniques and meta-analysis offered the 
potential to summarize existing knowledge of this area. As a part of this thesis I led a 
systematic review and meta-analysis to evaluate associations between obesity and 
PWV and AI in children and adolescents. I collaborated with Ms. Alicja Rapala (AR) 
and my supervisor Professor Viner for this. This systematic review was subsequently 
published (see publications arising from this thesis section above and the publication 
is included in appendix 9.2) : Hudson L, Rapala A, Khan T, Williams B,Viner RM. 
Evidence for contemporary arterial stiffening in obese children and adolescents using 
pulse wave velocity: a systematic review and meta-analysis. Atherosclerosis  2015 
[published Online First: doi: 10.1016/ j.atherosclerosis.2015.05.014.] 
1.9.1 Systematic review Methods 
Search strategy 
 
We performed a systematic search using PRISMA guidelines to identify studies that 
compared PWV and/or AI in both obese and non-obese children (< age 18). Two 
reviewers (LH and AR) searched PubMed, Embase and Web of Science electronic 
databases in September 2014 (see table 1.3 for search terms) independently. 
Inclusion criteria were: 1) studies measuring PWV and/or AI at any site; 2) 
participants <age 18 years; 3) use of accepted criteria to define childhood obesity. 
Exclusion criteria were: 1) genetic, syndromic or endocrine causes of obesity; 2) 
Studies of participants with chronic illness which might independently affect arterial 
stiffness 3) Studies using self-reported BMI.  
 
Table 1.3 : Summary of search terms for systematic review for each database. 
Database Search terms 
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Database Search terms 
Pubmed ("Pulse Wave Analysis"[Majr] OR "Vascular Stiffness"[Majr] OR 
augmentation index OR arterial stiffness) AND ("Child"[Mesh] OR 
"Adolescent"[Mesh]) AND ("Obesity"[Mesh] OR 
"Overweight"[Majr]) 
 
Note pulse wave velocity not included in search as was a 
component of PWA MESH 
 
Embase (child or adolescent) and (obesity or overweight) and (pulse 
wave analysis or pulse wave velocity or arterial stiffness or 
vascular stiffness or augmentation index) 
 
Web of 
knowledge 
(combines web 
of science, 
MEDLINE and 
BIOSIS) 
Topic=((obesity) OR (overweight)) AND Topic=((pulse wave 
analysis) OR (pulse wave velocity) OR (arterial stiffness) OR 
(vascular stiffness) OR augmentation index) AND Topic=((child 
OR adolescent)) 
 
 
Two reviewers (LH and AR) screened abstracts for inclusion separately, which were 
then adjudicated by RV. Potentially eligible studies were independently reviewed by 
LH and AR and data extracted and adjudicated by RV. Reviews and retrieved studies 
were hand-searched for additional eligible studies. Where inadequate information 
was provided, primary authors were contacted. Translations of non-English language 
studies were sought from authors or interpreters used.  
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Bias assessment and grading 
 
We decided to grade studies for bias risk using a method used in a previous review32 
as low, medium risk or high risk of bias, combining domains from the Cochrane 
Collaboration guidelines66 (inadequate blinding of outcome assessment, incomplete 
outcome data, and selective reporting) with two additional domains - “inappropriate 
measurement methods” (split into a. suitability and b. reliability) and use of an 
unrepresentative sample. These are summarized in table 1.4. A priori standards were 
agreed. Where it was not possible to grade as low or high bias, a medium risk was 
assigned. Although each study was assessed in each category, an overall bias 
assignment was assigned based on the highest risk score across all categories. 
Studies were independently assessed for bias by LH and AR and adjudicated by RV.  
 
Table 1.4 : Bias classification criteria for studies in systematic review 
Quality 
Assessment 
criteria 
Low risk of bias High risk of bias 
1. Blinding of 
outcome 
assessment 
 Researchers measuring 
observations blinded to 
BMI status or absence of 
blinding considered 
unlikely to have affected 
results 
 No blinding of researchers 
measuring observations to 
BMI status and absence of 
blinding considered likely to 
have affected results 
2.Incomplete 
outcome data 
 No missing data for 
participants or missing 
outcome data unlikely to 
be related to outcome  
 OR missing data 
 Some missing data for 
participants or  missing 
outcome data likely to be 
related to outcome  
 OR missing data not balanced  
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Quality 
Assessment 
criteria 
Low risk of bias High risk of bias 
balanced  across both 
groups  
 OR missing data 
methods used  
 OR effects of missing 
data unlikely to impact 
on an effect size that has 
a clinically significant 
implication. 
 
 
across both groups  
 OR effects of missing data 
likely to impact on an effect 
size that has a clinically 
significant implication. 
 
3. Selective 
Reporting 
 Study appears to report 
all of the pre-specified 
outcomes that were 
measured.  
 
 Study does not appear to 
report all of the pre-specified 
outcomes that were 
measured.  
 
4a. 
Measurement 
methods that 
were suitable 
 Appropriate protocols 
for pulse wave 
measurement used (e.g. 
resting beforehand) 
 Appropriate BP cuff sizes 
 Measurement of weight 
and height done using 
standardized equipment 
 
 No protocol for pulse wave 
measurement used (eg resting 
beforehand) 
 Inappropriate BP cuff sizes 
 Measurement of weight and 
height done without using 
standardized equipment 
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Quality 
Assessment 
criteria 
Low risk of bias High risk of bias 
4b.Measurement 
methods that 
were reliable 
 Trained operators used 
 Reproducibility quality 
assurance in place or 
sensitivity analysis done 
for multiple operators 
 Quality indices for PWV 
and AI  used  and 
reported 
 
 Number of operators not 
reported, or sensitivity 
analysis or reproducibility 
quality assurance not 
provided. 
 No evidence that quality 
indices were used. 
 
5. Use of a 
representative 
sample 
 Community drawn 
sample or from existing 
community cohort? 
 
 Statistically equal 
mixture of males and 
females between obese 
and non-obese subjects 
(within 10%) 
 
 Statistically equal age 
range between obese 
and non-obese subjects; 
and ideally groups would 
have a narrow age range 
within 2 years SD. 
 Non-community sample, eg 
clinic sample (especially 
obesity clinic) 
 
 
 Unequal mixture of males and 
females between obese and 
non-obese (greater than 10%) 
 
 
 Unequal age range between 
obese and non-obese 
subjects; with a large age 
range greater than 2 years SD. 
 
 Mixed ethnicities not taken 
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Quality 
Assessment 
criteria 
Low risk of bias High risk of bias 
 
 Single ethnicity or data 
presented by ethnicity 
 
into consideration in analyses. 
 
 
 
Once agreement was reached for which studies should be included, I pooled 
individual studies for meta-analysis using STATA version 13 (StataCorp, Texas, USA). 
As arterial stiffening is potentially influenced by a number of factors, I made an a 
priori decision to use a random effects model (DerSimonian & Laird method67). 
Weighted mean differences (WMD) (with 95% confidence intervals) were calculated 
for a) all site arterial stiffness and b) by site (carotid-femoral, carotid-radial), to 
examine for differences by region measured. In studies with multiple measures over 
time, we used baseline data. Some studies did not provide means and standard 
deviations, but reported medians and ranges instead. Hozo et al have published 
validated formulae to allow estimation of mean from median, and standard 
deviation from the range depending on sample size, and these techniques were used 
to derive mean and standard deviation in such studies.68 We also performed 
sensitivity analyses by performing analyses with or without studies with a higher risk 
of bias. Evidence of publication bias was examined using a funnel plot and Begg’s 
test69 and Egger’s test 70were used to additionally assess publication bias. I 
performed all analyses for the systematic review. 
1.9.2 Systematic review results 
Figure 1.4 shows the results of the search. 383 discrete studies were identified, and 
81 retrieved and reviewed. Fifteen studies were included in the study (summarized 
in table 1.6).71-85 One presented PWV data by sex separately and information for 
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males and females were entered into the meta-analysis separately. We contacted 
three authors for further data, which two authors71 83 provided and were used for 
analysis. For one study which was published in Russian, I contacted the authors 
directly who provided a translation into English. 
 
Quality  
 
Bias assessments for each study are shown in table 1.5, and overall bias assessment 
is included in table 1.6. Risk of bias was generally high. Because no study blinded 
researchers to weight status, all studies were graded as at least medium risk - 
effectively meaning that no study was considered low risk across all domains. The 
majority of studies either had one domain classed as high bias risk or at least 
medium risk in at least one domain. Studies were therefore grouped by studies as 
low/medium or high risk of bias.   
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Figure 1.4 : Summary of findings from the Pulse wave velocity and augmentation 
index systematic review 
 
 
 
Electronic	searches	(520	abstracts).	Hand	search	of	papers	and	reviews	(0	extra	studies)	
81	papers	retrieved	and	
reviewed	
383	poten ally	eligible	
abstracts	
137	duplicate	publica ons	
EXCLUSIONS:	N=302	
	
Included	adults	or	only	adults	in	analyses	(n	=	46)	
No	obesity	in	study	(n=	4)	
No	measurement	of	PWA	or	PWV	(n	=	63)	
Review,	le er,	guideline	or	protocol	(n	=	51)	
Conference	abstracts	(not	full	study)	(n	=	118)	
Chronic	illness	(n=	17)	
No	rela onship	between	PWA/PWV	and	BMIz	(n=	3)	
	
	
15	papers	included	in	study	
EXCLUDED	N=	66	
	
No	obesity	in	study	(n=1)	
Did	not	examine,	analyze	or	describe	a	rela onship	between	
PWV	or	PWA	and	BMI	cen le	or	z-score;	or	did	not	categorize	
PWV	or	PWA	by	group	(healthy,	overweight,	obese).	(n	=	23)	
Inadequate	defini on	of	obesity	(n	=	7)	
Included	adults	in	analyses		(n=	15);	or	adults	only	(n	=1)	
No	measurement	of	PWA	or	PWV		(n	=	15)	
Review,	le er,	guideline	or	protocol	(n	=	2)	
Duplica on	of	data	used	in	an	addi onal	study	already	used*	
(n	=	1)	
Data	presented	graphically	without	numerical	data,	with	no	
response	by	authors	(n=1).	
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Table 1.5 Summaries of bias assessment for each included study 
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Bolotova MEDIUM LOW LOW HIGH RISK HIGH RISK 
Cabrera-Rego 
et al. (2014) 
 
MEDIUM LOW LOW MEDIUM HIGH 
Çelik et al 
(2011) 
MEDIUM LOW LOW LOW HIGH 
Charakida et 
al. 
(2012) 
MEDIUM LOW LOW LOW MEDIUM 
Dangardt et 
al. 
(2013) 
MEDIUM LOW LOW LOW HIGH 
Hacıhamdioğl
u et al. (2014) 
 
MEDIUM LOW LOW LOW HIGH 
Harris et al. 
(2012) 
MEDIUM LOW LOW LOW HIGH 
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Jin et al. 
(2013) 
MEDIUM LOW LOW LOW MEDIUM 
Koopman et 
al. (2012) 
MEDIUM LOW LOW LOW HIGH 
Lurbe et al. 
(2012) 
MEDIUM LOW LOW MEDIUM HIGH 
Lydakis et al. 
(2012) 
MEDIUM LOW LOW MEDIUM LOW 
Martínez-
Costa (2014) 
 
MEDIUM LOW LOW LOW HIGH 
Montero 
(20130 
MEDIUM LOW LOW LOW HIGH 
Nunez et al. 
(2010) 
MEDIUM LOW LOW MEDIUM HIGH 
Pandit et al. 
(2011) 
MEDIUM LOW LOW MEDIUM MEDIUM 
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1.9.3 Meta-analysis results 
 
14 studies including 6677 total participants (1120 obese and 5557 non-obese) were 
suitable for meta-analysis for PWV, and 5 studies including 728 participants (411 
obese and 317 non-obese) for AI.  
 
Pulse wave velocity 
 
A forest plot for all studies investigating PWV is shown in Figure 1.4 with pooled 
estimates for low/medium risk of bias (3 studies studies; N= 5568, 418 obese and 
5150 non-obese) and high risk of bias (11 studies; N=1109, 702 obese and 407 non-
obese); and overall pooled estimate. A difference was found indicating higher PWV 
in obese versus non-obese subjects including all regions (WMD 0.45 (95% confidence 
interval 0.10 to 0.81 ms-1)); however this was not significant when analysis was 
restricted to low/medium risk of bias studies (0.34  (-0.49 to 1.16)). 
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Figure 1.4 : Forest plot of PWV of all studies stratified by bias assessment 
 Forest plot of PWV stratified by bias risk assessment and overall pooled estimate. Note : 
Weighted Mean difference (ms-1) between obese and non-obese subjects. Subgroup analysis 
was done for the studies that of low/medium and high potential for bias (Differences in mean 
change in PWV are calculated by inverse variance statistical method of random effects 
model) 
 
Figure 1.5 shows PWV studies grouped by anatomical region (figure 3). In studies of 
PWV measured at the carotid (5 studies; N=849, obese 582, non-obese 267), obese 
subjects had higher PWV (WMD 0.51 (0.35 to 0.67 ms-1) (figure 3). Restriction of this 
analysis studies at low/medium risk of bias (N = 282, obese 166, non-obese 116) 
increased the weighted mean difference (WMD 0.67 (0.47 to 0.87 ms-1). No 
differences were found for PWV in studies measured at the aorta using all methods 
(combining direct aortic measurements and carotid-femoral measurements) but 
studies measuring the aortic directly (3 studies, N = 221, 116 obese and 105 non-
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obese) showed greater PWV in obese subjects (WMD 1.33  (0.36 to 2.31),); all of 
these studies were however assessed as high risk for bias. 
 
 
Figure 1.5 Forest plot of PWV by anatomical region 
Forest plot of PWV by anatomical region measured and overall pooled estimate. Note : 
Weighted Mean difference (ms-1) between obese and non-obese subjects. Subgroup 
analysis was done for the studies that of low/medium and high potential for bias 
(Differences in mean change in PWV are calculated by inverse variance statistical 
method of random effects model) 
 
Augmentation index 
 
Figure 1.6 shows a forest plot for  studies measuring AI. No significant difference was 
found in AI for obese versus non-obese participants (WMD 4.75 (-3.95 to13.45)). As 
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all but one of the included AI studies were rated high risk of bias, sub-analyses risk of 
bias were not performed. 
 
 
 
Figure 1.6 : Forest plot of Augmentation Index studies 
Forest plot of AI and overall pooled estimate. Note : Weighted Mean difference (ms-1) 
between obese and non-obese subjects. Subgroup analysis was done for the studies that of 
low/medium and high potential for bias (Differences in mean change in PWV are calculated 
by inverse variance statistical method of random effects model) 
 
Quality measures for meta-analysis 
Heterogeneity was high (I2 >90% in all meta-analyses). A funnel plot was not 
perceived to demonstrate asymmetry (see figure 1.7). Low significance in both 
Begg’s test (p=0.6) and Egger’s test (p=0.14) supported this perception. There were 
an insufficient number of studies measuring PWA to assess publication bias 
adequately. 
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Figure 1.7 : Funnel plot of included PWV studies 
A funnel plot of included studies in the PWV meta-analyses. Whilst spread was wide, the 
appearance of scattering is symmetrical, and this perception is backed by non- significant 
Begg’s and Egger’s testing. 
 
 
 
 
57 
Table 1.6: Summary of included studies, individual study details, findings and overall risk assessment. 
 
Author  
(year) 
 
PWV or AI 
measuremen
t site and 
method 
Sample characteristics  
 
PWV 
obese 
versus 
non-obese 
 
Obesity 
definition 
Healthy 
controls 
include 
overweight? 
(>85th centile 
<95 centile) 
 
Sex , age and 
pubertal 
differences 
between obese and 
healthy controls? 
Other cardio-
metabolic differences 
Overall bias 
assessment 
Country, 
setting and 
recruitment. 
Number 
of 
subjects* 
Age (years) 
Mean (SD) or 
median (IQR) 
Sex 
Bolotova et 
al. (2014)71 
 
 
Aortic PWV 
and AI (using 
aorta 
directly). 
 
 
 
Single centre, 
Russia.  
Unclear where 
obese or 
control 
subjects were 
recruited from.  
25 obese  
 
20 non-
obese 
subjects 
 
 
 
Whole group 
median 12 
(range 11-16) 
Unclear PWV  in 
obese 
subjects 
 
 
 
≥ 95th BMI 
centile ** 
Unclear Unclear sex 
differences. 
 
wide variety of 
pubertal stage 
across all subjects 
SBP and DBP was 
greater in obese 
subjects.  
 
Triglycerides, 
cholesterol and 
HOMA were greater in 
obese subjects. 
 
High 
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 Ethnicities not 
reported. 
 
Cabrera-
Rego et al. 
(2014)72 
 
Carotid PWV 
 
(Carotid echo 
tracking :left 
and right 
common 
carotids 
averaged) 
 
 
Single centre, 
Cuba. Unclear 
recruitment 
methods 
 
66 (69%) 
obese 
30 (31%) 
non-
obese 
 
Obese :  
11.3 (2.7) 
 
Non-obese: 
12.0(2.9) 
Obese :  
62.1% 
male 
 
Non-
obese: 
% male 
PWV   in 
obese 
subjects 
 
 
 
≥ 97th BMI 
centile ** 
Unclear No differences in 
age and sex 
between obese and 
non-obese  
 
Puberty status not 
reported  
 
 
SBP (but not DBP) was 
greater in obese 
subjects. Triglycerides 
(but not cholesterol) 
and HOMA were 
greater in obese 
subjects. 
 
Ethnicities not 
reported. 
 
H 
Çelik et al 
(2011)73 
Aortic PWV. 
 
(Directly 
between 
aortic valve 
Single centre, 
Turkey. 
 
Sample from a 
clinic 
 
30 (50%) 
obese.  
 
Obese :  
Mean 
13.2(SD 2) 
 
Obese :  
40% male 
 
Non-
PWV   in 
obese 
subjects. 
≥ 95th BMI 
centile ** 
Yes No differences in 
age and sex 
between obese and 
non-obese 
 
SBP and DBP were 
greater in obese 
subjects. No 
differences in other 
blood cardio-
H 
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and 
diaphragm: 
Echocardiogr
aphy 
machine 
using 
doppler) 
separated into 
obese and 
non-obese  
30 (50%) 
non-
obese 
 
Non-obese: 
Mean 
12.5(SD 1.7) 
obese: 
43.3% 
male 
Puberty status not 
reported. 
 
metabolic markers 
measured (fasting 
glucose and lipids). 
 
Ethnicities not 
reported.  
 
 
Charakida et 
al. 
(2012)74 
Carotid-
Radial PWV. 
 
two site 
carotid artery 
and radial 
artery 
tonometry. 
 
 
Multi-centre, 
United 
Kingdom.  
 
Obese and non 
obese 
recruited from 
community 
birth cohort 
sample 
(ALSPAC);  
PWV data 
available 
on 6293 
subjects 
 
252 (4%) 
obese 
 
5034 
(80%) 
healthy 
Only 
reported age 
by whole 
sample and 
by sex. 
 
Males: 
median 10.6 
(IQR 10.5–
10.8)  
 
Whole 
sample 
only 
reported 
 
49% male. 
PWV  in 
obese 
subjects  
 
 
IOTF No Sex, puberty and 
age information by 
weight status 
grouping not 
reported.   
 
Pubertal range 
wide for whole 
group. 
SBP and DBP were 
greater in obese 
subjects. 
 
Higher lipids and in 
obese subjects. 
 
Ethnicities not 
reported.  
 
L/M 
 
60 
weight. 
 
 
Females 
Median 10.6 
(IQR 10.5–
10.8) 
 
 
Dangardt et 
al. 
(2013)75 
Carotid-
Radial PWV. 
 
two site 
carotid artery 
and radial 
artery 
tonometry. 
 
Single centre, 
Sweden. 
Obese from 
obesity clinic. 
Non-obese 
from regional 
schools).  
 
28 (67%) 
obese 
 
14 ( 33%) 
non-
obese 
 
 
Obese :  
Median 13.8 
(Range 10.2–
17.6) 
 
Non-obese: 
median 13.8 
(Range 11.5–
16.1) 
Obese :  
39% male 
 
Non-
obese: 
36% male 
No 
difference 
in PWV 
between 
obese and 
non-obese 
subjects.  
IOTF No No differences in 
age and sex 
between obese and 
non-obese subjects. 
Puberty status not 
reported. 
 
 
DBP (but not SBP) was 
greater in obese 
subjects.  
 
Differences in blood 
lipids and cholesterol 
markers between 
groups not reported. 
 
Ethnicities not 
reported.  
 
H 
 
61 
Hacıhamdio
ğlu et al. 
 (2014)76 
 
Carotid-
Femoral PWV  
 
two site 
carotid artery 
and femoral 
artery 
tonometry. 
 
Single centre,  
Turkey 
Obese 
recruited 
endocrine 
clinic.  
Non-obese 
unclear.  
 
 
61 (51%) 
obese 
 
58 (49%) 
non-
obese 
 
Obese :  
13.2 (1.8) 
 
Non-obese: 
Mean 13.2 
(2.1) 
Obese :  
49% male 
 
Non-
obese: 
48% male 
PWV   in 
obese 
subjects  
 
 
≥ 95th BMI 
centile ** 
No No differences in 
age and sex 
between obese and 
non-obese subjects. 
All children were 
reported as being in 
puberty, but 
staging not 
reported  
 
 
SBP and DBP greater 
in obese subjects.   
 
Differences in blood 
lipids and cholesterol 
markers between 
groups not reported. 
 
All subjects reported 
as Turkish. 
 
  
H 
Harris et al. 
(2012)77 
Aortic PWV  
 
(directly 
between the 
ascending 
and 
Single centre, 
Canada. 
Obese referred 
from an 
obesity 
program. 
61 (53%) 
obese 
 
55 (47%) 
non- 
obese. 
Obese :  
Mean 13.8 
(2.3) 
 
Non-obese: 
Mean 13.8 
Obese :  
56% male 
 
Non-
obese: 
40% male 
PWV   in 
obese 
subjects 
≥ 95th BMI 
centile ** 
Unclear No differences in 
age and sex 
between obese and 
non-obese subjects. 
Puberty status not 
reported. 
SBP (but not DBP) was 
greater in obese 
subject, but no 
correlation found 
between PWV and 
systolic BP in all 
subjects. 
H 
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descending 
aorta : 
Echocardiogr
aphy 
machine 
using 
doppler) 
 
 
 
Non obese 
unclear 
subjects were 
recruited from. 
(4.0)   
 
Triglycerides were 
abnormally high in 
obese subjects using 
adult reference data; 
lipid levels in non-
obese subjects not 
reported. 
 
Ethnicities not 
reported.  
 
Jin et al. 
(2013)78 
Carotid PWV 
 
(Both 
common 
carotids 
averaged 
Single centre, 
China. 
Obese subjects 
recruited from 
a paediatric 
centre (?clinic) 
 
71 (60%) 
obese 
 
47 (40%) 
non- 
Obese :  
Mean 10 
(1.6) 
 
Non-obese: 
Obese :  
73% male 
 
Non-
obese: 
PWV   in 
obese 
subjects 
 
 
≥ 95th BMI 
centile ** 
Unclear No statistical 
differences in age 
and sex between 
obese and non-
obese subjects. 
Puberty status not 
SBP and DBP were 
greater in obese 
subjects.   
 
Differences in blood 
lipids and cholesterol 
L/M 
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:Carotid 
dopplers)  
 
 
 
Non-obese 
subjects 
recruited from 
children  in the 
same 
department 
enrolled into 
an obesity 
prevention 
program. 
 
 
obese. Mean 9 (1.6) 72% male reported. 
 
markers between 
groups not reported. 
 
Ethnicities not 
reported.  
 
Koopman et 
al. (2012)79 
Carotid-
Femoral PWV 
& AI (radially 
derived) 
 
two site 
carotid artery 
 
Single centre, 
Canada. 
Obese subjects 
from lipid 
clinic.  
 
21 (44%) 
obese 
(but see 
methodol
ogical 
comments
Obese :  
14.2(2.0) 
 
Non-obese: 
Mean 13.9 
(2.3) 
Obese :  
81% male 
 
Non-
obese: 
81% male 
PWV   in 
obese 
subjects  
 
 
 
≥ 95th BMI 
centile ** 
No No statistical 
differences in age 
and sex between 
obese and non-
obese subjects. 
Puberty status not 
reported. 
Ethnicities not 
reported.  
 
SBP (but not DBP) was 
greater in obese 
subjects. Differences 
between other cardio-
H 
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and femoral 
artery 
tonometry; 
radial 
tonometry 
for AI 
 
 
Non-obese 
subjects from 
existing normal 
control group.  
 
 
) 
 
27(56%) 
non-
obese 
 
 
 metabolic markers not 
reported, however all 
of the obese subjects 
had lipid 
abnormalities (with 
two patient on lipid 
lowering medical 
treatment). 
Lurbe et al. 
(2012)80 
Carotid-
Radial PWV & 
AI (radially 
derived) 
 
two site 
carotid artery 
and femoral 
artery 
tonometry 
and cAI 
generated 
Single centre,  
Spain 
Obese and non 
obese subjects 
recruited from  
a clinic of 
referrals for 
vascular 
phenotype 
assessment.  
 
284(57%) 
obese 
 
79 (16%) 
healthy 
weight 
 
 
Obese :  
12.0 (2.2) 
 
Healthy 
weight: 
Mean 13.4 
(2.6) 
Obese :  
56% male 
 
Healthy: 
44% male 
PWV  in 
obese 
subjects 
≥ 95th BMI 
centile ** 
No Differences 
between age and 
sex presented by 
ANOVA across the 3 
groups (healthy 
weight, overweight, 
obese). No 
statistical 
differences in sexes 
across the three 
groups, but obese 
children younger.  
There was no 
difference between 
peripheral SBP and 
DBP across different 
weight status groups, 
however central DBP 
(but not SBP) was 
greater in obese 
subjects. were greater 
in obese subjects.   
Differences in blood 
lipids and cholesterol 
H 
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from radial 
tonometry. 
 
 
Puberty status not 
reported. 
 
markers between 
groups not reported. 
 
All subjects were 
Caucasian.  
Lydakis et 
al. (2012)81 
AI (brachial 
pulse 
derived) 
 
 
Single centre,  
Greece 
All subjects 
recruited from  
3 local schools. 
 
 
36(13%) 
obese 
 
157 (57%) 
healthy 
weight 
 
Further 84 
subjects 
(30%) 
were 
overweigh
All children 
aged 12. 
Obese :  
61% male 
 
Healthy: 
48% male 
No 
difference 
in AI 
across 
obese, 
overweigh
t and 
healthy 
subjects  
IOTF No All children aged 
12. 
 
Puberty status not 
reported. 
 
 
Peripheral and central 
SBP and DBP greater 
across groups with 
increasing degree of 
overweight using 
ANOVA. 
 
Differences in blood 
lipids and cholesterol 
markers between 
groups not reported. 
 
L/M 
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t not 
described 
or 
included 
here. 
 
Differences in blood 
lipids and cholesterol 
markers between 
groups not reported. 
 
All subjects were 
Caucasian. 
 
 
 
Martínez-
Costa 
(2014)82 
 
Carotid PWV 
  
(right 
common 
carotid 
Carotid echo-
tracking)  
 
Single centre, 
Cuba. 
All subjects 
recruited from 
paediatric 
clinic.  
66 (48%) 
obese 
 
42 (31%) 
healthy 
weight 
 
 
Obese :  
11.3 (3.0) 
 
Healthy 
weight: 
12.4 (2.4) 
Sex data 
only 
presented 
for all 137 
subjects, 
and not by 
weight 
category:  
64% male 
PWV   in 
obese 
subjects  
≥ 95th BMI 
centile  
*** 
No No differences in 
age between obese 
and non-obese 
subjects. Sex 
proportions by 
weight status not 
reported. 
 
Puberty status not 
SBP and DBP were 
greater in obese 
subjects. Blood 
triglycerides and 
HOMA were greater in 
obese subjects.  
 
All subjects were 
Caucasian. 
H 
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 reported  
 
 
 
Montero et 
al. 
(2013)83 
Upper and 
lower limb 
PWV (whole 
limb from 
clavicle to 
finger and 
groin to toe). 
 
Continuous 
wave Doppler 
and 
photoplethys
mography  
 
Single centre, 
France. 
Obese subjects 
from an 
obesity clinic. 
Controls 
unclear 
 
 
 
15 (45%) 
obese 
 
18 non-
obese 
(55%) 
Obese: 
 
15.20 (1.27) 
 
Non obese: 
13.38 (1.19) 
Obese :  
33 % male 
 
Non-
obese: 
39 % male 
Baseline 
upper limb 
: 
 
No 
significant 
difference 
between 
PWV in 
obese 
subjects 
and non 
obese   
 
Baseline 
lower 
limb: 
IOTF, but 
all severe 
> 3 SD BMI 
No No differences 
between 
proportions of sex 
between obese and 
non-obese subjects.  
Obese children 
were younger. 
Puberty status 
same across both 
groups Tanner 3 or 
4. 
 
No differences in BP 
between obese and 
non-obese subjects. 
 
Differences in blood 
lipids and cholesterol 
markers between 
groups not reported. 
 
Ethnicities not 
reported. 
 
 
H 
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PWV  in 
obese 
subjects   
 
 
Nunez et al. 
(2010)84 
Carotid PWV 
and AI 
(carotid 
derived, 
Right 
common 
carotid 
artery). 
Carotid 
dopplers  
Single centre, 
Spain. 
Obese subjects 
from an 
obesity clinic. 
 
Non-obese 
subjects from a 
cardiac 
murmur clinic. 
 
 
 
45 (57%) 
obese 
 
34 (43 %) 
non-
obese 
 
 
Obese :  
12.4 (2.2) 
 
Non-obese: 
Mean 11.6 
(1.9) 
Obese :  
71 % male 
 
Non-
obese: 
62 % male 
PWV  in 
obese 
subjects 
 
with PWV. 
≥ 2 SD BMI 
*** 
No No differences in 
age and sex 
between obese and 
non-obese subjects. 
Puberty status not 
reported  
 
SBP (but not DBP) was 
greater in obese 
subjects. Blood 
triglycerides and 
cholesterol were 
greater in obese 
group. 
 
Ethnicities not 
reported.  
 
H 
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Pandit et al. 
(2011)85 
Carotid PWV 
 
(Right 
common 
carotid 
artery, 
Carotid echo-
tracking ) 
 
 
Single centre, 
India 
All subjects 
recruited from  
Multiple 
centres (health 
clinics and 
schools).  
 
95 obese 
(46%)  
 
69 (33%) 
healthy 
weight 
 
 
Ages 
reported by 
sex 
 
Males 
Obese :  
11.31 (2.9) 
Healthy 
weight: 
12.35(2.7) 
 
Females 
Obese :  
10.73 (3.2) 
Obese :  
54% male 
 
Healthy 
weight: 
42 % male 
PWV  in 
obese 
subjects in 
both 
males and 
females 
≥ 95th BMI 
centile ** 
No No  differences in 
age between obese 
and non-obese 
subjects in males 
and females; sexes 
analysed 
separately.  
 
Puberty status not 
reported  
 
SBP and DBP were 
greater in obese 
subjects in both sexes 
– and relationship 
between BP and PWV 
reported. Blood 
triglycerides and 
cholesterol were 
greater in obese 
group in both sexes. 
 
Ethnicities not 
reported – but likely 
all South East Asian. 
 
L/M 
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*Proportions of overweight (i.e. not healthy and not obese proportions not included). ** Used regional data to establish centile/z-score *** Used CDC/WHO data to derive 
CDC/WHO data to establish centile/z-score. BP =Blood pressure; SBP = systolic blood pressure, DBP = diastolic blood pressure.  PWV = pulse wave velocity, AI = 
augmentation index. BMI = body mass index. BMI z = body mass index z-score. SD = standard deviation. IOTF = international obesity task force. HOMA. CDC = centre for 
disease control, WHO = world health organization. cAI = central augmentation index. 
Healthy 
weight: 
11.53 (2.4) 
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1.9.4 Systematic review discussion 
The systematic review found moderate evidence that obese children had greater 
arterial stiffness than healthy weight children as assessed by PWV. There was no 
evidence for a difference in AI. This may be because AI is a poorer marker of arterial 
stiffening, with published findings on AI in obese inconsistent86-88 but moreover, in 
contrast to PWV, AI appears to be a poorer marker of future cardiovascular risk from 
adult studies.64 65 I also think it is likely that AI has drawbacks because as a proxy of 
arterial stiffening, it is calculated from a constructed arterial pulse form not directly 
measured whereas PWV directly measures wave velocity between two points.  
There was also evidence of variation in stiffness (PWV) between regions; with 
increased stiffness in obese children found only at the carotid and direct measures at 
the aorta. This is concerning given the central location within the vascular system. 
Atherosclerotic changes in the carotid are recognized as a proxy for global CVD risk, 
89 and stiffness of the aorta may increase strain on the left ventricle, perhaps 
explaining thicker and more dilated left ventricles reported in obese children in two 
studies in our review,73 77 and reports of left ventricular changes published 
elsewhere in children with obesity.90-92  
The systematic review also showed that there was a paucity of longitudinal data 
looking at longer -term changes in PWV in children and adolescents, with only one 
study identified.  
The systematic review had a number of strengths and limitations. Independent 
raters assessed papers using agreed bias criteria. Included sample size of studies 
pooled was also large. Repeated analyses excluding studies with high risk of bias 
were performed and presented with findings. Variation between studies (e.g. age, 
sex, pubertal status, ethnicity, co-existing cardio-metabolic risk and measurement 
techniques and sex) likely contributed to bias when pooled. Indeed, most studies 
mixed pubertal stage, and even within studies where age grouping was in a similar, 
or tight range, there still would have been pubertal variation within groups. Such 
variation was expected and hence our a priori  decision to use a random effects 
model. A small number of studies combined overweight and healthy weight together 
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as controls (this was evident for 1 study and unclear for 4 others – see table 1.6), 
potentially blunting differences between obese and non-obese control stiffness. 
Four included studies that defined obesity using the more conservative Internal 
Obesity Task Force (IOTF) cut-offs, whilst the others used less conservative cut-offs. 
In a subgroup analysis no significant differences in WMD for PWV was found 
between obese and non-obese in studies using IOTF but significant differences found 
in studies using less conservative cut-offs (data not shown). However given that 
studies using lower centiles would have included obese children above IOTF centiles, 
grouping of studies in this way mixed bias ratings, and importantly studies using IOTF 
for PWV were all studies measuring upper limb PWV evident differences were most 
likely driven by regional variation rather than differences in cut-offs. Different 
measuring techniques in studies, ranging from direct regional echocardiographic 
methods to between sites using tonometers, were found. Regional variations in PWV 
within vessels have been demonstrated in magnetic resonance imaging (MRI) in 
adults,93 and it is possible that the echocardiographic techniques would have been 
subject to less regional variation – and this may explain the differences found 
between direct measures of PWV at the aorta compared to those measuring 
between the carotid and the femoral, as well as the findings in the carotid which all 
measured the carotid directly. 
Many studies in our review found greater average blood pressures in the obese and 
a number found associations between PWV and blood pressure, yet few controlled 
for blood pressure. The natural history of arterial stiffening in children and how it 
may relate to blood pressure or obesity is still limited. Normative data for PWV show 
a steady rise with age as discussed above,59 however one longitudinal study of aortic 
PWV in healthy children found a plateauing of PWV in early childhood independent 
of increases in BP, 94 with resumption of increases at 10 in females and 12 in boys. In 
our review, Charikida et al74 (studying 10 year olds), found greater artery diameter 
and lower carotid-radial PWV in obese subjects. Dangardt et al75 (studying 10-17 
year olds) also found greater arterial diameters in obese versus non-obese 
participants but no difference in carotid-radial PWV at baseline; and at 5 year follow 
up there was a greater increase in PWV in obese participants whilst radial diameter 
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continued to increase at similar rates in both obese and non-obese. The authors in 
both studies hypothesized for a compensatory vessel compliance in obesity in earlier 
childhood, preventing stiffening. Monero et al83 reported no differences in artery 
diameter between obese and non-obese participants aged 12-17 years, and 
Koopman et al79 found higher PWV in obese children with lower distension 
coefficients.  
It was evident to me from the systematic review that more research was needed on 
longitudinal changes in PWV in obesity, to see how PWV changes with BMI over 
time. Also research was needed to examine the differential interaction between 
overweight and blood pressure on PWV. Further study should also investigate the 
influence of puberty on PWV in obesity, which was absent in most studies that were 
found in the systematic review. 
1.10 Implications of findings presented in chapter one for the thesis  
In this chapter I have outlined what is known about the long term cardiovascular risk 
associated with obesity in children, and questioned the validity of cardio-metabolic 
risk markers like blood pressure and lipids as predictors of increased risk. I have 
summarized the evidence that currently exists, and shown that current evidence of 
arterial stiffness is a potential way of understanding risk by identifying evidence of 
contemporaneous arterial pathology. From the results of the systematic review, I felt 
that that the use of PWV is promising. I decided not to use augmentation index. I 
decided to study a group of adolescents with obesity from the HELP trial to 
investigate PWV: 
 
1. What cross-sectional and longitudinal relationships exist between PWV, 
obesity, blood pressure and other conventionally cited cardio-metabolic risk 
measures such as lipids and acanthosis nigricans within a group of 
adolescents with obesity? In particular how is change in PWV over time 
affected by changes in adiposity, blood pressure and cardio-metabolic risk 
factors? 
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2. What difference does partitioning degree of obesity make to PWV within 
partitioned groups, as a way of testing the validity of current definitions of 
severe obesity? 
3. Given the findings of the systematic review, do individual factors such as 
puberty, ethnicity and sex change the relationship between PWV, obesity, 
blood pressure and cardio-metabolic risk? 
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Chapter 2 : Relationship between stress, obesity and cardiovascular 
risk. 
2.1 Introduction 
In chapter one I explained that my interest in long-term cardiovascular risk in adolescents 
with obesity stemmed from my experiences and questions which emerged whilst working in 
a clinical obesity service for adolescents. I also explained that the opportunity as medical 
fellow for the HELP trial allowed me to study this concept which I present here in this thesis. 
In this chapter I will outline another area for the thesis which interested me and emerged 
whilst working in the obesity service, which relates to the aetiology of obesity and its long-
term complications, in how stress may play a part in this. Thus in this chapter I will address 
research questions 4-6 : 4)how measures of stress are associated with degree of adiposity at 
a cross-sectional and longitudinal level; 5) how measures of stress are associated with blood 
pressure at a cross-sectional and longitudinal level; and 6) how measures of stress are 
associated with pulse wave velocity at a cross-sectional and longitudinal level). 
Although an imbalance between energy intake and expenditure is a widely accepted 
explanation for the main process in the aetiology of overweight and obesity in children and 
adolescents,95-97  I was struck by the variation in development of degree of obesity and 
acquisition of components of MetS between individuals. Whilst on the one hand this led me 
to consider what the long-term implications of these findings meant for young people, I also 
wondered what other factors might be involved which might differentially affect young 
people I saw in the clinic. There are a number of potential factors which are reviewed well 
by Proctor.98 However, I was interested in the potential involvement of  stress  – and in 
particular in how it might influence degree of obesity, cardiovascular co-morbidities such as 
blood pressure and lipids; and moreover how stress might be associated with long-term 
cardiovascular risk within groups of obese children. As the fellow in The HELP trial I used the 
opportunity to investigate this question as part of the thesis. In this chapter I will explore 
the concept of stress and examine current knowledge on its association with obesity in 
children and adolescents; and then finally provide the rationale for further investigation 
presented in this thesis. 
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2.2 Stress and a potential relationship between stress, obesity and the 
metabolic syndrome 
The concept of stress comes originally from the physical sciences, with a stressor being a 
force that can act upon a system and cause change. The maintenance of biological systems 
within certain conditions against a stressor was first recognized and referred to by Cannon 
in 1929 as “homeostasis” which is now accepted as a fundamental principle in biology.99 
Seyle was the first to use the word “stress” in this biological context and developed the idea 
that rather than stress responses being simple relationships in single systems, the number 
of stressors, environmental changes and number of systems involved in maintaining the 
physiology due to a stressor within an animal is more complex – with a number of systems 
potentially involved.100 The ability for an animal to control its physiology through complex 
changing environments using multiple systems was later referred to as “allostasis”.101 This is 
characterized by complex systemic responses to multiple factors, importantly with the 
overall aim to maintain systems, like many biological systems, in the short term, ultimately 
with the aim of securing short term survival. The consequence of response and adaptation 
to stress therefore may be helpful in the short term but might lead to the development of 
longer-term consequences, which are potentially deleterious to health. 101 102 The concept 
that by adapting to stressors in the short term can lead to deleterious effects in the long 
term has produced a large body of research,100 and several journals dedicated to the study 
of stress in medicine now exist. In humans, stressors can be physical, behavioral and 
psychological; and the responses to them can be physical, physiological and behavioral.100 
Stressors are appraised by the CNS, processed and translated into both behaviours and via 
the physiological “stress response” through the hypothalamic-pituitary axis (HPA) and 
sympathetic nervous system (this is conceptualized graphically in figure 2.1). It has been 
hypothesized that stress may be a causal factor in obesity, and I examine this hypothesis 
further here.  
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Figure 2.1 : Conceptualization of how stressors can interact with physiological processes 
and lead to obesity and the metabolic syndrome 
Diagram illustrating how stressors can affect behaviour, and interact with the HPA axis and 
sympathetic nervous systems. The diagram also shows how these interactions can be measured at 
each level. 
 
 
One mechanism by which stress might influence body habitus is by influencing eating 
behaviour. This topic was recently systematically reviewed and meta-analysed by Hill et al. 
They pooled 13 studies including 28,070 participants aged 8-18 years and found that overall 
there was no association between stress and change in eating behaviour.103 However when 
they separated their analyses to look at younger and older children they found that stress 
was negatively associated with healthy eating in older children. Interestingly, the impact of 
stress was independent of type of stress measure or stressor.    Groups of children without 
obesity undergoing stress testing have shown higher levels of cortisol, and those with such 
cortisol responses have been shown to eat more in the absence of hunger,104 a finding 
which has also been demonstrated on stress testing in adults.105  
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It has also been postulated that chronic stress, mediated by prolonged stimulation of the 
hypothalamic-pituitary-axis (HPA), may also be an important factor in the development of 
obesity and associated cardiovascular co-morbidity,106-109 with the example of Cushing’s 
syndrome (where pathological excess of cortisol causes central adiposity, hypertension, 
insulin resistance and dyslipidemia) being used as an analogy.106 110 Peckett et al111 
performed a review of the literature looking at the effects of glucocorticoids on lipid 
metabolism, in particular the effects on adipose tissue, and highlighted that glucocorticoids 
stimulate the conversion of pre-adipocytes to mature adipocytes, thus having a role in 
adipose hypertrophy. Evidence from an animal study involving rats have shown that rats 
subjected to stress for a month subsequently developed larger adipocytes and tended to 
place fat centrally.112 Increased sympathetic nervous system activity might independently 
contribute to hypertension, insulin resistance and dyslipidaemia in obesity as part of the 
stress response,109 as well as influencing production of inflammatory cytokines.113 
Mechanisms linking the HPA-axis and sympathetic nervous system have also been 
proposed.114  
 
In research, stress has been measured by objective exposure to potential stressors or more 
subjective perceptions of stress in questionnaires by individuals,115 116 and also by measuring 
physiological markers such as cortisol117 and catecholamines.109 Of particular interest in 
health research is the cortisol awakening response (CAR). Cortisol secretion is known to be 
diurnal, with greater levels in the morning and lowest in the late evening.118 However, in 
most individuals, waking from sleep is accompanied by an increase in cortisol secretion 30-
45 minutes after waking see in Cortisol secretion.119 The CAR has been used to examine 
cortisol secretion using salivary cortisol techniques in stress research by measurement of 
rate of increase and area under the curve, and this has been used as a proxy for cortisol 
reactivity in stress, in particular in obesity.119 120 
2.3 Key adult reviews on stress and obesity 
There have been two important systematic reviews in adults of high relevance to this thesis 
looking at the potential relationship between stress and obesity: 
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1. Wardle et al121 systematically reviewed and performed a meta-analysis of 14 
longitudinal studies in adults looking for a relationship between stress and adiposity. 
Stressors were measured in studies using self-report questionnaires (for example 
perceived stress) and also objective stress exposure (for example job stress). Though 
there were variable findings between studies, on pooling all 14 studies, they found 
that stress was positively associated with obesity, though the effect size was small. 
Interestingly they also found no differential relationships between stress and 
location of obesity  (central adiposity versus total body obesity); they also found an 
interaction between stress, sex and obesity such that the association was greater in 
men compared to females. 
2. Incollingo Rodriguez et al120 systematically reviewed the adult literature on the HPA 
axis in obesity to look for evidence of dysregulation. They identified 34 relevant 
papers. They reported that for the cortisol awakening response, there were differing 
findings. 5 studies reported a negative relationship between obesity and the CAR, 2 
an exaggerated response and 2 studies with no relationship. They highlighted that all 
of these studies were cross-sectional and so did not examine for longitudinal 
relationships, which are important when trying to understand interactions and 
possible causal relationships. They also found 9 studies which looked at total daily 
cortisol production (using urine, blood and salivary cortisol). Again the findings were 
conflicting with around half showing raised cortisol and half normal or low. One key, 
consistent finding was that cortisol reactivity – in this case a spike in measured 
cortisol during stress – was greater in studies which investigated obese versus non 
obese responses; in particular abdominal adiposity seemed to be linked with cortisol 
reactivity. The overall conclusion of this paper was that the findings were 
inconsistent, and largely limited by quality of published data (given the paucity of 
longitudinal data, control for sex and chronicity of stress). 
As presented above, much of the published literature examining a relationship between 
stress, obesity and the MetS has been conducted in adults, or outcomes of childhood stress 
in adulthood.122-124 However, data for associations within childhood have begun to emerge, 
but have not yet been systematically reviewed. As part of my exploration  of the topic and 
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to plan investigation in this thesis, I led a systematic review of the literature for associations 
between measures of stress and obesity with or without the MetS specifically in childhood 
and adolescence (<18 years). 
2.4 Stress, obesity and the metabolic syndrome in children and young people: 
systematic review  
2.4.1 Systematic Review Methods  
 
Data sources and search strategy 
 
An initial systematic search (round one), was performed in July 2011 by myself with (Dr) 
Leena Zhou who was a visiting medical student to our department. This was updated 
without a second researcher by myself alone in September 2017 (round two) from 2011 
where the first round had left off. In both cases Professor Viner adjudicated inclusion of 
studies. For the purpose of the thesis, the results are presented together, however in the 
methodology and search results I will separate by search round.  
 
Searches used MEDLINE, PubMed, PyschINFO and Web-of-science databases to identify 
studies in childhood and adolescents under 18-years of age which investigated associations 
between stress and obesity +/- one or more components of the MetS (central adiposity, 
hypertension, dyslipidaemia and insulin resistance/type 2 diabetes). Databases were 
searched from inception date to date of search. Search terms used are summarized in table 
1. Searches consisted of database specific terms (e.g. MESH) relating to stress (psychological 
and physiological) AND (obesity/ body mass index / body fat) OR (components of the 
metabolic syndrome) AND children and adolescents (or where available, age restrictions <18 
were applied to searches). They are summarized in table 2.1. 
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Table 2.1: Summary of search terms and strategy for each database searched 
 
Database 
 
Stress 
 
Obesity and MetS 
 
Age 
PubMed  
 
(n =1713) 
 
"Stress, 
Physiological"[Mesh] 
OR "Stress Disorders, 
Post-
Traumatic"[Mesh] OR 
"Stress, 
Psychological"[Mesh] 
OR "Stress Disorders, 
Traumatic, 
Acute"[Mesh] OR 
"Stress Disorders, 
Traumatic"[Mesh] OR 
"Combat 
Disorders"[Mesh] OR 
“Cortisol”[Mesh] OR 
“Hydrocortisone”[Mes
h] OR “Life 
Event”[Mesh] 
"Abdominal obesity 
metabolic 
syndrome"[Suppleme
ntary Concept] OR 
"Obesity"[Mesh] OR 
"Obesity, 
Abdominal"[Mesh] OR 
"Obesity, 
Morbid"[Mesh] OR 
“Hyperlipidemias"[Me
sh] OR “Type 2 
Diabetes 
Mellitus"[Mesh] OR 
“Cardiovascular 
Diseases"[Mesh] OR 
“Dyslipidemias"[Mesh
] OR 
“Hypertension"[Mesh] 
OR “Body Mass 
Index"[Mesh] OR 
“BMI"[Mesh] 
"Child"[Mesh] OR 
"Disabled 
Children"[Mesh] OR 
"Adult 
Children"[Mesh] OR 
"Homeless 
Youth"[Mesh] OR 
"Child of Impaired 
Parents"[Mesh] OR 
"Child, 
Orphaned"[Mesh] OR 
"Only Child"[Mesh] OR 
"Child, 
Unwanted"[Mesh] OR 
"Child, 
Preschool"[Mesh] OR 
"Child, 
Institutionalized"[Mes
h] OR "Child, 
Hospitalized"[Mesh] 
OR "Child, 
Abandoned"[Mesh] 
OR 
"Adolescent"[Mesh] 
OR "Adolescent, 
Institutionalized"[Mes
h] OR "Adolescent, 
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Database 
 
Stress 
 
Obesity and MetS 
 
Age 
Hospitalized"[Mesh]  
PsychINF
O 
(n= 53) 
Cortisol or 
Hydrocortisone or 
Physiological Stress or 
Post-Traumatic Stress 
Disorders or 
Psychological Stress or 
Acute Traumatic 
Stress Disorders or 
Traumatic Stress 
Disorders or Combat 
Disorders or Life Event 
Abdominal obesity 
metabolic syndrome 
or Obesity or 
Abdominal Obesity or 
Morbid Obesity or 
Hyperlipidemias or 
Type 2 Diabetes 
Mellitus or 
Cardiovascular 
Diseases or 
Dyslipidemias or 
Hypertension or Body 
Mass Index or BMI 
Limit to: childhood 
<birth to 12 years> or 
adolescence <13 to 17 
years> 
 
 
(Also limited humans 
and English language) 
Medline 
(n= 944) 
Cortisol or 
Hydrocortisone or 
Physiological Stress or 
Post-Traumatic Stress 
Disorders or 
Psychological Stress or 
Acute Traumatic 
Stress Disorders or 
Traumatic Stress 
Disorders or Combat 
Disorders or Life Event 
Abdominal obesity 
metabolic syndrome 
or Obesity or 
Abdominal Obesity or 
Morbid Obesity or 
Hyperlipidemias or 
Type 2 Diabetes 
Mellitus or 
Cardiovascular 
Diseases or 
Dyslipidemias or 
Hypertension or Body 
Limit to : all child 0-18 
years 
 
(Also limited humans 
and English language) 
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Database 
 
Stress 
 
Obesity and MetS 
 
Age 
Mass Index or BMI 
Web Of 
Science 
(n = 231) 
 
TS=(Cortisol) OR 
TS=(Hydrocortisone) 
OR TS= (Physiological 
Stress) OR TS=(Post-
Traumatic Stress 
Disorders) OR 
TS=(Psychological 
Stress) OR TS=(Acute 
Traumatic Stress 
Disorders) OR 
TS=(Traumatic Stress 
Disorders) OR 
TS=(Combat 
Disorders) OR TS=(Life 
Event) 
TS=(Abdominal 
obesity metabolic 
syndrome) OR 
TS=(Obesity) OR 
TS=(Abdominal 
Obesity) OR 
TS=(Morbid Obesity) 
OR 
TS=(Hyperlipidemias) 
OR TS=(Type 2 
Diabetes Mellitus) OR 
TS=(Cardiovascular 
Diseases) OR 
TS=(Dyslipidemias) OR 
TS=(Hypertension) OR 
TS=(Body Mass Index) 
OR TS=(BMI)  
 
 
TS=(Child) OR TS= 
(Disabled Children) OR 
TS=(Adult Children) 
OR TS=(Homeless 
Youth) OR TS=(Child of 
Impaired Parents) OR 
TS=(Orphaned Child) 
OR TS=(Only Child) OR 
TS=(Unwanted Child) 
OR TS=(Preschool 
Child) OR 
TS=(Institutionalized 
Child) OR 
TS=(Hospitalized 
Child) OR 
TS=(Abandoned Child) 
OR TS=(Adolescent) 
OR 
TS=(Institutionalized 
Adolescent) OR 
TS=(Hospitalized 
Adolescent)  
*MeSH terms 
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Selection of studies 
In the first round (up to 2011) two reviewers (LH and LZ) screened abstracts identified in 
searches simultaneously to select studies meeting inclusion criteria for retrieval. In round 2, 
I alone selected studies but Professor Viner adjudicated in both rounds.  
Inclusion criteria were: 1) any study design except protocol papers, opinion papers or 
reviews (unless a systematic review); 2) studies investigating associations of stress and 
obesity (+/- MetS components) outcomes only in childhood and adolescents under 18 years 
of age (thus studies mixing children and adults in analyses or studies looking at the 
association of childhood stress and outcomes in adulthood were excluded); 3) studies 
measuring either psychological (by validated questionnaire or laboratory induced stress) or 
physiological (non-oxidative) stress involving the HPA or sympathetic nervous system; 4) 
studies using currently accepted criteria for obesity in childhood, i.e. centile (or equivalent z-
scores) for body mass index (BMI) at least ≥95th centile; 5) in studies investigating MetS 
components, participants must also have had obesity; 6) studies in English language and 
involving human subjects only.  
 
Exclusion criteria were: 1) Studies involving participants with genetic, syndromic or 
endocrine causes of obesity; 2) Studies which used self-reported rather than actual 
measured values to calculate BMI; 3) Psychological studies which reported perceptions of 
stress by a parent or guardian or exposure assessed as single events, not using a validated 
life event scale. 
 
Selected studies were then retrieved and independently reviewed by two reviewers (LH and 
LZ) in the first round, and just by myself in the 2nd round to: i) ensure inclusion criteria were 
met; ii) identify outcomes in each study and iii) critically appraise each paper. Information 
extraction and appraisal for each paper was done using a proforma as shown in tables 2-3, 
with reference to published guidelines on systematic reviews in etiological questions.125 
Reviews were also searched for additional eligible studies, as were reference lists of 
retrieved studies. Agreed final studies were selected for inclusion and findings were 
adjudicated by a third researcher (RV) for both rounds.  
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2.4.2 Systematic review results 
In the first round initial database searches yielded 2941 abstracts; 179 were retrieved for 
further review; 13 studies were identified for inclusion (see figure 2.1). In the second round 
database searches yielded 1285 abstracts; 63 were retrieved for further review and 8 were 
selected for inclusion (see figure 2.2). Studies are summarized in tables 2.2 and 2.3. Thus a 
total of 21 studies were included in the systematic review after both rounds. No additional 
studies were identified from reviews or hand-searching of retrieved papers. No randomized 
controlled trials were identified. 18 of the 21 studies included were cross-sectional and 3 
had some longitudinal component (though most also presented cross sectional data in 
addition at baseline): 12 used controls, or at least a control group within a cohort (with 
healthy weight). Thirteen of the included papers were from the USA and 8 were from 
Europe (Netherlands x 2, Germany, Sweden, Greece, Italy, Turkey and one paper was joint 
Anglo-French). Papers were published between 1991-2015.  
 
Findings are presented narratively with studies split into those looking for associations 
between stress and obesity and 1) physiological measures of stress and; 2) psychological 
measures of stress. All studies are summarized in tables 2.2 and 2.3. 
 
1. Physiological measures of stress  
Seventeen studies reported various measures of human cortisol126-142 (split below into 
blood, urine and saliva) with one study also investigating the sympathetic nervous system 
axis.133 Seven papers compared obese children to healthy weight children, two investigated 
within groups of obese children. All but two of the studies were of very small numbers; most 
did not analyze males and females separately, nor stratified by pubertal status. In 6 studies 
obese participants were recruited from patients of clinical obesity/medical services; in 1 
study participants were from a community cohort; in 3 studies it was unclear how patients 
had been recruited. Age ranges of children were from 5 years to 15 years, and would 
therefore have included a range of pubertal stages. 
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Cortisol levels from blood samples  
 
Five studies examined blood cortisol and obesity. In one of two papers identified, Chalew et 
al (1991)126 found that in a small group (n=16) of 5-16 year olds with obesity, 24-hour total  
integrated plasma levels of cortisol (IC-F) measured by repeated sampling were lower 
compared to data from lean children reported in a previous study. There was however no 
correlation between actual BMI and IC-F in those with obesity, nor was there any significant 
change in IC-F in a subgroup who were placed on a low caloric dietary regimen (though 
there were no measures of either compliance with the diet or effect on body mass index). In 
a second paper by the same author, Chalew et al (1997)127 reported that both integrated 24-
hour cortisol and cortisone levels (IC-E: a less active metabolite of cortisol) in a small sample 
of 10-15 year olds with obesity was lower than a small group of similarly aged lean controls 
(p<0.04).  
Misra et al131 reported no differences in mean overnight cortisol levels in 15 obese females 
aged between 12-17 years and 30 sex and bone-age matched healthy weight controls. 
Eliakim et al133 looked for differences between a small group of obese male and female 
children all aged between 12-13 years and similarly aged non-obese controls in fasting 
morning blood cortisol and blood cortisol levels immediately and again, 180 minutes post a 
30-minute exercise 
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Figure 2:1 Summary of searches for 1st round systematic review 
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Figure 2:2 Summary of searches for 2nd round systematic review 
 
 
regime. No differences were found in either fasting or post exercise cortisol between 
groups. Reinehr et al studied a small number of obese versus healthy weight children 
matched for age, sex, and puberty in a community lifestyle intervention; children were aged 
8.5 +/- 2.1 years.142 They measured serum glucocorticoids at baseline and then at follow up. 
They found that glucocorticoids were significantly higher in the obese versus controls at 
baseline, including cortisol and cortisone; and interestingly the children with obesity who 
lost weight at follow up showed a significant drop in cortisol levels compared to baseline. 
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Four studies looked for associations between blood cortisol values and components of the 
MetS in the context of obesity. Misra et al131 reported a positive association between the 
log mean overnight cortisol and amount of visceral adipose tissue (on MRI) (r=0.53,p=0.01) 
in obese and non-obese children combined, but this was not significant in the obese 
children alone. In a regression model controlling for BMI-SDS, log mean cortisol was 
independently associated with subcutaneous adipose tissue (p=0.02) in all children but not 
visceral adipose tissue. The log mean cortisol also correlated positively with HOMA-IR 
(r=0.56,p=0.004) and fasting triglycerides (r=0.41,p=0.046) in all children. Barat et al134 
studied a group of pre-pubertal obese children from 2 centres and found no correlation 
between first morning blood (fasting) cortisol and Adrenocorticotropic hormone (ACTH) and 
whole body fat mass (as measured by DEXA), but when adjusted for measures of whole 
body fat mass, first morning cortisol was positively correlated with truncal fat mass (r=0.38, 
p<0.05), fasting cholesterol (r=0.41, p<0.05) and triglycerides (r=0.44,p<0.05) but not 
HOMA.  Sen et al132 measured fasting morning blood cortisol and ACTH in 241 obese 2-17.6 
year old males and females and found that both mean fasting cortisol and ACTH were higher 
(p=0.023 and p=0.04s respectively) in the 44% of participants who met criteria for the MetS 
(using contemporaneous WHO and National Cholesterol Education Program Adult 
Treatment Panel-III guidelines). There was a positive correlation between ACTH and weight, 
blood pressure and fasting glucose in all children. However, only a weak positive correlation 
was found between fasting cortisol and systolic BP(r=0.12, p=0.05). Guzzetti et al141 studied 
1027 children and adolescents with obesity in an endocrine clinic. They divided their 
subjects into 3 groups by age: (1) 6 – 10 years, (2) 10-16 years and (3) 16-18 years. Looking 
at all subjects, they found blood cortisol was weakly associated with both diastolic and 
systolic blood pressure (when controlled for age, gender, puberty and BMI z). In the younger 
and middle age groups, cortisol was positively associated with fasting glucose, blood 
pressure and HOMA (after adjustment for age, sex, puberty and BMI z). Associations were 
weak. 
 
Urinary cortisol 
Four studies explored urinary excretion of cortisol and obesity. Russell et al128 reported 
higher levels of 24-hour urinary free cortisol (UFC) in a small group of obese 12-18 year old 
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females versus lean controls matched for pubertal stage and bone age (p=0.03). Misra et 
al128 also found higher levels of UFC in obese females compared to controls (p = 0.02) and 
that log UFC correlated with BMI z-score in obese females (r=0.633, p =0.01) and in obese 
and non obese combined (r=0.54, p=0.002).  
 
Three studies looked for associations between urinary cortisol and components of the MetS 
in the context of obesity. Russell et al128 found that UFC levels within obese subjects 
predicted higher highly sensitive CRP and Il-6 levels (when controlled for fat mass).  Misra et 
al131 found no association between UFC and visceral fat distribution or cardio-metabolic 
blood components of the metabolic syndrome (HOMA-IR and fasting lipids). Barat et al134 
(see above) did not find any association between 24-hour UFC and %body fat (by DEXA), 
measures of fat distribution nor fasting cardio-metabolic bloods (lipids and HOMA) in a 
subgroup of the obese children in their study. 
 
Salivary cortisol 
 
Eight studies investigated salivary cortisol and obesity, with two studies reporting 
longitudinal investigation. Rosmalen et al130 measured salivary cortisol at waking and 30 
minutes later (the cortisol awakening response) in a large number of male and female 
children (1768) aged 10-12 and as a part of their study, looked for associations with body 
mass index, although the proportion of children with obesity was small (2.5%). On analysis 
of all participants, no association was found between any salivary cortisol measure and BMI. 
However on separate analysis of females, there was a very small correlation between BMI 
and Area under the curve (AUC) between time 0 and 30 min cortisol (r=0.02, p=0.04). Tukey 
HSD analysis also showed greater cortisol levels at 30 minutes after waking in obese children 
as a group compared to non-obese (p=0.02) and AUC between time 0 and 30 was greater in 
obese compared to normal BMI children (p=0.04). Hershberger et al129 compared salivary 
cortisol levels throughout the day (including before and after meals and before and after 
exercise) in 10 obese male and female children (at either Tanner stage 1 and 2) with 11 non-
obese Tanner matched controls. No differences in fasting morning salivary cortisol levels 
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were found between groups and a normal diurnal pattern was seen in both groups. 
However, a mean increase in cortisol post-lunch was greater in the obese group (p<0.05). 
Mean cortisol decreased post exercise in the obese group compared to a rise seen in the 
non-obese group (p<0.05). Barat et al134 (see above) also measured salivary cortisol at 8am, 
11:30 and 12:00 in a subgroup of the obese children in their study. No association between 
morning salivary cortisol values were found with %body fat (by DEXA), body distribution or 
fasting cardio-metabolic bloods. Interestingly, a negative association was found between 
the salivary cortisol response to lunch (change between 11:30 and 12:30) and truncal fat 
mass (r=-0.43, p<0.05) in all children, but more prominently in females (r=-0.78, p<0.05). 
Guseman et al140 measured salivary cortisol levels across the day in a small number of 
adolescents with obesity and calculated total area under the curve (i.e total cortisol 
secretion through the day). They found that mean area under the curve cortisol did not vary 
by sex, or severity of obesity (comparing >95th centile BMI with >97th centile and >99th 
centile). There was no difference in area under the curve cortisol for those with the 
metabolic syndrome versus those who did not. Pervanidou et al 139 examined children in an 
obesity clinic and compared them to healthy weight controls. They measured salivary 
cortisol throughout the day (5 times per day) and created an area under the curve for 
analysis. They found that AUC for cortisol was lower in the obese group – however this 
significance was lost when controlled for age, gender and BMI z. Kjolhede et138 al measured 
salivary cortisol in 342 children aged 6-12 recruited from community schools at three time 
points, morning, afternoon and evening. They found that cortisol levels were lower in the 
obese than healthy weight when grouped by BMI category. 
 
Two studies provided longitudinal investigations using salivary cortisol. Hill et al137 measured 
awakening cortisol (single sample) in 649 children entered into a community based 
intervention to prevent weight gain, of which 12.8% had obesity at baseline. They compared 
means (adjusted for age) for morning cortisol between healthy weight and obese subjects 
(including separating by male and females) and found no statistical difference. Within the 
obese group at baseline, there was a weak, positive association between baseline salivary 
cortisol and both waist circumference and BMI z increase following the intervention. Ruttle 
et al135 measured salivary cortisol for 3 consecutive days running in children with measures 
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after waking, mid afternoon and evening salivary cortisol. They repeated these measures in 
the same individuals at ages 11, 13, 15 and 18 years. They found that there was a negative 
association between cortisol measures (in terms of time of day and also changes through 
the day) at proceeding ages and BMI at the next age (e.g. cortisol at 11 years and impact on 
BMI at age 13), including longitudinal cortisol on 18 year olds. Whilst their analyses were 
across all BMI groups (only around 10% at each age were obese), they did repeat analyses 
within obese group and found the same findings.  They also found that cortisol and pubertal 
stage was only associated at age 13, not other ages. This paper is important for the thesis 
because they used longitudinal, repeated measures to assess the relationship of cortisol 
with BMI, and used multi-level modeling – however they do not appear to have used 
longitudinal data with time as panel data, but rather as changes between groups between 
preceding and following year. 
Hair cortisol. 
Veldhorst 136compared scalp hair cortisol levels in 20 obese children with sex matched 
controls of similar age and found greater cortisol levels in the hair of obese children. 
 
Blood Catecholamines  
In addition to measuring cortisol, Eliakim et al133 (see above) measured blood 
catecholamines before and after a 30-minute exercise regime and found that 
catecholamines increased in greater amounts in non-obese children during exercise, though 
there were no differences in the baseline values. 
 
2. Psychological studies 
Only four studies meeting inclusion criteria used psychological assessments to measure 
stress and investigate for an association with obesity. Only one study looked at a 
component of the MetS in the context of obesity and stress. All studies investigated specific 
groups of obese patients involved in clinical obesity services. Only one study attempted to 
compare stress between a group of obese patients and healthy weight controls. 
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Stress measured using questionnaires 
 
Kubiak et al143 asked a small group of obese 14-17 year old females to record frequency of 
perceived daily hassles on electronic diaries whilst an inpatient for an obesity program and 
to also record frequency of associated rumination about eating. A mixed regression model 
showed a significant interaction between rumination and number of hassles (p<0.05) – the 
implication being that daily hassles was a measure of stress and thus its association with 
rumination would lead to increased eating with consequent impact on body mass. Zeller et 
al144 measured self-reports in an outpatient setting (using appropriate child and adolescent 
stratified questionnaires), one component of which measures self-perceived social stress. 
Regression analysis showed no significant relationship between social stress scoring and 
BMI z-score in both children and adolescents. Porter et al145 asked 135 children aged 
between 11-17 presenting to an obesity clinic to self-report if they felt a stressful event had 
triggered weight gain in their history – 66% reported an event. No further analysis or 
associations were made with regard to BMI or MetS. 
Response to induced psychological stress 
 
Ribeiro et al146 studied the blood pressure and forearm vascular conductance responses 
during an induced mental stress test in 39 obese children compared to 10 healthy weight 
controls. Mean blood pressure increased in obese children, but not healthy controls 
(p=0.01); there were no changes in heart rate. Obese participants were then placed on a 
diet and exercise regime and responses re-measured 4 months later after which time there 
was no difference between BP changes in obese compared to healthy controls following a 
mental stress test. 
2.4.3 Systematic review discussion 
At the time of writing, I believe this is the first systematic review on the potential role of 
stress in childhood obesity and the MetS. The first key finding was that the findings in 
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studies were inconsistent, and secondly most studies were cross-sectional and of low 
quality.  
 
A number of methods of measuring cortisol were used. Of the 5 studies investigating blood 
cortisol – 2 found lower levels in the obese, 2 no difference and 1 higher. However, results 
of analyses in studies examining the metabolic syndrome components within obese groups 
found positive associations. Of 4 studies investigating urinary cortisol levels, half found 
higher levels in obese participants and half found lower. Salivary cortisol measures were of 
particular interest to me as they allowed ambulatory measurements at different time 
points. Again findings were varied however, with most studies finding little difference cross-
sectionally, or difference in metabolic syndrome components. 
 
Within the psychological papers, only one study compared self-reported stress between an 
obese and non-obese group of children and found no differences. None of the papers 
included a measure of cortisol and psychological measures. 
 
The studies identified in this systematic review possess a number of methodological issues 
that may potentially introduce bias, and are of relevance to the design of my study included 
in this thesis. Most studies involved small numbers and recruited subjects from clinical 
settings. Some studies provided no explanation of how they had recruited participants. 
Longitudinal studies were few, and even in those that were longitudinal, baseline or 
previous time point values of cortisol were used to predict the next time point obesity 
measure, or cardio-metabolic marker; there was no use of more complex multi-level 
modeling using time in models. This leads to weaknesses in analysis associated with missing 
data and by grouping all participants together at set time points does not allow for 
differential gaps in measuring points over time. In addition, presence of components of the 
MetS and weight status may change within individuals overtime during adolescence,147  thus 
mathematical modeling needs to be more considerate of change in more complex ways.  
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Although some studies matched controls for sex, age and pubertal stage, a number of 
studies combined all three in analyses. This is problematic given the differential findings in 
some adult studies between sexes, and that cortisol levels may vary by both pubertal stage 
and age in the normal population.130 148-150   
 
The search strategy aimed to identify associations within the context of obesity and 
therefore a number of studies were excluded which combined overweight with obesity, or 
inappropriately defined obesity, reducing the number of studies in our review. The search 
strategy deliberately looked for papers that measured only self-reports of stress or 
physiological measurement within individuals. We therefore excluded a number of papers 
that reported exposure to potential stressors, as well as papers using parental-stress or 
parental perception of child stress. Although it is likely that some children and adolescents 
experience e.g. abuse, poor quality of life or difficult socio-economic circumstances that 
may lead to stress, there is likely to be a number of other mechanisms in addition to stress 
at work.  
 
A particular note here should be made on mental illness such as depression and anxiety. We 
did not include them as a measure of stress – and this is because whilst mental health 
problems can be stressors, they are not synonymous with stress. This is important to my 
thesis, because I measure and treat stress and mental health separately in analyses in this 
thesis (see below). Moreover, separate bodies of literature exist for the associations of 
obesity with mental health151 and with child abuse.152 Exclusion of parental report also limits 
the measurement of stress in very young children and children with disabilities. 
Physiological markers of stress may therefor be of particular value in measuring stress in 
such groups.  
I will also highlight one study here that was found during searches, but was not included in 
the thesis because it combined overweight and obese participants; yet provides an 
important theme for the thesis. Toledo et al measured cortisol using saliva and blood 
through the day and measured carotid artery intima-media thickness in a group of black and 
Hispanic overweight adolescents, and found that some measures of cortisol were associated 
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with increased arterial thickening in this group.153 As far as I am aware, at the time of 
writing, this is the only paper which examines a relationship of stress, either using 
physiological or psychological measures and arterial stiffening within the context of obesity 
in children and young people.  
 
2.5 Implications of findings presented in chapter two for the thesis 
This chapter has outlined the hypotheses linking stress to obesity, but also the existence of 
cardio-metabolic risk markers within the context of obesity and stress. I used salivary 
cortisol measures within the group of adolescents with obesity to measure possible 
relationships within this group and degree of obesity and co-existing cardio-metabolic risk 
markers. The use of salivary cortisol allowed ambulatory results from the participants, which 
provided information about cortisol profile throughout the day. I also decided to use a 
validated questionnaire for exposure to stressful events (the A-file : see 3.10.1) within the 
group. Importantly I wanted to study relationships not just at baseline, cross-sectionally, but 
also changes over time using more complex modeling of change over time.  By using a 
questionnaire focused on eating, I was also interested in understanding how much stress 
might be associated with eating behaviour, in particular level of binge eating, within an 
obese group of adolescents. I therefore wanted to address the following questions: 
 
1. Within the obese group of adolescents who took part in the HELP trial, what 
relationships existed between degree of obesity, conventional measures of 
cardiovascular risk such as blood pressure and lipids, pulse wave velocity  and 
physiological measures of stress (salivary cortisol) and measures of exposure to 
stressful events at cross-sectional and longitudinal levels? In particular, how do 
changes in stress measures, relate to changes in PWV, adiposity, blood pressure and 
other blood measures over time. 
 
2. What relationship, if any, was there between measures of cortisol and the validated 
questionnaire for stress exposure ? 
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3. What relationship, if any, was there between stress and binge eating behaviours? 
 
4. What relationships, if any, were there between measures of stress and measures of 
mental health co-morbidities within the group of adolescents? 
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Table 2.2: summary of studies of physiological measures of stress and obesity 
 
Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
Chalew 
(1991) 
CS:CC 
 
16 obese (5.3-
16.8yrs) 
recruited from 
hospital obesity 
clinic 
30 (7-17 year 
olds) controls 
with BMI range 
SDS ≥ -2  ≤ 2 
 controls 
Described in 
previous 
studies but 
unclear how 
recruited.  
No No Blood : 24 hour 
integrated  
cortisol(IC-F) 
(continuous 24 hour 
draw totalled) 
Lower IC-F in obese versus 
lean (t-test p<0.0001). No 
correlation  between BMI and 
IC-F. Low calorie diet in a small 
number re-measured later did 
not alter IC-F. 
Commented on similar 
findings in adult studies. 
Speculated that low 
cortisol may be a 
response to 
hyperinsulinism found in 
obesity. 
Chalew 
(1997) 
CS: CC 9 obese 
(12.3yrs +/- 3.2) 
recruited from 
hospital obesity 
15 non-obese 
with BMI range 
SDS ≥ -2  ≤ 2 
(12.7 yrs +/- 
Mixed but 
used sex as 
a variable in 
regression 
No Blood: 24 hour 
integrated  
cortisone (IC-E)  i.e. 
continuous 24 hour 
Mean IC-E in obese subjects 
lower (t-test p<0.04). IC-E 
levels highly correlated with 
the IC-F levels (p<0.0001).  
Concluded that IC-F 
converted to cortisone 
thus levels of cortisone 
lower in obesity due to 
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Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
clinic.  2.2). Described 
in previous 
studies but 
unclear how 
recruited. 
model draw totalled.  Multiple regression model for 
total IC-E using BMI SD and 
sex showed lower IC-E levels 
with increasing BMI SD 
(p<0.0054); more prominent 
in boys (p<0.043) 
lower IC-F.  
Hershberger 
(2004) 
CS:CC 10 obese 
(9.4yrs +/- 0.2;)  
Note controls 
<75th centile 
11 non-obese 
(<75th centile 
BMI) (age 9.2 
+/-0.7) 
No All cases and 
controls 
Tanner stage I 
or II and very 
close age. 
Salivary cortisol  
fasting 0900, then 
post-breakfast; pre-
and post 30 min 
exercise ; then pre- 
and post lunch 
(Enzyme 
immunoassay) 
No difference between fasting 
morning cortisol values. Mean 
change post-breakfast greater 
in obese group (t-test, 
p<0.05); Mean salivary cortisol 
decreased in the obese group 
post exercise, but increased in 
non-obese (p<0.05). Similar 
increases after lunch. Normal 
diurnal variation observed in 
both groups 
Paper’s predominant 
investigation was 
relationship between 
lipolysis and obesity and 
if it was related to 
cortisol. No relationship 
found – additional 
differences in cortisol 
between obese and lean 
groups highlighted here. 
 
100 
Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
Rosmalen 
(2005) 
CS: CH 1768 total 
2.9% obese. 
All children 
recruited from 
a population 
cohort study of 
children. This 
study at one 
assessment. 
Age range 
11.08 yrs(SD 
0.55) 
84.9%  <85th 
centile;12.2% 
>85th centile 
<95th 
Differences 
for whole 
group 
looked at, 
but not for 
analyses 
shown here. 
Each 
participant 
graded by 
Tanner 
pubertal 
stage. Looked 
at pubertal 
differences 
for whole 
group and no 
differences 
found within 
the group of 
cortisol 
findings by 
pubertal 
stage. 
Salivary cortisol at 
waking (07:00) and 
then 30 mins later 
(07:30)(morning 
response) and then 
at 20:00. 
(immunoassay) 
Values used to 
produce changes 
between times  and 
Area under curve 
(AUC). 
Tukey HSD showed 
significantly higher salivary 
cortisol levels 30 mins after 
waking between normal and 
obese (p= 0.015) and between 
overweight and obesity 
(p=0.043). AUC was 
significantly greater between 
normal and obese (p=0.006) 
and between overweight and 
obese (p=0.046). 
(Note- Other than that 
presented here : most 
analyses looking at BMI and 
saliva included obese, 
overweight and normal weight 
together) 
Main emphasis of trial 
was to look at HPA axis 
though salivary cortisol 
in cohort group and for 
influences. Analyses 
across all BMIs did not 
find significant 
relationship between 
any salivary cortisol 
values and BMI (no 
other metabolic factors 
measured); differences 
found at different BMI 
categories was not main 
focus and not much 
comment in the paper. 
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Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
 
Eliakim 
(2005) 
CC 25 obese (12.3 
+/- 0.5)  
Obese and non-
obese 
participants 
recruited by 
exercise 
research centre 
but no details 
on how or form 
where. 
25 healthy 
weight : BMI 
3.5-77.8th 
centile (12.8+/-
0.5; 12 male) 
No No Fasting blood 
cortisol taken in the 
morning, and then 
again immediately 
post, and 120 mins 
post, using an 
exercise protocol 
and Blood 
catecholamines 
(epinephrine, 
norepinephrine, 
dopamine). Fasting 
first morning pre- 
and then 
immediately post 
and  120 mins post 
an exercise protocol 
No differences between 
fasting, or post exercise 
cortisol levels between obese 
and non-obese groups No 
statistically significant 
differences in baseline 
catecholamines between 
obese and non-obese. 
Increases in all three 
catecholamines were smaller 
in obese children during 
exercise versus controls 
(mixed model ANOVA  
p<0.05).A negative correlation 
was found in all children 
between change in all three 
catecholamines during 
Study also looked at 
insulin and growth 
hormone changes 
during exercise but 
stress hormone results 
are presented here.The 
authors conclude that 
blunted catecholamine 
response in obese 
children during exercise 
may represent an 
underlying central 
attenuation of the stress 
response. 
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Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
by indwelling 
venous catheter 
inserted 30 mins 
prior to exercise. 
exercise and BMI centile (Dop 
r=-0.28, p=0.048;Epi r=-0.31, 
p=0.03 ; NA r=-0.29, p=0.043); 
as well as body fat% 
(measured by DEXA) (Dop r=-
0.46,p=0.0006;Epi r=-0.49, 
p=0.0004; NA -0.43, p=0.002) 
Barat (2007) CS 45 children with 
obesity (6-13 
years). 
Recruited from 
2 hospital 
obesity clinics. 
None Looked at 
mixed and 
individually 
Inclusion 
criteria pre-
pubertal 
(Tanner stage 
1) 
All children : Fasting 
blood cortisol and 
ACTH; 29 also had 
24 hour urinary 
cortisol and 0800, 
11:30 and 12:00 
salivary cortisol.  
No correlation between any 
HPA investigation and whole 
body fat mass (DEXA). When 
adjusted for whole body fat 
mass %, truncal fat mass was 
positively correlated with first 
morning cortisol in all boys 
and girls total (not separately) 
r = 0.38 (p<0.05). In all 
participants, adjusted for 
WBFM and TBFM, positive 
Noted that salivary 
cortisol did not show 
same relationship as 
blood cortisol, but that 
smaller numbers had 
been used.  Lunch 
response to cortisol 
opposite to what the 
authors have found in 
post-menopausal obese 
women (where response 
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Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
correlation between morning 
cortisol and fasting total 
cholesterol (r=0.41, p<0.05), 
and fasting triglycerides 
(r=0.44, p<0.05).  A negative 
correlation was found 
between TBFM and change in 
salivary cortisol post lunch (r= 
-0.43, p < 0.05) . In girls a 
positive correlation was found 
between glucocorticoid 
metabolites and Truncal fat 
(r=0.92, p<0.05) but not in 
males or the whole group. 
Salivary cortisol response to 
lunch not associated with 
other cardiometabolic risk in 
total group, but in boys 
negative correlation with 
same in those with 
abdominal versus 
peripheral fat). 
 
104 
Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
HOMA (r=-0.56, p<0.05). 
Sen (2008) CS 241 obese (2-
17.6yrs). 
 
Unclear where 
recruited from 
None No No blood cortisol 
(fasting) 08:00 and 
blood ACTH.  
 
All participants had obesity. 
Those with MetS (43.9% of 
participants) *3 had higher 
8am cortisol and ACTH (t-test 
p=0.023;p=0.042). ACTH 
correlated positively with 
weight (r=0.13, p=0.02), 
systolic (r=0.21,p=0.002) and 
diastolic (r=0.17,p=0.01) 
pressure, fasting glucose 
(r=0.17,p=0.01). Cortisol 
weakly correlated with systolic 
pressure (r=0.12,p=0.05). 
Suggested an 
association between 
HPA activity and 
metabolic syndrome in 
children with obesity. 
Misra 
(2008) 
CS: CC 15 obese (12-
18yrs) 
30 non-
overweight 
:15-18th 
All females Bone age 
matched (and 
race 
Overnight blood 
cortisol taken every 
20 minutes from 
Blood: No significant 
difference between obese and 
control group in overnight 
Higher cortisol measures 
associated with higher 
metabolic risk, but in all 
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Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
 
Unclear how 
recruited – 
either cases or 
controls. 
centiles BMI 
(12-18yrs) 
ethnicity) 
Tanner 2 and 
3 stages of 
puberty 
23:00-08:00 (RIA). 
24 hour urinary 
cortisol measured 
same time 
(Gamma-coat I-
RIA). Fasting 
cardiometabolic 
markers also 
measured 
mean cortisol. Log UFC greater 
in obese versus controls (t-
test, p=0.02). Positive 
correlation between logUFC 
and BMI in obese girls (r=0.63, 
p =0.01) and in whole group 
(r=0.54, p =0.002). Association 
between visceral adipose 
tissue log mean cortisol 
(r=0.53, p=0.01) in whole 
group. Regression model: 
controlling for BMI-SDS 
association with log mean 
cortisol with subcutaneous 
adipose tissue (p=0.02). Log 
mean cortisol positively 
associated with HOMA-IR in all 
(r=0.56, p =0.004). UFC was 
not. Fasting triglycerides 
participants not just 
obese (however small 
numbers when 
separated). 
 
106 
Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
positively associated with log 
mean cortisol in all group 
Russell 
(2009) 
CS: CC 15 obese (12-
18yrs old)  
Unclear where 
cases or 
controls 
recruited from 
15 healthy 
weight BMI 
between 15-
85th centile 
(15-18yrs) 
All females By bone age 
(within 1 
year) and 
pubertal 
stage and 
race & 
ethnicity 
24 hour free urinary 
cortisol   
Mean UFC greater in obese (t-
test p=0.03) versus non-obese; 
In all participants, those with 
higher CRP (>3mg/l) had 
greater UFC (t-test p=0.004). 
UFC was positively correlated 
(r=0.51,p=0.05) with IL-6 
levels. In a regression model, 
controlling for regional fat 
mass, UFC was positive 
correlated with log hsCRP (r2 
=0.24, p =0.03) in all subjects; 
and logIL-6 in obese (r2 =0.03, 
p =0.04)  and all subjects (r2 
=0.35, p =0.0008) 
Concluded that urinary 
cortisol levels associated 
with markers of long 
term cardiovascular risk. 
This paper also looked at 
growth hormone levels. 
Stipulates GH def may 
impact on 11 beta 
hydroxysteroid 
dehydrogenase type 1 
activity cortisol to 
cortisone 
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Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
Ruttle  
(2012) 
Longit
udinal 
Repea
ted 
measu
res at 
11,13,
15 and 
18 
years 
cohort 
11-18, 323 at 
baseline and 
303 followed by 
age 18. BMI 
stable 
10% obese 
approximately 
throughout 
Yes, sex was 
not 
associated 
with BMI at 
next age 
Yes, greater 
pubertal 
stage 
associated 
with BMI. 
Only 
associated 
with cortisol 
at age 13 
Salivary cortisol 
over 3 days – 
morning, mid day 
and evening. 
Negative association between 
cortisol indices pre-ceding age 
with next age (eg 13 to 15). 
Most were not obese but was 
repeated in obese participants 
alone and same finding. 
Good example of 
longitudinal measures, 
however each year used 
as predictor of next not 
using time in multilevel 
model. Not clear how 
many altered from 
obese or into obese over 
time. 
Hill et al 
(2011) 
CS 
cortiso
l 
measu
res 
but 
longit
649, of whom 
12% had 
obesity at 
baseline.  Age 
6.1-12.0 at 
baseline 
82% were 
overweight or 
healthy 
weight. 
Yes. In 
comparisons 
of cortisol 
between 
obese and 
healthy, 
Mean cortisol 
at baseline 
controlled for 
age, but not 
puberty. 
Salivary cortisol. 
Single awakening 
measure. 
No difference between 
salivary cortisol in obese 
versus healthy weight. Within 
the obese group, there was 
weak association positive with 
cortisol and weight change in 
Single measures of 
cortisol used as a 
predictor of subsequent 
weight gain. 
Longitudinal therefore. 
Obese proportion were 
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Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
udinal 
BMI 
and 
waist 
measu
remen
ts. 
Obesit
y 
interv
ention
. 
done by sex. the intervention.  small. 
Kjolhede et 
al. 
(2013) 
CS 
from 
school
s in 
Swede
n 
Total of 342 
children of 
whom 8.4% 
were obese.  
Age 6-12 years 
77.3% were 
healthy weight 
Yes, no 
differences 
between 
cortisol by 
sex 
Yes, no 
differences 
between 
cortisol by 
age. 
Three samples of 
salivary cortisol 
measured at am, 
afternoon and 
evening.  
Salivary cortisol levels were 
lower in the obese at all time 
points compared to healthy 
weight. 
No pubertal controls, 
and most girls in study 
would have been in 
puberty, likely not an 
issue for boys.  
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Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
Veldhorst et 
al. 
(2012) 
CS 
from 
obesit
y 
clinic. 
20 obese 
children 10-13 
years 
20 healthy 
weight 
controls 
Sex matched 
controls 
Of similar age 
but not 
pubertally 
assessed 
Scalp hair cortisol 
levels 
Hair cortisol concentration 
was greater in obese children 
Not pubertally matched. 
Reinehr et 
al (2013) 
Longit
udinal 
study 
followi
ng 
childre
n 
(some 
obese, 
some 
health
y 
weight
40 obese 
participants, 7-
10 
40 healthy 
weight 
controls, 
matched for 
gender, age 
and pubertal 
stage 
Controls 
matched for 
age, sex and 
pubertal 
stage 
Controls 
matched for 
age, sex and 
pubertal 
stage 
Serum steroid 
hormones 
Obese children had higher 
glucocorticoids in serum at 
baseline, and the obese 
children who lost weight 
showed a drop in the serum 
glucocorticoids. 
Longitudinal change in 
cortisol with weight loss. 
Small numbers, well 
matched controls. 
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Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
) in 
comm
unity 
lifestyl
e 
interv
ention 
Guzzetti et 
al (2014) 
CS.Pat
ients 
from 
an 
endoc
rine 
clinic 
1027 children 
and 
adolescents (6-
18 split into 
groups for 
analysis) 
None Yes analyses 
controlled 
for sex  
Age and 
puberty both 
adjusted for 
in analyses 
Blood cortisol Blood cortisol associated with 
a number of metabolic 
syndrome components – 
HOMA, blood pressure and 
fasting glucose after adjusting 
for age, gender and pubertal 
status 
Cross sectional, split into 
ages. 16-18 no 
associations but 
numbers larger for other 
age groups so likely 
power issue. 
Pervanidou 
et al 
(2014) 
CS 
salivar
y 
cortiso
110 obese 
participants, 
age 11-15 
31 healthy 
controls. Same 
age group 
Yes in 
analyses 
Age 
considered in 
analyses not 
puberty, 
Salivary cortisol, 5 
samples through 
the day used to 
create AUC for all 
Obese participants had lower 
salivary cortisol, but 
differences no longer 
significant when adjusted for 
Small numbers and so 
power likely to have 
been an issue for small 
effect sizes in adjusted 
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Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
l in an 
obese 
group 
from 
an 
obesit
y clinic 
versus 
health
y 
contro
ls 
though 
puberty 
measured 
day cortisol age and gender. analyses. 
Guseman et 
al 
(2015) 
CS. 
Patien
ts 
from a 
weight 
manag
50 obese 
patients aged 
12.3-18.9 mean 
14.8 
None Yes, no 
gender 
differences. 
30% male 
Yes. 
Considered in 
analyses, and 
no 
differences. 
Salivary cortisol  - 
measured through 
the day at time 
intervals, then area 
under curve derived 
from samples. 
Mean AUC cortisol was not 
associated with presence 
versus not of metabolic 
syndrome. Severity of obesity 
not associated with AUC 
cortisol. 
Small numbers. 69% had 
an initial increase after 
waking. 
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Author Design Numbers 
(ages); cases 
with obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately 
in analyses? 
Age or 
Puberty 
considered in 
analyses? 
Type of stress 
measurement  
Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
ement 
clinic 
KeyCC: case-control study;  CS: cross-sectional study; CH: Cohort study ; UFC = Urinary free cortisol; HPA : Hypothalamic-pituitary-adrenal axis. BMI = Body Mass Index. 
DEXA = dual-energy X-ray absorptiometry; SDS = standard deviation score; GH = growth hormone. WBTM = whole body fat mass. TBFM = Truncal body fat mass. ACTH = 
adrenocorticotropic hormone. RIA = radio-immunoassay cortisol measuring technique 
 
Table 2.3: summary of psychological papers 
 
Author Design Numbers 
(ages); 
cases 
with 
obesity* 
 
Numbers  
(ages) non-
obese 
(controls) 
Sex 
considered 
separately in 
analyses? 
Age or 
Puberty 
considered 
in analyses? 
Measure of stress Findings / other MetS 
features measured/ control 
for other confounders 
Comments  
 
113 
Zeller 
(2004) 
CS: Recruited 
from a 
pediatric 
interdisciplin
ary weight 
management 
clinic -69% of 
potentially 
eligible 
recruited  
121 
children 
(8-17 yrs) 
None No Separated 
into two 
groups: 
children 8-
11 and 
adolescents 
12-17. No 
pubertal 
consideratio
n 
Behaviour 
assessment system 
for children 
questionnaire – 
self-report (SRP-C 
and SRP-A) which 
includes a measure 
of social stress 
Intercorrelations and 
hierarchical regression 
analysis between z-BMI and 
self-report of social stress not 
significant in both children and 
adolescents. 
A number of other 
psychological domains 
examined in this paper – 
including depression, 
anxiety and reported 
parental psychological 
distress. These were not 
included in the 
systematic review. 
Riberio 
(2005) 
CC: 
consecutive 
patients 
obesity 
recruited 
from a 
hospital 
obesity 
clinic. 
 
39 
children 
  
(mean 
10yrs 
+/0.2yrs) 
10 aged 
matched lean 
controls: BMI 
<85th centile 
Unclear how 
controls 
recruited 
(mean 10+/-0.3 
yrs). 
No Age 
matched but 
no pubertal  
consideratio
n 
Mental stress test 
using a Stroop 
colour word test – 
identify colour not 
the word. Mean BP 
during test 
Mean BP increased in obese 
children but not in lean 
(graphically represented lean 
flat). Two-way ANOVA for 
changes between groups 
significant p=0.01. No 
difference in heart rate 
changes. Both diet alone and 
diet + exercise (4 months) 
reduced rise in BP in obese 
children (p<0.05) both cases, 
and were comparable to lean 
controls. 
Obese children have a 
higher BP response to 
stress event; this 
reduces after weight 
loss and weight loss with 
exercise. No exercise 
alone group included. 
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Kubiak 
(2008) 
CS. 
Participants 
on a 6-week 
inpatient 
weight 
management 
program. 
(Known to 
binge eat.) 
 
16 obese 
females 
(14-17, 
mean 
15.5 yrs). 
None All female No though 
most likely 
to be late 
puberty 
given age. 
Electronic diaries 
with prompt to 
complete 4 times 
per day for 7 days: 
i) daily hassle yes or 
no. ii) momentary 
negative mood 
(scale by Positive 
Negative Affect 
Schedule). iii) 
rumination about 
eating yes or no iv) 
current desire to 
eat (visual analogue 
scale 0 – 30) 
Random-intercept mixed 
regression model found 
significant interaction (p<0.05) 
between rumination and 
number of hassles as well as 
rumination and negative 
affect.  
 
Subjective report of 
what a daily hassle was. 
Small sample size. Was 
in a setting where food 
intake was restricted – 
may not represent 
normal life. 
Porter 
(2010) 
CS 
Initial intake 
interview 
into a weight 
management 
program 
135 aged 
11-18 yrs  
None Yes  
No gender 
differences 
were yielded 
among 
factors assoc. 
with 
psychological 
No 30-60 minute 
Interview 
questioning of 
perceived stressful 
events leading to 
weight gain. 
66%? (where is this value 
from) reported an event 
triggering weight gain (19% 
family event; medical issues 
13%, relocation 8%; 
interpersonal issues with 
peers 3%). 
No associations made 
between degree of 
obesity 
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well-being 
KeyCC: case-control study;  CS: cross-sectional study; CH: Cohort study ; UFC = Urinary free cortisol; HPA : Hypothalamic-pituitary-adrenal axis. BMI = body mass index 
AUC = area under the curve. 
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Chapter 3 : Methods 
Here I present the methodology of the thesis which was used to address all 6 
research questions. 
3.1 The Healthy Eating And Lifestyle Trial (HELP): the source of data for 
the thesis. 
The main HELP trial has now been published in detail and the reader is directed to 
the publication.2 However, I will outline key details here. As discussed in Chapter 1, I 
was employed as the medical research fellow for the HELP trial for the entirety of 
the trial.  
The HELP trial was a randomized controlled trial of an obesity intervention aimed at 
weight loss in adolescents with obesity. The intervention consisted of a ten session 
program using a manual, which worked with young people, and where possible their 
families, using motivational interviewing techniques and solution focused methods 
to help achieve weight loss. This was compared to control which was a single once 
off session with a General Practice Nurse. In the HELP trial, the intervention was not 
successful in supporting weight loss with no difference at 6 months between 
intervention and control for change in BMI (effect of the intervention at 6 months 
after controlling for age, sex and BMI at entry in the trial was -0.11 (95% confidence 
intervals -0.62 to 0.40, p = 0.7).2 There were also no differences in any other cardio-
metabolic marker or adiposity measure (waist circumference or fat mass).  
Participants of the HELP trial were recruited from the community sources such as 
GPs, schools, youth groups and self-referrals. Participants were recruited from the 
Greater London region. This was a study of adolescents with obesity (>95th centile 
BMI) with age group 12-19. Information on baseline characteristics is presented in 
Chapter 4. 
The following participants were excluded from the HELP trial: 
1. Individuals with chronic illnesses (excluding asthma, unless they had had 
more than 3 courses of oral steroid in the preceding year; and note 
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participants on inhaled steroids were included; or more minor chronic issues 
such as eczema) 
2. Individuals with known or suspected genetic or endocrine causes of obesity. 
3. Individuals with diagnosed learning difficulties and mental health diagnoses 
such as depression or anxiety  
 
Recruitment ran from January 2011- July 2013, and (as explained below in section 
4.2) participants were repeatedly measured at assessments at 4 discrete intervals :  
 
1)  Time of entry into the trial/ baseline (henceforth referred to as time 0/t0) 
2)  3 months (henceforth referred to as time 1/t1) post first assessment 
3)  6 months (henceforth referred to as time 2/t2) post first assessment 
4)  1 year (henceforth referred to as time 3/t3) post first assessment.  
 
Because of attrition, not all participants originally recruited had data collected at 
each time point, and totals at each time point are presented in chapter 6 which 
focuses on longitudinal results and analyses. Some participants also had home visits 
organized for subsequent data collection to maximize information for the outcomes 
measured in the HELP trial (this is discussed in more detail below). For a small group 
of participants data for time point 3 were chased some time after 1 year, but for 
most time point 3 was close to 1 year. This is evident and described in the 
longitudinal analyses in chapter 6. 
Recruitment and retention was indeed a significant issue for the HELP trial, as it is for 
many trials.154 155 Leading and providing input on recruitment, which included visiting 
GP surgeries, communicating with the media and leading a group of research 
assistants in recruitment, was key part of my role as the research fellow. Final power 
was reached for the study, but mid study it was possible that the trial would be 
closed down to the ethics of recruiting to a trial that was not expected to meet 
power. The experience of problems and solutions for recruiting was a key part of 
collecting information for this thesis.  Concern about any additional burden on 
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participants in collecting the additional data for my thesis was an important factor in 
a number of decisions relating to the methodology in my thesis, which I will outline 
with each aspect of data description below.  
Ethics permission for the HELP study was provided by the regional, central London 
ethics committee, with all extra data collected as presented below for this thesis 
were accepted as amendments by the ethics committee.  
 
3.2 Medical assessments and outline of data collected at each visit 
3.2.1 General background to the assessment and time points 
A summary of data collected on participants relevant to this thesis at each visit over 
time is shown in table 3.1 below. As mentioned above, some participants did not 
attend all visits and some had more rudimentary data collected from a visit at an 
agreed location closer to the participant’s home, which included visiting them in 
their home. Ethics permission was sought and achieved for this change in the 
original protocol. 
Participants were initially invited to attend an initial visit at the Clinical Research 
Facility at Great Ormond Street Hospital (CRF-GOSH) at time 0. This visit served three 
purposes :  1) for face-face discussion of the trial and consent, 2) to collect 
information to allow screening for inclusion and exclusion criteria and 3) to collect 
data at baseline (before randomization into the trial). It was my responsibly to obtain 
consent from all participants at the first visit. We obtained signed consent from the 
parents of participants under the age of 16 and signed assent from participants aged 
under 16. Participants aged 16 or over were asked to sign consent forms themselves. 
I undertook good clinical practice training prior to the start of the trial to ensure 
appropriate skills and acknowledge around consent and conduct during research. 
 
Data collection was the shared responsibility of the nursing staff at the CRF-GOSH 
and myself, though certain data collection tasks were unique to individuals, and this 
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is explained as individual data collection descriptions below. For the HELP trial, all 
individuals measuring any variables over time (thus myself and the nursing staff) 
were blinded to the intervention/control status of the participants. I was involved 
with coordination of the main data collection at time 0 and time 2; nursing staff 
were responsible for data collection at time 1 and 3: this was mostly handing out and 
collecting questionnaires, and measuring adiposity and blood pressure 
measurements. Nurses at all 4 time points measured adiposity and blood pressure 
measurements. The same equipment, technique and protocols were used for all 
visits and all participants throughout the trial. As mentioned above, whilst most of 
the assessment happened at the CRF-GOSH, some visits happened at home by a 
trained researcher, and not all participants had data at each time point.  
 
Table 3.1: Summary of information collected at each time point of the HELP trial. 
TIME Time 0  
(0) 
 
Time 1 
(3 months) 
Time 2 
(6 months) 
Time 3 
(1 year) 
Function Of 
Assessment 
Assessment 
for eligibility 
and for data 
collection.  
Data 
collection 
(by now in 
the 
intervention) 
Data 
collection 
Data collection 
 
 
Demographic data: 
Ethnicity 
Smoking status 
Deprivation score 
(from postcode) 
 
 
 
 
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TIME Time 0  
(0) 
 
Time 1 
(3 months) 
Time 2 
(6 months) 
Time 3 
(1 year) 
Puberty     
Anthropometry     
Blood pressure     
Pulse wave velocity     
Blood testing     
Salivary Cortisol 
collection 
    
Questionnaires 
 
 
 
 
 
  
 
 
 
 
3.2.2 Details on the medical assessments 
 
I provided an initial medical assessment for all participants at baseline. The focus of 
this assessment was to assess whether participants met inclusion and exclusion 
criteria. For all participants the following was performed: 
 Physical assessment for any signs of syndromes – in particular potential 
genetic syndromes and Cushing’s syndrome. 
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 Details of parental heights were taken to establish predicted height to check 
that the participant did not have short stature, which would alert to short 
stature, which might point to an endocrinopathy. 
 Previous and current medical history assessment to screen for chronic 
conditions and medicines use. 
 Mental health screen for existing involvement with CAMHS. Screening 
questionnaire for suicidal thoughts. 
 Assessment for presence and grade of acanthosis nigricans : see section 4.5 
below. 
3.2.3 Risk and safeguarding 
As the medical lead for the trial I was responsible for safeguarding children. I 
provided a safeguarding course for the non-clinical research team members. There 
was a clear protocol for what would happen if safeguarding issues were raised 
amongst the research team. Whilst patients were at the CRF-GOSH, hospital 
safeguarding protocols were in place. 
There were three areas of medical risk identified at screening and assessments in the 
trial: 
1. Identification of potential medical problems such as endocrinopathy at 
assessments. This also included finding significant hypertension. The protocol 
here was for me to contact the participant’s GP and request referral to local 
secondary care pathways. This was the case for two young people (not 
entered into the trial and not included in this thesis) one of whom was found 
to have Diabetes Mellitus Type 2 on screening with HbA1c (see below) and 
was successfully referred to a secondary diabetes service; and a second 
young person who was identified to have abnormal liver function testing and 
was referred to a regional liver unit for further investigation. 
2. Identification of potential too rapid weight loss leading to medical 
instability156 – see comments on blood pressure below. 
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3. Identification of significant and serious co-morbid mental health disorders. A 
questionnaire, the E-26, used in the trial (see 3.11.4 below) asked for suicidal 
ideation in the last 6 months.157 The protocol here was for me to contact the 
GP directly and recommend referral urgently to local child and adolescent 
mental health services, as well as ensuring that the young person was leaving 
the CRF-GOSH to a place of safety (either home with parents or to accident 
and emergency). This was the case for two young people (not entered into 
the trial and not included in thesis) who were found to be actively suicidal 
and were successfully picked up by their GP urgently. 
3.3 Demographic data collected 
3.3.1 Ethnicity 
Ethnicity was self-reported at baseline on questionnaire and then grouped into 4 
groups – white, black, Asian (South Asian e.g. Indian, Pakistani, origin) or 
mixed/other (e.g. Chinese) for use in analyses.  
3.3.3 Smoking status 
Because of the possible relevance to arterial stiffening, information was also 
collected on cigarette smoking by written questionnaires at baseline. Participants 
grouped as either: 1) never smoked; 2) currently smoked; or 3)  either currently 
smoked or had smoked in the past; with these groups used for analyses. 
3.3.4 Index of Multiple Deprivation 
Index of Multiple Deprivation (IMD) scores were calculated using postcode for usual 
place of residence (so in the case of subjects whose parents were separated, main 
place/most frequent place of residence was used) at baseline.  IMD is the official 
measure of the UK government for relative deprivation for small regions in UK.158 For 
each participant raw IMD score was used for analyses (with greater score meaning 
more deprivation).  Greater IMD score implies greater deprivation. IMD information 
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was also available as quintile of the population in the UK and this was used for 
summary of participants at baseline. 
3.4 Pubertal assessment 
It was decided that direct measurement of puberty would have been of too higher 
burden on participants, and so therefore participants were asked to self-report their 
pubertal status by Tanner stage using a published pictures chart which used pubic 
hair for both sexes, genital appearance for males and breast appearance for 
females.159 Puberty was recorded at all time collection points (time 0-3). Female 
participants were also asked to provide information on whether they had reached 
menarche. Once this information had been collected, pubertal status was then 
grouped into three stages – pre/early (Tanner 1 and 2), mid (Tanner 3 and 4), 
late/complete (5) for use in analyses. Any girl who reported that they had reached 
menarche was grouped as late/complete by default.  
3.5 Assessment of acanthosis nigricans 
I measured AN at the neck by clinical inspection for each participant using a 
previously reported grading system 160 as follows:  
1. Absent  
2. Mild (limited to base of skull not reaching lateral margins of the neck) 
3.  Moderate (extending to lateral margins of neck but not visible from front) 
4. severe (visible from the front).  
AN was recorded at all 4 time collection points. These findings were then 
dichotomized into two variables for analysis : 1) AN present or not and 2) severe 
grade or not (i.e. milder grade or not present).  
3.6 Anthropometric data collected 
All participants were measured for anthropometry by trained nurses at the Clincial 
Research Institute, Great Ormond Street Hospital using protocols. 
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3.6.1 Height  
Heights were measured to the nearest 0.1cm using an electronic stadiometer (Seca 
242 Electronic Measuring Rod, Seca GmbH & Co.KG, Germany). Participants were 
asked to remove shoes before having their height measured. Participants were 
instructed to stand underneath the head stop, with their back to measuring rod, 
with feet together and flat on the floor and heels touching the base plate. With legs 
straight, buttocks and scapula against the wall and arms loosely at their side, the 
head stop on stadiometer was lowered until it touched the participant’s head. It was 
ensured that head was in the Frankfurt Plane (corner of the eyes horizontal to the 
middle of the ear). Participants were asked to breathe in normally and exhale, with 
the measurer exerting upward pressure on the mastoids as the measurement was 
read. Height was recorded at all 4 time points (t 0-3). 
3.6.2 Weight  
Weights were measured to the nearest 0.01 Kg on the Tanita BC 418MA (Tanita, UK) 
with scales on a solid surface. The participant was weighed bare foot, in loose 
clothing. Participants were asked to empty their pockets of mobile phones, change 
and wallets etc. Heavy jewelry was also removed. 1 kg was removed from each 
measurement and for each participant to allow for the weight of remaining over 
clothing. Height was recorded at all 4 time points (t 0-3) 
3.6.3 Fat mass and fat mass index.  
Total impedance from the Tanita BC 418MA (Tanita, UK) was used to generate a 
value for fat mass using a validated formula published for use in adolescents : Free 
fat mass = -2.211 + 1.115(height2/impedance).19 Fat mass was then converted into a 
fat-mass-index which was derived by fat mass / height2, analogous therefore to BMI; 
and was used for analyses rather than raw fat mass. Fat mass was measured and 
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index derived at all 4 time points (t 0-3). Throughout this thesis, fat mass index is 
referred to as fat mass index or FMI in tables and graphs. 
3.6.4 Measures of abdominal circumference 
 
Waist circumference was measured midway between the 10th rib and iliac crest to 
the nearest mm using a non-elastic flexible tape in the standing position.16 Waist 
circumference was measured three times and averaged.  Waist circumference was 
recorded at all 4 time points (t 0-3). 
 
Anterior-posterior sagittal abdominal dimension (SAD) was measured to the nearest 
0.1cm by caliper (Holtain Kahn abdominal caliper, Holtan Ltd UK) at the centre of the 
abdomen following exhalation with participants in a supine position.17 18 161 The 
caliper was initially slid to its fullest height. The participants were then asked to raise 
their hips so that the base of the caliper could be slid below the lumbar-sacral region 
of the back. The caliper was then adjusted via its upper arm down until it was just 
above the mid-abdomen. The caliper contains a bubble which acts as a spirit level. 
This was used to ensure that the vertical angle of the caliper was 90 degrees to the 
surface that participant was lying on. Participants were then instructed to inhale and 
then fully exhale and hold, whilst the top arm of the caliper was slid down to touch 
the skin of the abdomen, resting without compressing. The diameter of the 
abdomen was then read to the nearest 0.1cm. SAD was recorded at all 4 time points 
(t 0-3). 
 
3.6.5 Derived variables from anthropometry measurements 
BMI was calculated using weight and height (weight (Kg)/height (m)2), and fat mass 
index was calculated from fat mass (Kg) / height (m)2. BMI and waist circumference 
z-score (BMI z and waist z) were generated using the LMSgrowth program version 
2.69 (Harlow Healthcare, UK) which utilizes UK 1990 population growth reference 
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data.162 163 As discussed above (4.6.3), fat mass derived from the Tanita machine and 
validated formula was converted into fat mass index. As no validated standardized 
data is currently available for fat mass index and SAD, raw data were used for 
analyses. Participants were further grouped by BMI z into above/below  2.5 z 164 and 
3.5z1 as two conventionally referred to cut-offs for severe obesity as discussed in 
Chapter 1. Throughout this thesis, BMI z-score is referred to as BMI z and waist z-
score as waist z. 
3.7 Blood pressure measurement 
Blood pressure (BP) was measured using an automated machine (Philiips IntelliVue 
MP30 Monitor, Koninklijke Phillips N.V, Holland). Blood pressure was measured 
using an appropriate sized cuff as per published guidelines for obesity.1  Participants 
were rested, seated for 20 minutes then the BP was taken at the right arm three 
times serially, with the third value recorded as data. Tight or restrictive clothing was 
removed from the participant’s arm and the participant’s arm was positioned 
horizontally at the level of the mid-sternum and ensured that it was well supported. 
Systolic and diastolic blood pressure was recorded at all 4 time points (t 0-3). 
  
Systolic and diastolic BP were then converted to z scores using LMSgrowth program 
version 2.69 (Harlow Healthcare, UK) which utilizes UK BP population data.163 165  
Throughout this thesis, systolic BP z-score is referred to as systolic z and diastolic BP 
z-score is referred to as diastolic z. 
Hypertension was defined >98th centile hypertension (>2.06 SD above the mean) for 
either systolic or diastolic BP.1 
A lying and standing blood pressure measurement for comparison, as well as resting 
pulse was taken as a screen for potentially rapid weight loss, as explained above; but 
were not used in analyses as part of the thesis. 
 
  
 
127 
3.8 Pulse wave velocity measurement 
I was trained to measure PWV on participants by the Vascular Physiology 
Department at the UCL Institute of Child Health using Sphygmocor, (AtCor Medical, 
Sydney Australia) using carotid-radial method. Training included demonstrating 
sufficient accuracy and reproducibility to a trainer (Alicja Rapala – see 
acknowledgements). I performed all PWV measurements on participants. It was a 
decision made by the trial leads that the carotid-radial methodology be used rather 
than carotid-femoral to limit burden on participants for the main trial (in the context 
of the issues with recruitment and retention for the HELP trial: see 4.1). It was also 
decided that measurements should only be measured once at  0 and time 2.  
 
How PWV is calculated and derived is explained in a theoretical sense in Chapter 1. 
Here I will describe the practical points for measuring PWV on participants for this 
thesis. Patients were in a fasted state and rested for 30 minutes prior to 
measurement with room temperature 20-22 degrees. Pulse waves were measured 
at carotid and the radial pulses using tonometry and equipment associated software 
(Sphygmocor, AtCor Medical, Sydney Australia). The distance between the carotid 
and sternal notch, and sternal notch to the radial point (via the mid shoulder) were 
also measured, and combined with waveforms, ECG readings from 3 applied leads, 
and peripheral blood pressures using the software to derived carotid-radial PWV 
values.  
 
I used the standard quality control measures for Sphygmocor. Specifically this was to 
ensure a standard deviation of derived PWV < 10% of the PWV value, all PWV wave 
forms within window and that the timing SD < 6%. If time allowed I repeated 
measures at time points to reach quality control. Data was only recorded if it met 
quality control measures. PWV was only measured once per participant at time 0 
and 2. 
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3.9 Blood testing 
Blood was taken by venesection, the majority of the time by the nurses of the CRF-
GOSH, however I also took bloods if there was difficulty obtaining blood samples or a 
nurse was not available. 
 
Blood was drawn following a 10-12 hour fast. Bloods were analyzed for cholesterol 
(including HDL), triglycerides, glucose, % glycated haemoglobin (HbA1c), insulin and 
Alanine aminotransferase (ALT). Blood was processed at Great Ormond Street 
Hospital laboratory. HOMA-IR was derived by using formula (insulin x glucose/22.5). 
Additional abnormal binary variables were generated for individual blood variables 
for above/below abnormal cut-offs based on a UK consensus statement,1 and as 
described in chapter one, as follows : “Abnormal HOMA-IR” above 4.4, “Raised 
insulin” for insulin levels above/below values based upon pubertal stage (>10 mU/L 
pre/early puberty, >30 mU/L mid puberty, mU/L>20 late and complete puberty),  
“Low HDL” below <0.9 mmol/L, “Raised triglycerides “ above >1.47 mmol/L, “Raised 
cholesterol” above >5.2 mmol/L, “Abnormal HDL/C ratio” above 4.3. 
 
Blood results were checked within the first 24 hours after processing to screen for 
diabetes mellitus. Any participant with fasting glucose or HbA1c suggestive of 
diabetes was excluded from the trial and referred on for medical follow-up as 
explained in the risk section above (4.2.3). Similarly, anyone who was found to have 
an ALT > 100 were excluded and referred on to a liver specialist. Though most raised 
ALT were expected to be due to fatty infiltration of the liver associated with obesity, 
it was decided that this was important for the well-being of participants.  
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3.10 Stress measures collected 
3.10.1 Salivary cortisol 
Salivary cortisol has been demonstrated to correlate well with free plasma 
cortisol,166 and represents a less invasive mode of measuring cortisol and allows 
ambulatory measurement. This is valuable as multiple measures through the day 
allow more accurate measurement of daily cortisol profile. 
 
Salivary cortisol samples were collected at time 0, 2 and 3 HELP visits. Morning 
salivary cortisol samples were collected at home using a swab before attending 
assessments (Salivette® cortisol swabs, Sarstedt, USA.) which participants brought 
with them. The use of such swabs have been validated for use in human experiments 
and have been shown to effectively correlate with blood cortisol levels. 
166Participants were instructed to put swabs in their mouth and chew for 45 seconds 
until the swab was completely wet, and then place it in a protective plastic shell 
which was provided. Participants were instructed to take a sample as soon as they 
woke and then 30 minutes later (they were asked to put samples by their bed the 
night before the assessment and were contacted the day before as a reminder), and 
also asked to record the time of the samples taken. On arrival at assessments, 
salivary cortisol samples were collected along with times of the samples which were 
recorded as data. Samples were then frozen and stored at -20 degrees Celsius at the 
CRF-GOSH. 
 
Additional evening samples were added to the protocol after the study had started 
after discussion at the PhD upgrade with the aim of increasing the day cortisol 
profile available. Participants were asked to take an evening salivary sample as close 
to 22:00 as possible (on the same day as the assessment – see figure). Participants 
were then asked to record the exact time of sample collection and send in the post 
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to the research team, the research team providing a pre-paid envelope. Samples are 
known to be stable at room temperature for several weeks.167 When samples were 
received by the research team they were frozen and stored at -20 degrees Celsius.  
 
Samples were then sent in batches to Dr Clemens Kirschbaum, Technische 
Universität Dresden (TU Dresden) in Germany. Dr Kirschbaum provided the following 
information on the process: “After thawing, salivettes were centrifuged at 3,000 rpm 
for 5 min, which resulted in a clear supernatant of low viscosity. Salivary 
concentrations were measured using commercially available chemiluminescence 
immunoassay with high sensitivity (IBL International, Hamburg, Germany). Sample 
and reagent handling was semi-automated using a liquid handling robot (Genesis, 
Tecan, Switzerland) and quality control samples of low, medium, and high cortisol 
concentrations were run on each microtiter plate assayed. The intra and interassay 
coefficients for cortisol were both below 8%.”  
 
The unit for salivary cortisol was nmol/L. Salivary cortisol values for awakening, 30 
minutes post awakening and evening were then used to generate 6 variables for 
analysis to measure different aspects of day cortisol levels (see figure 3.1). These 
were as follows : 1) Cortisol on waking (C-wake) 2) Cortisol awakening response rate 
of change (CAR-Rate) 3) Cortisol awakening response are under the curve (CAR-AUC) 
4) Evening cortisol (C-evening) 5) Ratio of Cortisol evening to cortisol on waking (C-
ratio) : evening:awake calculated by evening/cortisol on wakening values and 6) 
Total day cortisol area under the curve from awake to evening (C-DayAUC). Where 
30 minute after waking cortisol values were less than the cortisol on waking value, it 
was likely that the CAR had been missed due to timing mismatch of collection, which 
is well recognized as a common phenomenon when collecting samples for CAR in an 
ambulatory setting.119 168 Negative values of CAR-AUC and CAR-Rate were therefore 
not entered into analyses as they were not expected to be true measures of the CAR. 
All cortisol data were used for the other derived variables.   
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Figure 3.1. Cortisol variables and how they were derived 
 Participants were asked to provide salivary cortisol samples at time of wakening (A, 
t0), 30 minutes after waiting (B,t30) and then an evening sample (C,te) : Six variables 
were then derived for analysis : 1) Raw value at waking, A (=C-wake); 2) rate of 
increase on wakening (B-A)/t30) (=CAR-Rate); 3) Area under the curve A to B (0.5*B-
A*t30 + t30 * A) (=CAR_AUC); 4) raw evening value, C (=C-evening;) 5) Ratio of evening 
to wakening C/A (=C-ratio) and 6) Area under the curve for the day (C * te – t30 +(0.5 
* B-c) x (te – t30) + Area of the curve A to B (=C-DayAUC). Note t abbreviations here 
refer to timing of cortisol measurements not HELP trial visits 
 
3.10.1 A-FILE questionnaire 
The A-FILE questionnaire (Adolescent family inventory )169 was used as a 
questionnaire to measure exposure to stressful life events affecting the participant 
individually and their family as measure of systemic stress in the preceding 12 
months to assessment. Some of these events are normative (e.g. starting school), 
and others non-normative (experience of death of a parent). Designed for 12 to 18 
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year olds, The A-FILE consists of 50 items reported as yes or no, which are scored as 
1 or 0 respectively. A number of sub scores by category are provided, but the 
recommendation (and as used in this thesis) is to give a total score out of 50, “called 
Total Recent Life Changes”, with a greater score meaning greater perceived stressful 
events. McCubbin and Patterson have published validation of this score in 1981, 
which reported an internal reliability of alpha 0.69 using Cronbach’s alpha, and a 
test-retest reliability of r =0.82.170 The A-file was used at time 0 and 2. The 
questionnaire was delivered in paper form and scored by the data manager for the 
HELP trial. This questionnaire, along with the other questionnaires in this thesis are 
included as an appendix. 
3.11 Other relevant questionnaires 
3.11.1 Strengths and difficulties questionnaire (SDQ) 
The SDQ is a validated questionnaire which looks at different domains of potential 
mental health problems (emotional difficulties, conduct difficulties, 
hyperactivity/inattention difficulties, peer relationship difficulties and prosocial 
behavioural difficulties.171 172 The SDQ provides a total score (with higher score 
meaning more difficulties) and then a graded high versus low risk binary score for 
any disorder and a disorder in the above listed domains. The questionnaire was 
delivered in paper form and scored by the data manager for the HELP trial at time 0 
and time 2; the paper questionnaires are included in this thesis as an appendix. For 
analysis, participants were classified as probable mental health diagnosis or not. 
3.11.2 Developmental and wellbeing assessment (DAWBA) 
The DAWBA is a validated package of questionnaires,173 which was delivered on the 
computer before arriving for the first assessment. Input was requested from young 
people and their parents, and the answers were then used by the DAWBA team to 
derive predictions for important mental health diagnosis based on DSM-IV. If 
participants and their families had not been able to complete the questionnaires at 
home then an opportunity to do so was provided at the CSF-GOSH. Predictions were 
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derived even if only a young person or parent completed the questionnaire alone. 
The DAWBA categorises young people into one of six probability bands for each 
mental health disorder (from >0.1% to >70% chance).174 DAWBA is a well established 
and frequently used research tool, and is also used in clinical contexts as a predictor 
for mental health.175 Because few young people had > 70% risk for any mental health 
disorder, a binary variable was created for >50% or below 50% risk. 
3.11.3 Rosenberg’s Self Esteem Score (RSE) 
The RSE is a validated questionnaire, which was originally designed for use in 
adolescents in the 1960s.176 Since then it has been used in many research settings 
and is established as a principle method for assessing esteem by self-report in 
research.177 178 A greater score implies higher self-esteem. The questionnaire was 
delivered in paper form and scored by the data manager for the HELP trial at time 0 
and time 2; the paper questionnaires are included in this thesis as an appendix  
3.11.4 The Eating Attitudes Test (EAT-26) 
The EAT-26 is a widely used, standardized questionnaire for self-report of symptoms 
associated with eating disordered pathology.157 It is mostly used to establish eating 
disorder risk and is used in clinical and research contexts. Here, the particular 
feature of this questionnaire that I was interested in was to look for evidence of 
binge eating, which is asked and coded in binary form as “Have you gone on eating 
binges where you feel that you may not be able to stop? (Eating much more than 
most people would eat under the same circumstances)”. I was particularly interested 
in this as it allowed an opportunity to look for associations between stress measures 
(cortisol and A-FILE questionnaire) and eating behaviour that might be causal in 
degree of obesity, so to look for a potential mechanism how stress might influence 
cardiovascular risk (as discussed in chapter 2). Another question which was allied to 
the binary question about behaviours around binge eating was asking for number of 
binges in the last 6 month, which provided a continuous variable to look for 
associations between stress and degree of binging for mechanism. This 
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questionnaire was completed at time 0 and time 2. The questionnaire is shown, with 
other questionnaires, in the appendix 
3.12 Analysis of HELP data in this thesis 
3.12.1 General analysis methods 
I collected and collated all data at each assessment apart from the measurements 
performed at home. Data were entered into the HELP trial database by a trained 
data manager. I performed all analyses using STATA version 13 (StataCorp, Texas, 
USA). Statistical significance level, as per convention was set at a p <0.05 for type 1 
errors in statistical analysis. In tables statistical significance is marked by the 
presence of an asterix “*”. P values were rounded to 1 decimal place ≥ 0.2 and to 
decimal places < 0.2. 
 
Where non normally distributed data were presented in tables, summaries were 
provided using median and inter-quartile ranges, and for normally distributed data 
means and standard deviations. Comparisons of normally distributed distributions 
where matching of pairs was not required (see longitudinal data analysis below) 
were done using t-tests, for non normally distributed data Mann-Whitney U.  
 
At baseline, data were examined for normality by graphical assessment of 
distributions as well as application of STATA’s normality testing function which uses 
the Jarque-Bera test, which looks for goodness-of-fit as to whether a sample variable 
has skewness and kurtosis in keeping with normally distributed data.179 Where data 
were found to be not normally distributed, the ladder of powers function was used 
on STATA which provides 9 logarithmic transformations (cubic, square, identity, 
square root, log, 1/(square root), inverse, 1/square, 1/cubic) and provides Jarque-
Bera testing for derived transformed data to allow selection of best goodness-to-fit 
for normality. As I will show in the results, some of the skewed data were unable to 
be normalized by transformation. Regression models were repeated for non-
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transformed and transformed variables, with transformed variables used in models 
only if there was a significant difference.  
3.12.2 Cross sectional regression analyses 
To test hypotheses of possible associations at baseline,  associations (in chapter four 
and five) between variables were examined by using linear regression. Univariable 
models were presented with numbers used in the model, coefficients, 95% 
confidence intervals for coefficients and corresponding p-value. Individual variables 
found to be associated with at p <0.10 were entered into multivariable regression 
models. For binary outcomes (for example abnormal HOMA yes or no), logistic 
regression was used instead of linear regression, similarly using univariable 
regressions in the first instance and then building up models with variables found to 
be significant (with odds ratios presented instead of coefficients). As BMI z, waist z, 
FMI and SAD are recognized as proxies for adiposity (whilst also independently 
associated), each was entered into univariable and multivariable regression models 
discretely. Effect sizes of models were described using coefficients of determination 
(R2) for univariable and multivariable models, with small, medium and large effects 
defined conventionally as R2 >0.02, >0.13 and >0.26 respectively.180 Non normally 
distributed continuous variables were transformed for use in univariable regression 
analysis. If the transformation did not alter the models significantly, models using 
non-transformed variable were presented.  
3.12.3 Longitudinal analysis of variables measured at two time points (t0 
and t2) 
Whilst standardized measures of adiposity such as BMI z and  waist z are the optimal 
method for assessing adiposity in cross-sectional analyses, for longitudinal analysis 
looking for change in BMI, using a standardized score such as BMI z presents 
challenges. This is because most of the participants in the trial were at extreme ends 
of the BMI normal distribution, and as such it would take a large change in weight or 
BMI within an individual in order to effect  quite a small change in BMI z. Cole et al 
have demonstrated that change in BMI z or centile in children and adolescents over 
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time are poor measures of change in body fat (DEXA), and have recommended using 
raw BMI rather than standardized BMI.181 182 Thus analyses focusing on longitudinal 
changes used changes in raw scores of waist circumference and BMI rather than by 
z-score. Raw FMI and SAD were used, as they were not standardized anyway. For 
completeness, both raw blood pressures and z-scores of blood pressures were 
included in longitudinal analyses as it is less clear in children what the best measure 
of change in blood pressure would be (standardized or raw). 
All participants would have been randomized to either an intervention or control at 
times 1-3, and therefore any longitudinal analyses were adjusted for control or 
intervention status in the HELP trial. Whilst the intervention in the HELP trial did not 
alter the outcomes measured, there were a number of factors measured and 
unmeasured in this thesis that might have potentially been affected by the 
intervention status so I felt it was important to control for it. 
Variables with measures at time 0 and time 2 were compared for differences 
between time points using paired t-test. Whilst some of the data were not normally 
distributed, t-tests were applied consistently, and this is appropriate for larger 
sample sizes > 50; 183 however for completeness, for non-normally distributed 
variables at baseline, results from differences between time 0 and time 2 using t-
tests were confirmed using the non-parametric test of the Wilcoxson signed rank 
test. 
To look for associations between change in PWV between 0 and time 2 and changes 
in the adiposity measures, blood pressure and cardio-metabolic blood markers 
between time 0 and time2, multivariable linear regression models were used. 
Models were created to predict variables (e.g PWV) at time 2 as a dependent 
variable. In these models predictors were 1) the variable at time zero; 2) predictor 
variables (eg BMI) at time 0 and time 2; and 3) time between t0 and t2 (in years). So 
for example to examine for a potential relationship between change in BMI between 
time 0 and 2 and change in PWV the following model was used: 
 
PWV2 = αPWV0 + βtime_difference + γBMI2 + δBMI0 + constant. 
 
137 
 
Similar models were used for the cardio-metabolic blood variables measured only at 
time 0 and time 2. Sensitivity analyses were also run to include intervention status in 
each of these models, and were presented in models if there was a significant 
change in the model. 
3.12.3 Multi-level longitudinal analysis for variables measured at four 
time points (t0-3) 
To investigate the change of variables over time, multi-level random effects models 
were used. This is a repeated-measures analysis method that allows for variation in 
the actual timing of repeated measures, allows for missing data at certain time 
points, and also takes account of how the individual changes over time within the 
group being studied. Firstly, the database was reshaped to long format so that each 
participant had a measure of variables which were measured at three or more time 
points (adiposity measures, blood pressure and cortisol).  
To examine the change of variables over time, initially models were created using 
time as a predictor for each adiposity measure, each cortisol measure and systolic 
and diastolic blood pressure individually. Most individual trajectories in variables 
were parallel, so random intercept models were produced which provided fixed 
effects components (presented as coefficient, 95% confidence intervals for 
coefficients, constants and 95% confidence intervals for constants; and random 
effects information on the variance (reported as SD) for the constant (providing 
information about the between subject variation) and on residuals (providing 
information about the within subject variation). Models are presented in tables in 
Chapter 6. In these tables, coefficient describes the change in predicted variable by 
one unit increase in the predictor (so in the case of models predicting BMI over time, 
the increase in BMI in Kg/m2); and constants represent average baseline value for 
the predicted variable (with 95% confidence intervals also presented). 
Standard deviations reported for constant and residuals were then used to calculate 
the % of variance in the dependent variable in the model (e.g. BMI) due to 
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unobserved participant specific (so within the individual) characteristics that not 
explained by components in the model, as follows:184  
 
SD constant2 
SD constant2 + SD residual2 
 
Once univariable models for variables over time were created, additional variables 
including baseline demographic information were also added (as well as adiposity 
measures over time to models of systolic and diastolic blood pressure to examine 
the relationship between the two over time). Lastly, to assess the association of 
cortisol measures over time upon adiposity measures, and on BP and systolic BP, 
cortisol measures were added to individual models of adiposity and blood pressure 
measure over time.  
For each model using time, time2 was also added to examine whether non-linear 
models existed 
3.12.4 A note on power in the thesis. 
The data in this thesis were collected as part of the HELP trial, which was powered to 
detect an intervention effect of 0.5 standard deviation change in BMI at 0.8 power 
and 5% significance. The sample size was also inflated to account for the clustering 
effect of therapists using in the HELP trial. The trial was not powered to examine the 
outcomes examined in this thesis. Thus it was not possible to power the sample size 
used in this thesis for its hypotheses. This is discussed in detail in the discussion. 
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Chapter 4 : Results : cross sectional analyses cardio-metabolic 
factors and PWV. 
Here I present the baseline data from the HELP trial and present analyses to address 
cross-sectional aspects of research questions 1-3 (namely 1) how degree of adiposity 
is associated with pulse wave velocity as a proxy of arterial stiffening at a cross-
sectional level; 2) how blood pressure is associated with pulse wave velocity as a 
proxy of arterial stiffening at a cross-sectional level; and 3) how other conventional 
measures of cardio-metabolic risk such as blood testing and acanthosis nigricans are 
associated with pulse wave velocity as a proxy of arterial stiffening at a cross-
sectional level). 
4.1 Baseline characteristics of anthropometric, cardio-metabolic 
markers and pulse wave velocity data of participants entered into the 
HELP trial. 
Of 519 contacts with young people or their families for potential eligibility into the 
HELP trial, 210 were invited for baseline assessment. 25 of these young people were 
found not to meet criteria at assessment, 9 declined to participate and 2 were lost 
before being entered into the trial.  A total of 174 children were recruited and 
randomized into the HELP trial (65 (37%) male). Source of recruitment for these 
participants is shown in table 4.1 below. 
Table 4.1  : Summary of recruitment routes for participants. 
Origin of recruitment Number (%) 
Not eligible for other younger community 
weight loss programs 
7 (4%) 
Picked up from advertising in attending 
clinics in secondary care 
12 (7%) 
Contacted by GPs who know young person 98 (56%) 
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Origin of recruitment Number (%) 
had obesity or refereed by GP directly or 
primary care trust 
School referrals from teachers, school nurses 23 (13%) 
Responded to newspaper adverts 5 (3%) 
Word of mouth 14 (8%) 
Community dieticians 2 (1%) 
Pharmacists (advertisements in pharmacies 
and then referred on) 
6 (3%) 
Directly from website 4 (2%) 
Advertisements within universities  3 (2%) 
Unknown/unrecorded 1 (1%) 
 
The participants were ethnically diverse. Proportions in each ethnic group were: 
white 66 (38%), black 53 (30%), South Asian 36 (21%), mixed/other 19 (11%). 
Proportions at each pubertal stage were pre/early (Tanner 1/2) 21 (12%), mid (3/4) 
38 (22%), late/post (5) 115 (66%). There were more females in complete/late 
puberty than in other stages (89% versus 12%, p <0.01). The sex ratio was similar in 
all ethnic groups. 14 (8%) of participants were current smokers and 48 (29%) were 
either current or ex-smokers. Deprivation level in the sample was high, with mean 
IMD score 29.80 (SD 13.50) which lies in the 4th quintile nationally. 
Characteristics of continuous variables for the study group are shown in Table 4.2. 
Age was not normally distributed, but the sample appeared evenly distributed across 
age groups. Males were taller than females but similar in height z-score, while 
females had greater waist z and FMI. Males had greater metabolic markers as 
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triglycerides, fasting glucose and ALT. 126 participants (72%) had BMI z > 2.5  and 17 
(10%) exceeded 3.5.  
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Table 4.2 Summary of baseline variables at time 0. 
 Males Females All subjects 
Variable n Mean Median SD IQR n Mean Median SD IQR n Mean Median SD IQR 
Age (years) 65  15.0  3.2 109  15.6  2.9 174  15.3  3.2 
IMD score 65 32.0   14.3 109  28.5 12.8
3 
 174 29.81  13.5  
Weight (kg) 65  87.4  23 109  85.4  20.6 174  86.2  22 
Height (cm) 65 168.4*  9.6 13.2 109 164.3  6.5  174 165.8  8.1  
Height z 65 0.39  0.88  109 0.52  1.00  174 0.47  0.96  
BMI (kg/m2) 65  30.9  5.9 109  32.5  6.1 174  32  6.1 
BMI z 65 2.83  0.47  109 2.78  0.59  174 2.80  0.55  
Waist (cm) 65  101  15 109  95.4  17 174  99  15.9 
Waist z 65 2.97*  0.51  109 3.68  0.68  174 3.45  0.72  
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 Males Females All subjects 
Variable n Mean Median SD IQR n Mean Median SD IQR n Mean Median SD IQR 
SAD (cm) 57 23.1  3.2  102 22.3  3.5  159 22.6  3.4  
FMI (kg/m2) 63 12.5*  4.0  108 15.0  3.6  171 14.1  3.89  
Systolic BP 
(mmHg) 
63 109  10  109 106  10.  172 107  10  
Systolic BP z-
score 
63 -1.05  1.03  109 -1.09  1.08  172 -1.07  1.06  
Diastolic BP 
(mmHg) 
63 53  9  109 54  10  172 54  9  
Diastolic BP z-
score 
63 -0.60  1.10  109 -0.63  1.19  172 -0.61  1.15  
Cholesterol 
(mmol/L) 
65 4.5  0.9  109 4.3  0.8  174 4.4  0.8  
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 Males Females All subjects 
Variable n Mean Median SD IQR n Mean Median SD IQR n Mean Median SD IQR 
Triglycerides 
(mmol/L)  
64  1.1*  0.6 109  0.9  0.6 173  1.0  0.6 
ALT (mmol/L) 65  32*  27 109  24  13 174  26  16 
HDL (mmol/L) 62  1.1  0.4 108  1.1  0.3 171  1.1  0.3 
HbA1c (%) 62  5.5  0.5 105  5.4  0..4 167  5.4  0.5 
HOMA 65  3.0  2.9 108  2.4  2.1 173  2.6  2.6 
Fasting Insulin 
(mU/L) 
65  15  14.1 109  12.1  10.5 174  13  11.1 
Fasting Glucose 
(mmol/L) 
65  4.6*  0.6 108  4.4  0.45 173  4.4  0.5 
PWV (ms-1) 54 7.3  1.1  92 7.1  1.2  146 7.1  1.2  
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4.2 Baseline Metabolic risk summary  
4.2.1 Summary of metabolic risk factors 
No participant had systolic hypertension or evidence of impaired fasting glucose. 
Four (2%) had diastolic hypertension, 35 (20%) raised HOMA, 34 (20%) raised insulin 
for pubertal stage, 29 (17%) elevated cholesterol, 29 (17%) raised triglycerides, 20 
(12%) low HDL, and 66 (39%) had an elevated HDL/C ratio. As such only two 
participants met any of the criteria for the metabolic syndrome using criteria shown 
above (IDF criteria). Abnormal fasting insulin was associated with BMI z and pubertal 
stage : abnormal insulin: odds ratio 8.94, 95% CI 3.49 to 22.92, p < 0.01 for BMI z and 
odd’s ratio 0.16, 95% CI 0.04 to 0.60, p <0.01 for mid puberty versus pre/early; 0.30, 
0.11 to 0.80, p = 0.02 for late/post versus pre/early. Abnormal HOMA-IR was 
associated with BMI z: odds ratio 5.02, 95% CI 2.20 to 11.46, p < 0.01. 
4.2.2.Relationship between BMI and systolic BP and diastolic BP at 
baseline 
Regression analyses for associations between adiposity measures and raw systolic, 
systolic-z, diastolic raw and diastolic z blood pressure measures are shown in tables 
4.3-4.6. There was a positive association between waist circumference and raw 
systolic blood pressure (coefficient 0.15, 95& CI 0.01 -0.28, p= 0.03; with a small 
effect size of r2 = 0.03), SAD and both raw diastolic BP (coefficient 0.48, 95% CI 0.04 
to 0.92, p = 0.03, with a small effect size of r2 = 0.03) and diastolic z BP (0.06, 95% CI 
0.02-0.12, p = 0.02, with a small effect size of r2 = 0.04); but no other adiposity 
measures. 
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Table 4.3 : Linear regression analyses of adiposity markers as predictors of raw 
systolic blood pressure. 
Systolic BP N Coefficient 95% CI 
coefficient 
p 
BMI 172 0.14 -0.21 to 0.50 0.4 
BMI z 172 1.00 -1.80 to 3.81 0.4 
Fat mass 
index 
169 0.09 -0.31 to 0.38 0.7 
waist 172 0.15 0.01 to 0.28 0.03* 
Waist z 172 0.75 -1.38 to 2.90 0.5 
SAD 157 0.40 -0.07 to 0.88 0.09 
 
Table 4.4 : Linear regression analyses of adiposity markers as predictors of systolic 
blood pressure z-score. 
systolic z N Coefficient 95% CI 
coefficient 
p 
BMI 172 0.01 -0.04 to 0.04 0.9 
BMI z 172 0.15 -0.14 to 0.44 0.3 
Fat mass 
index 
169 0.02 -0.02 to 0.06 0.4 
waist 172 0.01 -0.01 to 0.02 0.19 
Waist z 172 0.15 -0.07 to 0.37 0.19 
SAD 157 0.03 -0.02 to 0.07 0.3 
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Table 4.5 : Linear regression analyses of adiposity markers as predictors of raw 
diastolic  blood pressure. 
diastolic N Coefficient 95% CI 
coefficient 
p 
BMI 172 0.01 -0.32 to 0.33 0.9 
BMI z 172 -1.31 -3.90 to 1.28 0.3 
Fat mass 
index 
169 0.05 -0.32 to 0.42 0.8 
waist 172 -0.01 -0.13 to 0.13 0.9 
Waist z 172 0.34 -1.63 to 2.33 0.7 
SAD 157 0.48 0.04 to 0.92 0.03 * 
 
Table 4.6 : Linear regression analyses of adiposity markers as predictors of diastolic 
blood pressure z-score. 
diastolic z N Coefficient 95% CI 
coefficient 
p 
BMI 172 -0.01 -0.05 to 0.03 0.6 
BMI z 172 -0.12 -0.44 to 0.20 0.5 
Fat mass 
index 
169 -0.01 -0.05 to 0.04 0.8 
waist 172 -0.00 -0.02 to 0.02 0.9 
Waist z 172 0.04 -0.30 to 0.21 0.8 
SAD 157 0.06 0.02 to 0.12 0.02* 
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4.3 Baseline Pulse Wave velocity regression analysis 
 
Pulse wave data were available for 146 (84%) participants. Cases were missing 
mostly because of lack of time during HELP assessments to collect core data for the 
HELP trial, and some young people did not want to wait to have PWV measured. 
PWV was not associated with heart rate (coefficient 0.02, 95%CI 0.00 to 0.07, p = 
0.8). 
Univariable regression analyses between PWV and anthropometric, cardio-metabolic 
and demographic markers are shown in table 4.7. Significant positive associations 
were found between PWV and age, all adiposity markers (BMI z, FMI, waist z and 
SAD), and abnormal triglyceride grouping (effects sizes were however small, R2 = 
0.05, 0.04, 0.03, 0.03, 0.03, 0.02 respectively). Ethnic South Asians, and to a lesser 
extent blacks, had higher PWV compared with ethnic whites. PWV was  lower in the  
low HDL group. Abnormal triglyceride grouping was no longer significant once 
adjusted for age, ethnicity and BMI z (data not shown). Low HDL grouping remained 
negatively associated with PWV when controlled for BMI z, age, ethnicity group 
(coefficient -0.60 (95% CI -1.17 to -0.03), beta -0.17, p = 0.04,  R2= 0.17). There were 
no differences in PWV by sex, pubertal stage, smoking or cardio-metabolic markers 
(including systolic and diastolic blood pressure). Scatterplots of PWV versus 
measures of adiposity, with fitted regression lines, are shown in in figure 4.1; In 
general the associations were weak. 
Multivariable regression models for each adiposity measure adjusting for age, 
ethnicity, abnormal triglycerides and abnormally low HDL, are shown in Table 4.8. 
Although the significance of ALT in univariable regression was <0.1, it was not 
included in the final model as its statistical significance was poor on inclusion in 
models for each adiposity measure; and it also did not affect the quality of the 
overall models (data not shown). There was a positive association between PWV and 
all adiposity measures except SAD. Effect sizes for adjusted models for each 
adiposity measure were medium in size (R2 in adjusted models for BMI z = 0.16, 
waist z = 0.13 and FMI = 0.15)  
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Participants with BMI z > 2.5 SD and > 3.5 SD had greater PWV on average than 
those below the cut-offs (>2.5 SD : 7.1 vs. 6.8, p =0.04; >3.5 SD: 7.6 vs. 7.0, p = 0.03), 
however the groups overlapped substantially (see Figure 4.2). 
Elements of this analysis were published in: Hudson L, Kinra S, Wong I, et al. Is 
arterial stiffening associated with adiposity, severity of obesity and other 
contemporary cardiometabolic markers in a community sample of adolescents with 
obesity in the UK? BMJ Paediatrics Open 2017;1:e000061. doi:10.1136/ bmjpo-2017-
000061 and is included in appendix 9.3. 
 
Table 4.7 : Univariable regression analyses of PWV with demographic, 
anthropometric and cardio-metabolic variables. 
Variable predicting PWV n Coefficient 95% CI coefficient P 
Age 146 0.12 0.03 to 0.21 <0.01* 
Female sex (reference male) 146 -0.19 -0.59 to 0.21 0.3 
Pubertal stage (reference 
late/complete) 
146 
 
   
 pre/early (1&2)  -0.15 -0.84 to 0.54 0.7 
 mid (3/4)  -0.12 -0.58 to 0.34 0.7 
Ethnicity (reference white) 146    
 Black  0.42 -0.03 to 0.88 0.07 
 South Asian  0.67 0.15 to 1.19 0.01* 
 Mixed other  0.18  0.6 
IMD 146 0.01 -0.01 to 0.02 0.6 
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Variable predicting PWV n Coefficient 95% CI coefficient P 
Current smoker 146 0.27 -0.41 to 0.96 0.4 
Ever smoked 146 0.15 -0.27 to 0.59 0.5 
Height z-score 146 -0.13 -0.34 to 0.06 0.18 
BMI 146 0.08 0.03 to 0.12 <0.01* 
BMI z 146 0.44 0.08 to 0.79 0.01* 
FMI 144 0.05 0.00 to 0.10 0.03* 
Waist z 146 0.27 0.00 to 0.53 0.04* 
SAD 132 0.06 0.00 to 0.12 0.04* 
Systolic BP 146 0.01 -0.01 to 0.03 0.17 
Diastolic BP 146 0.01 -0.00 to 0.03 0.18 
Systolic z-score 146 0.02 -0.17 to 0.22 0.8 
Diastolic z-score 146 0.08 -0.09 to 0.25 0.3 
Cholesterol 146 0.16 -0.06 to 0.39 0.16 
High cholesterol versus low 146 -0.35 -0.87 to 0.18 0.2 
HDL 142 0.16 -0.60 to 0.91 0.7 
Low HDL versus high 142 - 0.63 -1.22 to 0.03 0.04* 
Triglycerides 145 0.24 -0.07 to 0.56 0.13 
Abnormal Triglycerides versus 
normal 
145 0.52 0.02 to 1.03 0.04* 
ALT 146 0.01 -0.00 to 0.02 0.08 
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Variable predicting PWV n Coefficient 95% CI coefficient P 
Fasting glucose 146 0.04 -0.40 to 0.48 0.9 
HbA1c 146 0.23 -0.36 to 0.74 0.4 
Fasting Insulin 146 0.01 -0.01 to -0.02 0.5 
Abnormal insulin versus normal 146 0.17 -0.33 to 0.69 0.5 
HOMA 146 0.01 -0.06 to 0.08 0.8 
Abnormal HOMA versus normal 146 0.03 -0.45 to 0.51 0.9 
 
Table 5.8  : Multivariable analyses of PWV on adiposity measures (adjusted for age, 
ethnicity, abnormal triglyceride, and low HDL). 
 n Coefficient (95% CI) P 
BMI z 145 0.49 (0.14 to 0.84) <0.01* 
Waist z 145 0.26 (0.01 to 0.52) 0.04* 
FMI 144 0.05 (0.01 to 0.10) <0.01* 
SAD 131 0.05 (-0.13 to 0.10) 0.13 
 
 
152 
 
Figure 4.1 : Scatter with fitted regression lines for measures of adiposity against 
PWV (ms-1)  
 
 
Figure 4.2 : Box plots of distribution of PWV (ms-1) when grouped by presence or 
not of severe obesity (classified by >2.5z BMI and >3.5z respectively.). Central lines 
are median PWV. 
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4.4 Acanthosis Nigricans regression analyses 
Assessment of AN was possible in 173 subjects, with AN present in 109 (63%) and 75 
(43%) of the sample having severe grade AN. Presence of AN was associated with 
BMI z (OR 2.12, 95%CI 1.17 to 3.82, p =0.01); and was more common in all non-white 
ethnic groups (black OR 29.65, 95% CI 9.38 to 93.75, p <0.01; South Asian OR 8.47, 
95%CI 3.27 to 21.92, p <0.01; mixed OR 5.24, 95%CI 1.73 to 15.85, p < 0.01). 
There was no association between presence or severity of AN and sex, age or 
pubertal stage. Severe grade AN was associated with BMI z (OR 2.06, 95% CI 1.15 to 
3.67, p = 0.02) and was more common in all non-white ethnic groups compared to 
white: (black – OR 21.92, 95% CI 8.31 to 57.78 p <0.001; South Asian OR 8.90, 95%CI 
3.30 to 23.96, p <0.01; mixed OR 4.15, 95%CI 1.26 to 13.66, p = 0.02). 
Presence of AN was positively associated with fasting cholesterol after adjustment 
for BMI z (OR 1.62, 95% CI 1.08 to 2.42, p = 0.01) but not fasting triglycerides, 
diastolic z or systolic z blood pressure. Severe AN was positively associated with 
diastolic z blood pressure after adjustment for BMI z (OR 1.36, 95% CI 1.03 to 1.81, p 
= 0.03) but no other cardio-metabolic marker. 
Univariable models for associations of any or severe grade AN with fasting 
hyperinsulinaemia and abnormal HOMA-IR are shown in table 4.9. Presence of AN 
was associated with both fasting hyperinsulinaemia and abnormal HOMA-IR; 
however this association was attenuated after adjusting for BMI z and pubertal stage 
(table 4.10); with BMI z remaining strongly associated with insulin resistance in these 
adjusted models (OR 9.19, 95% CI 3.40 to 25.02, p <0.01, 4.91 for abnormal insulin, 
OR 4.56, 95% CI 1.91 to 10.87, p < 0.01) 
Univariable models of associations between presence of any AN and severe AN and 
PWV is shown in table 4.11. Severe grade AN was associated with PWV, however, 
this association was attenuated in a multivariable model adjusting for BMI z, ethnic 
grouping and age, shown in table 4.12. BMI z remained associated with PWV in this 
multivariable model. 
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Thus the finding of any AN (or severity) in an obese group of adolescents does not 
provide additional information about individual cardio-metabolic risk beyond the 
degree of obesity itself. Elements of this analysis were published (and presented in 
appendix 9.3) :Hudson L, Kinra S, Wong I, et al. Is arterial stiffening associated with 
adiposity, severity of obesity and other contemporary cardiometabolic markers in a 
community sample of adolescents with obesity in the UK? BMJ Paediatrics Open 
2017;1:e000061. doi:10.1136/ bmjpo-2017-000061  
 
Table 4. 9 univariable models with presence of acanthosis nigricans and presence 
of severe acanthosis nigricans as predictors of insulin resistance 
 Fasting hyperinsulinism Abnormal HOMA 
 N OR (95% 
CI) 
p N OR (95% CI) p 
Any AN present 173 2.68 (1.09 
to 6.58) 
0.03* 173 1.88(0.88 
to 4.00) 
0.10 
Severe AN 
present 
173 3.44 (1.34 
to 8.8) 
0.01* 173 1.98 (0.94 
to 4.21) 
0.07 
 
Table 4.10 a multivariable, adjusted model (for BMI z and pubertal stage) as 
predictors of acanthosis nigricans and insulin resistance. The relationships 
between AN and hyperinsulinism are no longer significant. 
 Fasting hyperinsulinism Abnormal HOMA 
 N OR (95% 
CI) 
p N OR (95% CI) p 
Any AN 
present 
173 2.40 (0.85 
to 6.76) 
0.10 172 2.60 (0.96 
to 7.01) 
0.06 
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Table 4.11 univariable regression model of acanthosis nigricans and presence of 
severe AN as predictors of pulse wave velocity 
PWV N Coefficient 
(95% CI) 
p 
Any AN 
present 
145 0.36 (-0.03 
to 0.76) 
0.07 
Severe AN 
present 
145 0.51 (0.12 
to 0.89) 
0.01 * 
 
Table 4.12 multivariable, adjusted model (for BMI z, ethnicity and age) of presence 
of severe acanthosis nigricans as a predictor of pulse wave velocity. The 
relationship between severe AN and PWV is no longer significant. 
PWV N Coefficient 
(95% CI) 
p 
Severe AN 
present 
145 0.37 (-0.07 
to 0.80) 
0.10 
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Chapter 5 : Results : cross-sectional stress, obesity, cardio-
metabolic markers and PWV. 
Here I present the baseline data from the HELP trial and present analyses to address 
cross-sectional components of research questions 4-6 (namely 4) how measures of 
stress are associated with degree of adiposity at a cross-sectional level; 5) how 
measures of stress are associated with blood pressure at a cross-sectional level; and 
6) how measures of stress are associated with pulse wave velocity at a cross-
sectional level). 
5.1 Baseline characteristics of stress variables 
Table 5.1 summarizes the stress variables measured at baseline for all participants, 
separated by male and female. There were no significant differences between the 
means and medians of all stress measures between sexes. None of the stress 
variables were normally distributed. Only rate of change awakening cortisol, evening 
cortisol, ratio of eve to am could be transformed to be normally distributed. 
Analyses with transformed variables made no difference. All participants exhibited a 
normal diurnal pattern of salivary cortisol with lower values in the evening than 
upon awakening. In 32 cases, the CAR as AUC and rate were negative and so were 
not included in analyses looking at rate and AUC for the CAR.  
Table 5.1 Baseline characteristics of stress measures (cortisol and A-FILE 
questionnaire) presented as all subjects and by sex. 
 Males Females All subjects 
Variable n Median IQR n Median IQR n Median IQR 
Awakening 
cortisol 
60 12.71 7.75 103 14.23 9.4 163 13.56 8.8 
Rate of 
change 
awakening 
45 24.32 32.72 86 21.93 20.56 131 22.54 25.24 
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 Males Females All subjects 
Variable n Median IQR n Median IQR n Median IQR 
cortisol 
Evening 
cortisol 
20 1.7 2.12 33 1.52 1.33 53 1.54 1.69 
Ratio 
awakening 
to evening 
cortisol  
20 0.15 0.14 33 0.10 0.06 53 0.11 0.11 
Awakening 
cortisol 
AUC 
45 9.69 4.35 86 10.29 5.34 131 10 4.97 
Day cortisol 
AUC 
20 188.16 136.39 33 193.76 98.65 53 193.76 137.42 
A-File Total 
Recent life 
Changes 
64 5 8 108 7 6.5 172 6.5 7.5 
 
5.2 Associations of stress variables with baseline participant 
demographic characteristics 
Regression analyses examining associations between the individual stress measures 
and participant demographic characteristics are show in tables 5.2 to 5.8. There 
were few associations found. CAR-Rate and C-DayAUC were both positively 
associated with deprivation (coefficient 0.28, 95% CI 0.03 to 0.53, p = 0.03; 
coefficient 1.84, 95%CI 0.31 to 3.36, p = 0.02 respectively), CAR-AUC was positively 
associated with black ethnicity compared to white (coefficient 2.55, 95% CI 0.16 to 
4.73, p =0.04) 
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Table 5.2 Linear regression analyses of demographic associations with C-wake 
C-wake Univariable analyses 
 n Coefficient  95% CI p 
Age 163 0.44 -0.24 to 1.14 0.2 
Sex 163 1.32 -1.71 to 4.36 0.4 
Pubertal stage 
Mid Puberty versus pre/early 
Late/post versus pre/early 
163  
0.81 
2.31 
 
-4.56 to 6.18 
-2.35 to 6.96 
 
0.8 
0.3 
Ethnicity  
Black versus white 
Asian versus white 
Mixed versus white 
163  
0.37 
1.26 
-2.05 
 
-3.21 to 3.95 
-2.78 to 5.30 
-7.07 to 2.97 
 
0.8 
0.5 
0.4 
Ever smoked 158 3.10 -0.18 to 6.36 0.06 
IMD score 163 0.05 -0.06 to 0.16 0.3 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.3 Linear regression analyses of demographic associations CAR-Rate 
 
CAR-Rate Univariable analyses 
 n Coefficient  95% CI P 
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CAR-Rate Univariable analyses 
 n Coefficient  95% CI P 
Age 131 -0.85 -2.46 to 0.75 0.3 
Sex 131 -5.07 -12.12 to 1.97 0.16 
Pubertal stage 
Mid Puberty versus pre/early 
Late/post versus pre/early 
131  
1.78 
0.72 
 
-11.15 to 14.70 
-10.38 to 11.84 
 
0.8 
0.9 
Ethnicity  
Black versus white 
Asian versus white 
Mixed versus white 
131  
1.96 
7.43 
-4.22 
 
-6.33 to 10.25 
-1.49 to 16.36 
-15.48 to 7.04 
 
0.6 
0.10 
0.5 
Ever smoked 128 -1.08 -8.72 to 6.56 0.8 
IMD score 131 0.28 0.03 to 0.53 0.03* 
 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.4 Linear regression analyses of demographic associations with C-evening 
 
C-evening Univariable analyses 
 n Coefficient  95% CI P 
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C-evening Univariable analyses 
 n Coefficient  95% CI P 
Age 53 -0.08 -0.31 to 0.15 0.5 
Sex 53 -0.44 -1.51 to 0.63 0.4 
Pubertal stage 
Mid Puberty versus pre/early 
Late/post versus pre/early 
53  
-0.91 
-0.70 
 
-2.67 to 0.84 
-2.22 to 0.81 
 
0.3 
0.4 
Ethnicity  
Black versus white 
Asian versus white 
Mixed versus white 
53  
-0.13 
0.32 
0.68 
 
-1.42 to 1.17 
-1.06 to 1.70 
-1.45 to 2.81 
 
0.8 
0.7 
0.5 
Ever smoked 50 0.12 -1.27 to 1.50 0.9 
IMD score 53 0.01 -0.02 to 0.04 0.5 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.5 Linear regression analyses of demographic associations with C-Ratio 
C-Ratio Univariable analyses 
 n Coefficient  95% CI P 
Age 53 -0.12 -0.6 to 0.03 0.6 
Sex 53 -0.02 -0.22 to 0.19 0.8 
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C-Ratio Univariable analyses 
 n Coefficient  95% CI P 
Pubertal stage 
Mid Puberty versus pre/early 
Late/post versus pre/early 
53  
-0.08 
0.05 
 
-0.42 to 0.26 
-0.24 to 0.35 
 
0.6 
0.7 
Ethnicity  
Black versus white 
Asian versus white 
Mixed versus white 
53  
-0.06 
0.09 
0.32 
 
-0.30 to 0.17 
-0.16 to 0.34 
-0.06 to 0.71 
 
0.6 
0.5 
0.10 
Ever smoked 50 -0.11 -0.37 to 0.15 0.4 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.6 Linear regression analyses of demographic associations with CAR-AUC 
 
CAR-AUC Univariable model components 
 n Coefficient  95% CI P 
Age 131 0.15 -0.30 to 0.59 0.5 
Sex 131 1.16 -0.81 to 3.11 0.3 
Pubertal stage 
Mid Puberty versus pre/early 
131  
-0.05 
 
-3.58 to 3.47 
 
0.9 
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CAR-AUC Univariable model components 
 n Coefficient  95% CI P 
Late/post versus pre/early 1.74 -1.29 to 4.77 0.2 
Ethnicity  
Black versus white 
Asian versus white 
Mixed versus white 
131  
2.55 
1.67 
-0.92 
 
0.16 to 4.73 
-0.76 to 4.11 
-4.07 to 2.25 
 
0.04 
0.18 
0.6 
Ever smoked 126 1.53 -0.61 to 3.67 0.16 
IMD score 131 0.06 -0.01 to 0.13 0.07 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.7 Linear regression analyses of demographic associations with C-DayAUC 
 
C-DayAUC Univariable model components 
 n Coefficient  95% CI P 
Age 53 0.69 -10.36 to 11.75 0.9 
Sex 53 16.33 -35.43 to 68.09 0.5 
Pubertal stage 
Mid Puberty versus pre/early 
Late/post versus pre/early 
53  
9.37 
38.84 
 
-77.33 to 96.08 
-36.83 to 114.51 
 
0.8 
0.2 
 
163 
C-DayAUC Univariable model components 
 n Coefficient  95% CI P 
Ethnicity  
Black versus white 
Asian versus white 
Mixed versus white 
53  
16.17 
50.58 
-44.19 
 
-44.47 to 76.81 
-12.72 to 113.88 
-142.05 to 53.66 
 
0.6 
0.12 
0.4 
Ever smoked 50 40.67 -23.27 to 104.56 0.2 
IMD score 53 1.84 0.31 to 3.36 0.02 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.8 Linear regression analyses of demographic associations with A-File 
questionnaire 
 
A-File Total Recent life Changes Univariable model components 
 n Coefficient  95% CI P 
Age 172 0.21 -0.18 to 0.61 0.3 
Sex 172 0.98 -0.71 to 2.68 0.3 
Pubertal stage 
Mid Puberty versus pre/early 
Late/post versus pre/early 
172  
0.62 
1.97 
 
-2.30 to 3.55 
-0.57 to 4.52 
 
0.7 
0.13 
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Ethnicity  
Black versus white 
Asian versus white 
Mixed versus white 
172  
1.94 
-1.60 
2.15 
 
0.0 to 3.88 
-3.79 to 0.60 
-0.59 to 4.88 
 
0.05 
0.8 
0.6 
Ever smoked 168 0.85 -1.00 t0 2.71 0.4 
IMD score 172 0.04 -0.02 to 0.10 0.2 
 
5.3 Associations of cortisol variables and A-file questionnaire. 
Regression analyses for possible associations between the A-FILE questionnaire at 
baseline and cortisol measures are shown in table 5.9. There were no associations 
found. 
Table 5.9 Linear regression analyses of cortisol measures associations with A-File 
questionnaire. 
A-File Total Recent life Changes Univariable models 
 n Coefficient  95% CI P 
C-wake 162 0.02 -0.07 to 0.11 0.7 
CAR-Rate 131 -0.01 -0.06 to 0.04 0.7 
C-evening 53 -0.01 -0.19 to 0.17 0.8 
C-Ratio 52 0.14 -3.59 to 3.62 0.9 
CAR-AUC 131 -0.12 -0.19 to 0.17 0.8 
C-Day AUC 52 0.01 -0.01 to 0.02 0.8 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
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evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
5.4 Associations of stress variables with adiposity and cardio-metabolic 
measures. 
To test if adiposity and cardiovascular risk markers were associated with the stress 
measures, linear regressions were performed with each stress measure in 
univariable analyses as predictors of the adiposity measures and other 
cardiovascular risk measures at baseline. These are shown in tables 5.10- 6.22. The 
only association found was a negative association between C-Ratio and systolic 
blood pressure (coefficient -0.94, 95% CI -1.82 to -0.06, p = 0.04). 
 
Table 5.10 Univariable linear regression analyses of stress measures as predictors 
of BMI z. 
BMI z Univariable regression models 
 n coefficient 95% CI P 
C-wake 163 0.001 -0.01 to 0.01 0.8 
CAR-Rate 131 0.001 -0.005 to 0.005 0.9 
C-evening 53 -0.03 -0.10 to 0.05 0.5 
C-Ratio  53 -0.36 -0.79 to 0.07 0.10 
CAR-AUC 131 -0.01 -0.02 to 0.02 0.8 
C-DayAUC 53 0.001 -0.00 to 0.003 0.13 
A-File Total Recent life Changes 172 0.02 0.00 to 0.03 0.05  
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C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.11 Univariable linear regression analyses of stress measures as predictors 
of fatmass index. 
 
Fat massindex Univariable regression models 
 n coefficient 95% CI P 
C-wake 160 0.03 -0.05 to 0.07 0.8 
CAR-Rate 131 -0.003 -0.04 to 0.03 0.8 
C-evening 53 -0.38 -0.91 to 0.16 0.16 
C-Ratio  53 -2.55 -5.42 to 0.32 0.08 
CAR-AUC 130 0.02 -0.11 to 0.14 0.8 
C-DayAUC 53 0.01 -0.003 to 0.02 0.14 
A-File Total Recent life Changes 169 0.09 -0.02 to 0.19 0.12 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
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Table 5.12 Univariable linear regression analyses of stress measures as predictors 
of waist z. 
 
waist z Univariable regression models 
 n coefficient 95% CI p 
C-wake 163 0.01 -0.01 to 0.02 0.40 
CAR-Rate 131 -0.002 -0.01 to 0.004 0.5 
C-evening 53 -0.04 -0.13 to 0.05 0.4 
C-Ratio  53 -0.35 -0.84 to 0.14 0.16 
CAR-AUC 131 0.01 -0.01 to 0.03 0.4 
C-DayAUC 53 0.002 -0.000 to 0.004 0.05 
A-File Total Recent life Changes 172 0.02 -0.003 to 0.04 0.10 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.13 Univariable linear regression analyses of stress measures as predictors 
of SAD. 
 
SAD Univariable regression models 
 n coefficient 95% CI P 
C-wake 148 -0.01 -0.06 to 0.05 0.8 
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SAD Univariable regression models 
 n coefficient 95% CI P 
CAR-Rate 121 0.01 -0.04 to 0.02 0.5 
C-evening 50 0.05 -0.41 to 0.51 0.8 
C-Ratio  50 -1.01 -3.36 to 1.34 0.4 
CAR-AUC 121 -0.03 -0.12 to 0.07 0.6 
C-DayAUC 50 0.002 -0.01 to 0.01 0.7 
A-File Total Recent life Changes 158 0.05 -0.05 to 0.15 0.3 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.14 Univariable linear regression analyses of stress measures as predictors 
of systolic z. 
 
systolic z Univariable regression models 
 n coefficient 95% CI p 
C-wake 161 0.003 -0.01 to 0.02 0.7 
CAR-Rate 129 0.001 -0.01 to 0.01 0.7 
C-evening 51 -0.07 -0.24 to 0.10 0.4 
C-Ratio  51 -0.94 -1.82 to -0.06 0.04* 
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systolic z Univariable regression models 
 n coefficient 95% CI p 
CAR-AUC 129 0.004 -0.03 to 0.04 0.8 
C-DayAUC 51 0.002 -0.002 to 0.005 0.4 
A-File Total Recent life Changes 170 -0.01 -0.04 to 0.02 0.50 
 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.15 Univariable linear regression analyses of stress measures as predictors 
of diastolic z  
 
diastolic z Univariable regression models 
 n coefficient 95% CI p 
C-wake 161 0.00 -0.01 to 0.02 0.9 
CAR-Rate 129 -0.01 -0.02 to 0.00 0.3 
C-evening 51 -0.03 -0.18 to 0.12 0.7 
C-Ratio  51 -0.51 -1.32 to 0.30 0.2 
CAR-AUC 129 -0.01 -0.05 to 0.03 0.6 
C-DayAUC 51 0.00 -0.004 to 0.003 0.6 
A-File Total Recent life Changes 170 -0.02 -0.05 to 0.01 0.19 
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C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
Table 5.16 Univariable linear regression analyses of stress measures as predictors 
of PWV. 
 
PWV Univariable regression models 
 n coefficient 95% CI P 
C-wake 136 0.002 -0.02 to 0.02 0.8 
CAR-Rate 109 0.001 -0.01 to 0.01 0.8 
C-evening 38 -0.05 -0.21 to 0.12 0.6 
C-Ratio  38 -0.12 -1.15 to 0.90 0.8 
CAR-AUC 109 0.004 -0.03 to 0.05 0.9 
C-DayAUC 38 -0.00 -0.01 to 0.00 0.6 
A-File Total Recent life Changes 145 0.03 -0.01 to 0.07 0.14 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.17 Univariable linear regression analyses of stress measures as predictors 
of cholesterol. 
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Cholesterol Univariable regression models 
 n coefficient 95% CI P 
C-wake 163 -0.002 -0.02 to 0.01 0.8 
CAR-Rate 131 -0.01  -0.01 to 0.001 0.09 
C-evening 53 0.03 -0.10 to 0.15 0.7 
C-Ratio  53 -0.09 -0.76 to 0.58 0.8 
CAR-AUC 131 -0.03 -0.05 to 0.001 0.06 
C-DayAUC 53 -0.000 -0.003 to 0.003 0.9 
A-File Total Recent life Changes 172 -0.01 -0.03 to 0.01 0.3 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.18 Univariable linear regression analyses of stress measures as predictors 
of HDL. 
 
HDL Univariable regression models 
 n coefficient 95% CI P 
C-wake 160 0.000 -0.003 to 0.004 0.9 
CAR-Rate 129 -0.00 -0.002 to 0.002 0.6 
C-evening 52 0.01 -0.03 to 0.05 0.8 
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HDL Univariable regression models 
 n coefficient 95% CI P 
C-Ratio  52 0.00 -0.21 to 0.21 0.9 
CAR-AUC 129 0.000 -0.01 to 0.01 0.9 
C-DayAUC 52 -0.00 -0.00 to 0.00 0.8 
A-File Total Recent life Changes 168 -0.002 -0.01 to 0.01 0.6 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.19 Univariable linear regression analyses of stress measures as predictors 
of triglycerides. 
 
Triglycerides Univariable regression models 
 n coefficient 95% CI P 
C-wake 163 0.01 -0.01 to 0.02 0.6 
CAR-Rate 131 -.00 -0.01 to 0.00 0.8 
C-evening 53 0.01 -0.09 to 0.08 0.8 
C-Ratio  53 0.70 -0.53 to 0.36 0.7 
CAR-AUC 131 -0.00 -0.02 to 0.02 0.9 
C-DayAUC 53 0.00 -0.00 to 0.00 0.3 
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Triglycerides Univariable regression models 
 n coefficient 95% CI P 
A-File Total Recent life Changes 171 -0.06 -0.02 to 0.01 0.4 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.20 Univariable linear regression analyses of stress measures as predictors 
of fasting insulin. 
 
Fasting insulin Univariable regression models 
 n coeffici
ent 
95% CI P 
C-wake 163 -0.04 -0.18 to 0.17 0.9 
CAR-Rate 131 -0.01 -0.11 to 0.08 0.7 
C-evening 53 -0.13 -1.18 to 0.92 0.8 
C-Ratio  53 -3.86 -9.47 to 1.76 0.17 
CAR-AUC 131 -0.21 -0.57 to 0.15 0.3 
C-DayAUC 53 0.02 -0.00 to 0.04 0.10 
A-File Total Recent life Changes 172 0.15 -0.15 to 0.46 0.3 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
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evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
Table 5.21 Univariable linear regression analyses of stress measures as predictors 
of HOMA. 
HOMA Univariable regression models 
 n Coefficient 95% CI p 
C-wake 162 0.01 -0.05 to 0.04 0.8 
CAR-Rate 130 -0.01 -0.02 to 0.02 0.9 
C-evening 52 0.01 -0.25 to 0.24 0.9 
C-Ratio  52 -0.72 -2.04 to 0.58 0.3 
CAR-AUC 130 -0.04 -0.13 to 0.04 0.3 
C-DayAUC 52 0.03 -0.01 to 0.01 0.13 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.22 Univariable linear regression analyses of stress measures as predictors 
of HbA1c. 
 
HbA1c Univariable regression models 
 n coefficient 95% CI P 
C-wake 157 0.01 -0.01 to 0.01 0.14 
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HbA1c Univariable regression models 
 n coefficient 95% CI P 
CAR-Rate 126 -0.02 -0.00 to 0.01 0.13 
C-evening 53 -0.02 -0.07 to 0.04 0.5 
C-Ratio  53 -0.09 -0.38 to 0.21 0.6 
CAR-AUC 126 0.00 -0.01 to 0.01 0.9 
C-DayAUC 53 -0.00 -0.00 to 0.00 0.5 
A-File Total Recent life Changes 166 0.01 -0.01 to 0.02 0.4 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
5.5 Associations between mental health screening, stress and 
cardiovascular risk. 
5.5.1 The DAWBA 
The DAWBA was completed by 106 young people completely and 24 partially; and 
was completed by 116 parents completely and 20 partially completed. DAWBA 
scores were able to be determined for 133 young people, of whom 45 (33%) were 
scored as having > 50 % chance of a mental health disorder. Logistic regression 
models for stress measures and adiposity and blood pressure measures as predictors 
of <50% chance of mental health disorder or not are shown in table 5.23 and 5.24 
respectively. There were no associations. 
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Table 5.23. Univariable logistic regression analyses of stress measures as predictors 
of >50% chance of any disorder from DAWBA outputs 
DAWBA any disorder Univariable logistic regression models 
 n Odd’s 
ratio 
95% CI p 
C-wake 124 0.97 0.92 to 1.01 0.19 
CAR-Rate 103 0.99 0.97 to 1.01 0.7 
C-evening 48 104 0.77 to 1.42 0.8 
C-Ratio  48 1.10 0.16 to 7.51 0.9 
CAR-AUC 103 0.96 0.89 to 1.04 0.3 
C-DayAUC 48 1.00 0.00 to 1.01 0.3 
A-File Total Recent life Changes 131 1.06 0.99 to 1.14 0.06 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.24. Univariable logistic regression analyses of adiposity and blood pressure 
measures as predictors of >50% chance of any disorder from DAWBA outputs 
 
DAWBA any disorder Univariable logistic regression models 
 n Odd’s 
ratio 
95% CI p 
BMI z 133 1.05 0.55 to 1.99 0.9 
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DAWBA any disorder Univariable logistic regression models 
 n Odd’s 
ratio 
95% CI p 
FMI 132 1.02 0.93 to 1.12  0.7 
waist 133 0.99 0.97 to 1.03 0.8 
Waist z 133 1.05 0.64 to 1.75 0.8 
SAD 124 0.98 0.88 to 1.09 0.7 
Systolic z 131 0.82 0.59 to 1.15 0.3 
Diastolic z 131 0.86 0.63 to 1.17 0.3 
 
5.5.2 The Strengths and difficulties questionnaire (SDQ) 
137 young people completed the SDQ. Of these 34 (25.8%) were estimated that a 
mental health disorder was probable. Logistic regressions of stress measures and 
adiposity and blood pressure measures as predictor of probable diagnosis or not are 
shown in tables 5.25 and 5.26 respectively. There was a small, positive association 
between risk of probable disorder and greater A-FILE score : OR 1.08 (1.01 to 1.16, p 
=0.02). There was no association between probable disorder and age, deprivation 
score, sex or puberty, though participants of Asian ethnicity were less likely to be 
categorised as probable mental health disorder compared to white participants (OR 
0.15, 95% CI 0.03 to 0.72, p = 0.02), Both the relationship of AFILE score and 
ethnicity and SDQ prediction remained significant after combining in a multivariable 
model. Further analysis looking at potential diagnosis provided by the SDQ : 
emotional, behavioural or hyperactivity did not show significant associations with 
the A-FILE. 
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Table 5.25. Univariable logistic regression analyses of stress measures as predictors 
of  probable any mental health disorder from SDQ.  
 
SDQ any disorder probable Univariable logistic regression models 
 n Odd’s 
ratio 
95% CI P 
C-wake 128 0.99 0.95 to 1.03 0.7 
CAR-Rate 105 0.99 0.97 to 1.01 0.4 
C-evening 48 1.28 0.92 to 1.78 0.15 
C-Ratio  48 0.81 0.09 0.6 
CAR-AUC 105 0.99 0.92 to 1.07 0.8 
C-DayAUC 48 1.00 0.99 to 1.01 0.12 
A-File Total Recent life Changes 135 1.08 1.01 to 1.16 0.02 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
Table 5.26. Univariable logistic regression analyses of adiposity and blood pressure 
measures as predictors of  probable any mental health disorder from SDQ.  
 
SDQ Univariable logistic regression models 
 n Odd’s 
ratio 
95% CI P 
BMI z 137 0.98 0.50 to 1.94 0.95 
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SDQ Univariable logistic regression models 
 n Odd’s 
ratio 
95% CI P 
FMI 135 0.95 0.85 to 1.06 0.4 
Waist 137 0.98 0.95 to 1.02 0.4 
Waist z 137 0.93 0.53 to 1.61 0.8 
SAD 127 0.95 0.84 to 1.06 0.4 
Systolic z 135 0.95 0.66 to 1.36 0.8 
Diastolic z 135 0.91 0.65 to 1.26 0.5 
 
5.5.3 Rosenberg’s Self Esteem Score (RSE) 
It is important to point out here that a greater RSE score means greater self esteem. 
Mean score for males was greater than females : 20.10 (SD 4.74) vs. 17.27 (SD 5.73), 
t-test : t = 3.24, df 163, p <0.01; i.e. females had lower self esteem than males in the 
sample. RSE  was not associated with ethnicity, pubertal stage or age. There was a 
positive relationship with greater IMD score (i.e greater self esteem associated with 
greater degree of deprivation) : coefficient 0.07, 95% CI 0.01 to 0.13, p = 0.04. 
Regression analyses examining relationships between the RSE with stress measures 
as predictors and adiposity and blood pressure are shown in table 5.27 and 5.28 
respectively. The A-FILE was associated negatively with RSE, i.e greater stressor 
exposures was associated with lower self esteem, and this was robust to a 
multivariable model adjusting for sex (as was the relationship with sex):  coefficient 
for A-FILE as predictor for RSE score, adjusted for sex : -0.21 (-0.36 to 0.05, p <0.01) 
however r2 = 0.08, which was small.  
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Fat mass index and waist circumference were negatively associated with RSE score, 
however they were not significant when adjusted for sex. 
Table 5.27. Univariable regression analyses of stress measures and the RSE score  
 
Rosenberg’s Univariable regression models 
 n Co-
efficient 
95% CI P 
C-wake 156 -0.01 -0.10 to 0.09 0.9 
CAR-Rate 126 0.04 -0.01 to 0.09 0.08 
C-evening 50 0.04 -0.76 to 0.85 0.9 
C-Ratio  50 1.45 -2.91 to 5.82 0.5 
CAR-AUC 126 0.09 -0.08 to 0.28 0.3 
C-DayAUC 50 -0.01 -0.02 to 0.01 0.5 
A-File Total Recent life Changes 164 -0.22 -0.37 to -0.07 <0.01 * 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
Table 5.28. Univariable regression analyses of adiposity and blood pressure 
measures and the RSE score  
 
Rosenberg’s Univariable regression models 
 n Coefficient 95% CI P 
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Rosenberg’s Univariable regression models 
 n Coefficient 95% CI P 
BMI z 165 -0.39 -1.98 TO 1.20 0.6 
Fat mass index 162 -0.30 -50 TO -0.05 0.01 * 
waist 165 -0.01 -0.08 TO 0.06 0.8 
Waist z 165 -1.26 -2.42 to -0.10 0.03 * 
SAD 152 -0.02 -0.29 to 0.25 0.9 
Systolic z 163 -0.56 -1.36 to 0.23 0.17 
Diastolic z 163 0.32 -0.43 to 1.09 0.4 
 
5.5.4 EAT-26 questionnaire : binge eating  
50 participants (28.9%) reported that they had previously binge eaten (and unable to 
stop eating) at baseline. 47 of those who had reported binge eating reported the 
number of times they had done so in the last 6 months. Median number of binge 
eating episodes in the previous 6 months was 3 episodes (IQR 2 to 10). Risk of 
bingeing was less for Asian ethnicity compared to white (Odd’s ratio 0.31, 95% CI 
0.11 to 0.91, p = 0.03), but there were no associations with other ethnic groups. Risk 
of bingeing was not significantly associated with age, sex, pubertal stage or 
deprivation score. Univariable logistic regression models with stress measures as 
predictors of self-reported bingeing is shown in table 5.29. There were no 
associations between any of the cortisol measures and risk of binge eating, however 
there was a positive association between A-FILE score (i.e. exposure to stressors in 
the last 12 months) and risk of binge eating. The effect size was however small, r2 = 
0.05.  
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Univariable logistic regression models with adiposity and blood pressure and risk of 
binge eating are shown in table 5.30. There were positive associations between most 
adiposity markers and risk of binge eating, and between systolic blood pressure and 
risk of binge eating. Effects sizes for all of these univariable models were small with 
all r2 < 0.05. 
Multivariable logistic regression models were created to predict risk of binge eating 
with the A-FILE, ethnicity, systolic z and individual adiposity measures (added in 
individually as per analysis plan : so BMI z, waist z for example not included in 
models together) as predictors. The A-FILE remained robust to adjustment in all 
models, as did systolic-z, and Asian ethnicity. The only adiposity marker that 
remained significant in multivariable modeling was SAD, with components of this 
model shown in table 5.31. R2 for this model was 0.16. 
There were no associations between any stress measure (cortisol and A-FILE), 
adiposity measure or blood pressure measure and number of times binged in 
univariable regression models (data not shown). 
There were no associations between binge eating and any of the blood markers at 
baseline, or PWV. 
Table 5.29. Univariable logistic regression analyses of stress measures and risk of 
binging from self-report (EAT-26) 
 
Risk of binge eating Univariable regression models 
 n Odd’s 
ratio 
95% CI P 
C-wake 156 0.99 0.95 to 1.03 0.8 
CAR-Rate 126 1.00 -.99 to 1.02 0.6 
C-evening 50 1.04 0.77 to1.41 0.8 
C-Ratio  50 0.40 0.04 to 4.20 0.4 
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Risk of binge eating Univariable regression models 
 n Odd’s 
ratio 
95% CI P 
CAR-AUC 126 0.97 0.89 to 1.05 0.5 
C-DayAUC 50 1.00 0.99 to 1.01 0.3 
A-File Total Recent life Changes 172 1.11 1.04 to 1.18 <0.01* 
C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of 
change. CAR-AUC : cortisol awakening response area under the curve. C-evening : 
evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day 
cortisol from awakening to evening AUC 
 
Table 5.30. Univariable logistic regression analyses of adiposity and blood pressure 
measures and risk of binging from self-report (EAT-26) 
 
Risk of binge eating Univariable regression models 
 N Odd’s 
ratio 
95%CI P 
BMI z 173 1.89 1.00 to 3.54 0.05 
Fat mass index 170 1.10 1.01 to 1.20 0.03* 
waist 173 1.04 1.01 to 1.06 0.03* 
Waist z 173 1.87 1.15 to 3.00 0.01* 
SAD 158 1.16 1.04 to 1.29 <0.01* 
Systolic z 171 1.45 1.04 to 2.01 0.03* 
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Risk of binge eating Univariable regression models 
 N Odd’s 
ratio 
95%CI P 
Diastolic z 171 0.92 0.69 to 1.23 0.6 
 
Table 5.31. Multivariable logistic regression analyses of A-FILE score, SAD, Asian 
ethnic group and systolic z blood pressure to predict risk of bingeing from self-
report (EAT-26) 
 
Variable in model  
 N Odd’s 
ratio 
95%CI P 
A-FILE score 156 
 
 
1.12 1.04 to 1.20 <0.01* 
SAD 1.18 1.05 to 1.33 0.01* 
Asian ethnicity versus white 0.20 0.06 to0.72 0.01* 
Systolic z 1.59 1.09 to 2.33 0.02* 
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Chapter 6: Longitudinal data 
Here I present the longitudinal data from the HELP trial and present analyses to 
address longitudinal aspects of all 6 research questions (namely 1) how degree of 
adiposity is associated with pulse wave velocity as a proxy of arterial stiffening at a 
longitudinal level; 2) how blood pressure is associated with pulse wave velocity as a 
proxy of arterial stiffening at a longitudinal level; and 3) how other conventional 
measures of cardio-metabolic risk such as blood testing and acanthosis nigricans are 
associated with pulse wave velocity as a proxy of arterial stiffening at a longitudinal 
level) 4) how measures of stress are associated with degree of adiposity at a 
longitudinal level; 5) how measures of stress are associated with blood pressure at a 
longitudinal level; and 6) how measures of stress are associated with pulse wave 
velocity at a longitudinal level). 
6.1 Analysis of change for variables between time points t0 and t2 
Of the 174 young people entered into the HELP trial, 87 were randomized to the 
intervention and 87 to the control. As highlighted in chapter 3 in the summary of the 
HELP trial, there were no differences in change in BMI at t2 between control and 
intervention. There were also no differences in change in any of the anthropometry 
measures, blood tests or psychological measures between control and intervention 
at time 2. 
Differences in matched pairs between time 0 and 2 are shown in table 6.1 below 
using paired t-testing. Though some of these variables were non normally 
distributed, changes were confirmed using non parametric testing and results were 
consistent (see methods). A number of variables changed between time point 0 and 
2, however the particular variable of interest, PWV, did not change between times 0 
and 2; which was the only time it was measured. The sample distributions of PWV at 
time 0 and 2 are illustrated in figure 6.1, which also demonstrates the stability of 
PWW between the two time points. 
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Table 6.1 Summary of changes in key variables measured at time 0 and 2 with 
paired t-testing. 
Variable n Mean time 0 
(SD) 
Mean time 2 
(SD) 
Mean 
difference 
(95% CI) 
t p 
PWV 72 7.26 (1.25) 7.03 (1.25) -1.29 (-0.07 
GO 0.52) 
1.46 0.15 
BMI 145 32.44 (4.45) 32.66 (4.74) 0.22 (-0.47 to 
0.02) 
-1.78 0.08 
waist 125 99.68 (11.33) 99.49 
(12.13) 
-0.19 (-098 to 
1.36) 
0.32 0.8 
Fat mass 
index 
115 13.85 (3.94) 14.28 (4.08) 0.42 (-0.67 to 
-0.17) 
-3.31 <0.01 * 
SAD 130 22.59 (3.52) 22.38 (3.60) -0.21 (-0.49 
to 0.91) 
0.58 0.6 
Systolic BP 141 106.98 
(10.34) 
109.38 
(10.47) 
2.40 (-4.34 to 
-0.45) 
-2.43 0.02 * 
Systolic z 141 -1.06 (1.08) -0.88 (1.03) 0.17 (-0.38 to 
0.02) 
-1.74 0.08 
Diastolic BP 141 54.36 (9.60) 57.01 
(11.19) 
2.65 (-4.81 to 
-0.50) 
-2.42 0.02 * 
Diastolic z 141 -0.56 (1.17) -0.29 (1.29) 0.27 (-0.53 to 
-0.01) 
-2.00 0.04 * 
Cholesterol 117 4.36 (0.91) 4.15 (0.79) -0.22 (0.12 to 
0.32) 
4.49 <0.01 * 
HDL 113 1.12 (0.23) 1.13 (0.24) 0.03 (-0.06 to -2.08 0.04 
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Variable n Mean time 0 
(SD) 
Mean time 2 
(SD) 
Mean 
difference 
(95% CI) 
t p 
-0.01) 
Triglycerides 116 1.13 (0.64) 1.08 (0.56) -0.06 (-0.05 
to 0.16) 
1.09 0.3 
Fasting insulin 117 14.88 (11.92) 18.75 
(12.41) 
3.88 (-5.61 to 
-2.15) 
-4.45 <0.01 * 
HOMA-IR 116 3.06 (0.26) 3.84 (0.24) 0.79 (-1.18 to 
-0.39) 
-3.90 <0.01 * 
HbA1c 111 5.46 (0.38) 5.44 (0.98) -0.02 (-0.17 
to 0.21) 
0.24 0.8 
C-wake 121 15.74 (10.05) 17.21 (9.10) 1.47 (-4.04 to 
1.10) 
-1.13 0.3 
CAR-Rate 72 23.54 (16.54) 24.00 
(28.43) 
0.46 (-8.37 to 
7.45) 
-0.11 0.9 
C-evening 31 1.92 (1.87) 4.03 (5.16) 2.10 (-4.01 to 
-0.19) 
-2.24 0.03 * 
C-Ratio  31 0.19 (0.32) 0.21 (0.21) 0.02 (-0.16 to 
0.10) 
-0.45 0.7 
CAR-AUC 72 10.52 (4.73) 10.79 (6.52) 0.26 (-2.11 to 
1.58) 
-0.28 0.8 
C-DayAUC 31 194.85 (86.9) 216.13 
(102.01) 
21.28 (-64.51 
to 21.95) 
-1.01 0.3 
A-FILE 132 7.66 (5.21) 5.39 (4.63) -2.28 (1.56 to 
3.00) 
6.23 <0.01* 
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Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening 
response rate of change. CAR-AUC : cortisol awakening response area under the 
curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-
DayAUC : total day cortisol from awakening to evening AUC 
 
 
Figure 6.1 Box plot of distribution of PWV at time 0 and time 2. 
 
6.2 Regression analyses using change in variables between t0 and t2 to 
predict pulse wave velocity at t2 
Regression analyses using the models described in 3.12.3 are shown in tables 6.2-
6.10. Sensitivity analyses including intervention status in models made no difference 
to models, and as explained above, there were no differences in any of the measures 
used in models between intervention and control groups in the HELP trial. 
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Table 6.2 Regression models to predict PWV at time 2 using demographic, 
adiposity, blood pressure, blood risk measures, and stress measures as predictors, 
adjusted for the same variable at time 0, PWV at time 0 and time between 
measurements for time 2 and 0 in years. 
Pulse Wave Velocity Time 2. Multivariable model components 
 n Coefficient  95% CI P 
PWV time 0 72 0.49 0.28 to 0.71 <0.01 * 
Sex  -0.31 -0.86 0.23 0.3 
Time from 0 to 2  -1.86 -4.75 to 1.03 0.20 
PWV time 0 72 0.46 0.24 to 0.68 <0.01 * 
Ethnicity      
Black versus white  0.32 -0.29 to 0.91 0.3 
Asian versus white  0.68 -0.11 to 1.47 0.3 
Mixed versus white  0.14 -0.87 to 1.13 0.8 
Time from 0 to 2  -1.44 -4.39 to 1.50 0.3 
PWV time 0 70 0.48 0.26 to 0.71 <0.01 * 
Pubertal stage time 0     
Mid Puberty versus pre/early  0.70 -0.48 to 1.87 0.2 
Late/post versus pre/early  0.99 -1.04 to 3.02 0.3 
Pubertal stage time 2     
Mid Puberty versus pre/early  -0.38 -1.91 to 1.15 0.6 
Late/post versus pre/early  -1.03 -3.33 to 1.25 0.4 
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Pulse Wave Velocity Time 2. Multivariable model components 
 n Coefficient  95% CI P 
     
Time from 0 to 2  -2.02 -5.05 to 1.01 0.19 
PWV time 0 72 0.48 0.27 to 0.70 <0.01 * 
Intervention  0.04 -0.48 to 0.57 0.8 
Time from 0 to 2  -1.75 -4.66 TO 1.16 0.2 
PWV time 0 72 0.49 0.28 to 0.69 <0.01 * 
IMD  0.02 0.01 to 0.04 0.01 * 
Time from 0 to 2  -1.94 -4.73 TO 0.84 0.17 
PWV time 0 70 0.49 0.27 to 0.70 <0.01 * 
Ever smoked  0.04 -0.61 to 0.70 0.9 
Time from 0 to 2  -1.81 -4.83 to 1.22 0.2 
PWV time 0 72 0.54 0.31 to 0.78 <0.01 * 
BMI time 0  -0.02 -0.24 to 0.19 0.8 
BMI time 2  -0.02 -0.21 to 0.18 0.9 
Time from 0 to 2  -1.72 -4.63   to 1.18 0.2 
PWV time 0 69 0.64 0.42 to 0.85 <0.01 * 
Fat mass index time 0  -0.10 -0.29 to 0.10 0.3 
Fat mass index time 2  -0.02 -0.211 to 0.16 0.8 
Time from 0 to 2  -1.81 -4.48 to 0.84 0.18 
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Pulse Wave Velocity Time 2. Multivariable model components 
 n Coefficient  95% CI P 
PWV time 0 72 0.56 0.34 to 0.78 <0.01 * 
waist time 0  -0.01 -0.05 to 0.05 0.9 
waist time 2  -0.02 -0.07 to 0.02 0.3 
Time from 0 to 2  -1.68 -4.55 to 1.19 0.3 
PWV time 0 60 0.45 0.22 to 0.69 <0.01 * 
SAD time 0  0.05 -0.04 to 0.15 0.3 
SAD time 2  0.03 -0.06 to 0.12 0.5 
Time from 0 to 2  -0.89 -3.96 to 2.17 0.6 
PWV time 0 72 0.47 0.26 to 0.69 <0.01 * 
Systolic BP time 0  0.0003 -0.03 to 0.03 0.9 
Systolic BP time 2  0.02 -0.01 to 0.05 0.3 
Time from 0 to 2  -1.92 -4.86 to 1.01 0.2 
PWV time 0 72 0.49 0.27 to 0.71 <0.01 * 
Systolic z BP time 0  -0.04 -0.34 to 0.26 0.8 
Systolic z BP time 2  0.11 -0.18to 0.40 0.5 
Time from 0 to 2  -1.86 -4.82 to 1.10 0.2 
PWV time 0 72 0.48 0.25 to 0.70 <0.01 * 
Diastolic BP time 0  0.01 -0.01 to 0.04 0.5 
Diastolic BP time 2  0.001 -0.03 to 0.03 0.94 
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Pulse Wave Velocity Time 2. Multivariable model components 
 n Coefficient  95% CI P 
Time from 0 to 2  -1.62 -4.72 to 1.58 0.3 
PWV time 0 72 0.48 0.26 to 0.70 <0.01 * 
Diastolic z BP time 0  0.09 -0.14 to 0.32 0.5 
Diastolic z BP time 2  -0.003 -0.25 to 0.25 0.9 
Time from 0 to 2  -1.56 -4.66 to 1.54 0.3 
PWV time 0 72 0.46 0.24 to 0.68 <0.01 * 
Fasting insulin time 0  -0.002 -0.03 to 0.02 0.9 
Fasting insulin time 2  0.012 -0.01 to 0.04 0.4 
Time from 0 to 2  -1.56 -4.50 to 1.37 0.3 
PWV time 0 72 0.47 0.25 to 0.69 <0.01 * 
HOMA -IR time 0  0.01 -0.11 to 0.12 0.9 
HOMA-IR time 2  0.04 -0.08 to 0.17 0.5 
Time from 0 to 2  -1.53 -4.48 to 1.41 0.3 
PWV time 0 
Abnormal fasting insulin time 0 
Abnormal  fasting insulin time 2 
Time from 0 to 2 
70 0.49 
0.24 
0.11 
-1.45 
0.26 to 0.70 
-0.51 to 0.99 
-0.52 to 0.73 
-4.47 to 1.56 
<0.01 * 
0.5 
0.7 
0.3 
PWV time 0 
Abnormal HOMA-IR time 0 
Abnormal HOMA-IR time 2 
72 0.49 
0.22 
-0.02 
0.27 to 0.71 
-0.44 to 0.87 
-0.63 to 0.59 
<0.01 * 
0.5 
0.9 
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Pulse Wave Velocity Time 2. Multivariable model components 
 n Coefficient  95% CI P 
Time from 0 to 2 -1.61 -4.56 to 1.34 0.3 
PWV time 0 69 0.46 0.23 to 0.68 <0.01 * 
HbA1c time 0  0.16 -0.55 to 0.88 0.7 
HbA1c time 2  0.05 -0.17 to 0.28 0.6 
Time from 0 to 2  -1.89 -4.91 to 1.13 0.2 
PWV time 0 72 0.52 0.31 to 0.72 <0.01 * 
Cholesterol time 0  0.71 0.25 to 1.17 0.03* 
Cholesterol time 2  -0.63 -1.15 to -0.12 0.02* 
Time from 0 to 2  -1.39 -4.15 to 1.36 0.3 
PWV time 0 70 0.48 0.27 to 0.69 <0.001 * 
HDL time 0  2.15 0.64 to 3.66 0.01 * 
HDL time 2  -2.01 -3.49 to -0.54 0.01 * 
Time from 0 to 2  -1.81 -4.62 to 0.98 0.2 
PWV time 0 71 0.47 0.25 to 0.69 <0.001 * 
Triglycerides  time 0  0.02 -0.66 to 0.71 0.9 
Triglycerides  time 2  0.23 -0.46 to 0.91 0.5 
Time from 0 to 2  -1.57 -4.53 to 1.37 0.3 
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Pulse Wave Velocity Time 2. Multivariable model components 
 n Coefficient  95% CI P 
PWV time 0 
C-wake 0 
C-wake 2 
Time from 0 to 2 
64 0.44 
0.02 
0.03 
-2.20 
0.22 to 0.65 
-0.01 to 0.04 
-0.01 to 0.08 
-4.98 to 0.57 
<0.01 * 
0.17 
0.09 
0.12 
PWV time 0 
CAR-Rate 0 
CAR-Rate 2 
Cholesterol time 0 
45 
 
 
 
0.51 
0.01 
0.01 
-2.67 
0.23 to 0.78 
-0.01 to 0.03 
-0.02 to 0.03 
-6.62 to 1.27 
<0.01* 
0.4 
0.9 
0.18 
PWV time 0 
C-evening 0 
C-evening 2 
Time from 0 to 2 
20 
 
 
0.13 
0.20 
0.05 
-0.53 
-0.48 to 0.74 
-0.25 to 0.65 
-0.10 to 0.22 
-19.4 to 18.34 
0.7 
0.4 
0.4 
0.9 
PWV time 0 
C-Ratio 0 
C-Ratio 2 
Time from 0 to 2 
20 0.14 
2.29 
-0.70 
-3.77 
-0.51 to 0.78 
-5.35 to 9.94 
-3.81 to 2.42 
-28.52 to 20.98 
0.7 
0.5 
0.6 
0.8 
PWV time 0 
CAR-AUC 0 
CAR-AUC 2 
Time from 0 to 2 
45 0.53 
0.08 
0.03 
-3.11 
0.27 to 0.80 
0.01 to 0.15 
-0.04 to 0.11 
-6.73 to 0.50 
<0.01 * 
0.03 
0.4 
0.09 
PWV time 0 
C-DayAUC time 0 
20 0.06 
0.004 
-0.61 to 0.72 
-0.001 to 0.01 
0.9 
0.08 
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Pulse Wave Velocity Time 2. Multivariable model components 
 n Coefficient  95% CI P 
C-DayAUC 2 
Time from 0 to 2 
0.001 
8.13 
-0.004 to 0.006 
-18.45 to 34.71 
0.6 
0.5 
PWV time 0 70 0.49 0.27 to 0.72 <0.01 * 
A-File Total recent life changes 
time 0 
 -0.03 -0.10 to 0.04 0.4 
A-File Total recent life changes 
time 2 
 0.03 -0.06 to 0.11 0.5 
Time from 0 to 2  -1.88 -4.86 to 1.09 0.2 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening 
response rate of change. CAR-AUC : cortisol awakening response area under the 
curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-
DayAUC : total day cortisol from awakening to evening AUC 
 
Table 6.3 Regression models to predict Cholesterol at time 2 using demographic, 
adiposity, blood pressure, blood risk measures, and stress measures as predictors, 
adjusted for the same variable at time 0, PWV at time 0 and time between 
measurements for time 2 and 0 in years. 
Cholesterol Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Cholesterol time 0 117 0.71 0.62 to 0.81 <0.01 * 
Sex  0.04 -0.14 to 0.22 0.6 
Time from 0 to 2  -0.34 -1.03 to 0.35 0.3 
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Cholesterol Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Cholesterol time 0 117    
Ethnicity      
Black versus white  0.01 -0.19 to 0.22 0.8 
Asian versus white  0.03 -0.21 to 0.27 0.7 
Mixed versus white  0.01 -0.30 to 0.31 0.9 
Time from 0 to 2  -0.35 -1.07 to 0.37 0.3 
Cholesterol time 0 115 0.73 0.64 to 0.83 <0.01 * 
Pubertal stage time 0         
Mid Puberty versus pre/early  -0.12 -0.46 to 0.22 0.4 
Late/post versus pre/early  -0.03 -0.57 to 0.50 0.9 
Pubertal stage time 2     
Mid Puberty versus pre/early  0.25 -0.23 to 0.73 0.3 
Late/post versus pre/early  0.25 -0.41 to 0.92 0.4 
     
Time from 0 to 2  -0.41 -1.09 to 0.28 0.2 
Cholesterol time 0 117 0.71 0.62 to 0.81 <0.01 * 
Intervention  0.12 -0.05 to 0.28 0.17 
Time from 0 to 2  -0.37 -1.05 to 0.31 0.3 
Cholesterol time 0 117 0.71 0.62 to 0.80 <0.01 * 
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Cholesterol Time 2 Multivariable model components 
 n Coefficient  95% CI P 
IMD  0.001 -0.01 to 0.01 0.8 
Time from 0 to 2  -0.36 -1.05 to 0.32 0.3 
Cholesterol time 0 114 0.72 0.62 to 0.81 <0.01* 
Eversmoked  0.02 -0.18 to 0.22 0.8 
Time from 0 to 2  -0.36 -1.06 to 0.33 0.3 
Cholesterol time 0 
BMI time 0 
BMI time 2 
Time from 0 to 2 
117 0.69 
0.03 
-0.01 
-0.34 
-0.60 to 0.79 
-0.04 to 0.10 
-0.07 to 0.06 
-1.02 to 0.33 
<0.01 * 
0.4 
0.8 
0.3 
Cholesterol time 0 113 0.71 0.62 to 0.80 <0.01 * 
Fat mass index time 0  0.01 -0.05 to 0.08 0.6 
Fat mass index time 2  0.01 -0.05 to 0.08 0.6 
Time from 0 to 2  -0.30 -0.99 to 0.39 0.4 
Cholesterol time 0 117 0.70 0.61 to 0.80 <0.01 * 
waist time 0  0.00 -0.02 to 0.01 0.7 
waist time 2  0.01 -0.01 to 0.02 0.2 
Time from 0 to 2  -0.40 -1.09 to 0.28 0.3 
Cholesterol time 0 104 0.71 0.61 to 0.80 <0.01 * 
SAD time 0  <0.001 * -0.03 to 0.03 0.9 
SAD time 2  0.01 -0.02 to 0.03 0.7 
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Cholesterol Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Time from 0 to 2  -0.28 -0.98 to 0.42 0.4 
Cholesterol time 0 116 0.70 0.61 to 0.80 <0.01 * 
Systolic BP time 0  0.001 -0.01 to 0.01 0.9 
Systolic BP time 2  0.004 -0.01 to 0.01 0.4 
Time from 0 to 2  -0.37 -1.07 to 0.33 0.3 
Cholesterol time 0 116 0.71 0.61 to 0.80 <0.01 * 
Systolic z BP time 0  <0.001 * -0.08 to 0.09 0.9 
Systolic z BP time 2  0.02 -0.07 to 0.12 0.6 
Time from 0 to 2  -0.35 -1.05 to 0.36 0.3 
Cholesterol time 0 116 0.71 0.62 to 0.81 <0.01 * 
Diastolic BP time 0  <0.001 * -0.01 to 0.01 0.9 
Diastolic BP time 2  <0.001 * -0.01 to 0.01 0.9 
Time from 0 to 2  -0.37 -1.07 to 0.33 0.3 
Cholesterol time 0 116 0.71 0.62 to 0.81 <0.01 * 
Diastolic z BP time 0  -0.01 -0.09 to 0.06 0.7 
Diastolic z BP time 2  -0.002 -0.08 to 0.07 0.9 
Time from 0 to 2  -0.37 -1.07 to 0.33 0.3 
Cholesterol time 0 103 0.68 0.57 to 0.79 <0.01 * 
C-wake 0  -0.003 -0.01 to 0.01 0.5 
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Cholesterol Time 2 Multivariable model components 
 n Coefficient  95% CI P 
C-wake 2  -0.002 -0.01 to 0.01 0.6 
Time from 0 to 2  -0.31 -1.03 to 0.42 0.4 
Cholesterol time 0 62 0.67 0.52 to 0.81 <0.01 * 
CAR-Rate 0  -0.005 -0.01 to 0.002 0.18 
CAR-Rate 2  -0.005 -0.01 to 0.003 0.2 
Cholesterol time 0  0.57 -0.67 to 1.81 0.3 
Cholesterol time 0 26 0.52 0.27 to 0.77 <0.01 * 
CAR-evening time 0  -0.003 -0.11 to 0.11 0.9 
CAR-evening 2  0.001 -0.05 to 0.05 0.9 
Time from 0 to 2  1.83 -3.76 to 7.42 0.5 
Cholesterol time 0 26 0.51 0.23 to 0.8 0.01 
C-ratio 0  -0.1 -0.82 to 0.63 0.7 
C-ratio 2  -0.13 -1.49 to 1.23 0.8 
Time from 0 to 2  2.53 -4.1 to 9.16 0.4 
Cholesterol time 0 62 0.69 0.54 to 0.83 <0.01 * 
CAR-AUC 0  -0.01 -0.03 to 0.02 0.6 
CAR-AUC time 2  -0.003 -0.03 to 0.02 0.7 
Time from 0 to 2  0.32 -0.94 to 1.58 0.6 
Cholesterol time 0 26 0.51 0.26 to 0.77 <0.01 * 
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Cholesterol Time 2 Multivariable model components 
 n Coefficient  95% CI P 
C-DayAUC time 0  -0.001 -0.004 to 0.002 0.4 
C-DayAUC time 2  <0.001 * -0.002 to 0.003 0.7 
Time from 0 to 2  2.63 -3.69 to 8.94 0.4 
Cholesterol time 0 115 0.72 0.62 to 0.81 <0.01 * 
A-File Total recent life changes 
time 0 
 
<0.001 * -0.02 to 0.02 0.9 
A-File Total recent life changes 
time 2 
 
0.01 -0.02 to 0.03 0.6 
Time from 0 to 2  -0.39 -1.09 to 0.3 0.3 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening 
response rate of change. CAR-AUC : cortisol awakening response area under the 
curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-
DayAUC : total day cortisol from awakening to evening AUC 
 
Table 6.4 Regression models to predict triglycerides at time 2 using demographic, 
adiposity, blood pressure, blood risk measures, and stress measures as predictors, 
adjusted for the same variable at time 0, PWV at time 0 and time between 
measurements for time 2 and 0 in years. 
 
Triglycerides Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Triglycerides time 0 116 0.51 0.38 to 0.64 <0.01 * 
 
201 
Triglycerides Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Sex  -0.08 -0.26 to 0.1 0.4 
Time from 0 to 2  0.11 -0.57 to 0.79 0.7 
Triglycerides time 0 116 0.46 0.32 to 0.6 <0.01 * 
Ethnicity      
Black versus white  -0.22 -0.42 to -0.02 0.03 
Asian versus white  0.08 -0.16 to 0.32 0.5 
Mixed versus white  -0.05 -0.34 to 0.24 0.7 
Time from 0 to 2  0.09 -0.6 to 0.78 0.8 
Triglycerides time 0 114 0.5 0.37 to 0.64 <0.01 * 
Pubertal stage time 0         
Mid Puberty versus pre/early  -0.06 -0.4 to 0.27 0.7 
Late/post versus pre/early  -0.37 -0.91 to 0.17 0.17 
Pubertal stage time 2     
Mid Puberty versus pre/early  -0.05 -0.58 to 0.48 0.8 
Late/post versus pre/early  0.29 -0.41 to 0.99 0.4 
     
Time from 0 to 2  0.1 -0.59 to 0.8 0.7 
Triglycerides time 0 116 0.51 0.38 to 0.64 <0.01 
Intervention  0.03 -0.14 to 0.20 0.7 
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Triglycerides Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Time from 0 to 2  0.14 -0.53 to 0.82 0.6 
Triglycerides time 0 116 0.52 0.39 to 0.65 <0.01 * 
IMD  -0.01 -0.01 to 0.001 0.01 
Time from 0 to 2  0.16 -0.51 to 0.83 0.6 
Triglycerides time 0 113 0.49 0.36 to 0.63 <0.01* 
Eversmoked  -0.13 -0.33 to 0.06 0.18 
Time from 0 to 2  0.20 -0.47 to 0.88 0.5 
Triglycerides time 0 116 0.52 0.38 to 0.65 <0.01 * 
BMI time 0  -0.35 -0.81 to 0.10 0.13 
BMI time 2  0.40 -0.005 to 0.80 0.05 
Time from 0 to 2  0.10 -0.57 to 0.77 0.7 
Triglycerides time 0 112 0.51 0.38 to 0.64 <0.01 * 
Fat mass index time 0  -0.03 -0.10 to 0.03 0.3 
Fat mass index time 2  0.04 -0.02 to 0.11 0.2 
Time from 0 to 2  0.08 -0.62 to 0.78 0.8 
Triglycerides time 0 116 0.50 0.37 to 0.63 <0.01 * 
waist time 0  0.00 -0.01 to 0.02 0.8 
waist time 2  0.01 -0.01 to 0.02 0.3 
Time from 0 to 2  0.11 -0.56 to 0.77 0.7 
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Triglycerides Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Triglycerides time 0 77 0.65 0.47 to 0.82 <0.01 * 
waist z time 0  -0.08 -0.39 to 0.23 0.6 
waist z time 2  0.12 -0.15 to 0.40 0.4 
Time from 0 to 2  0.41 -0.71 to 1.54 0.5 
Triglycerides time 0 103 0.51 0.37 to 0.64 <0.01 * 
SAD time 0  0.01 -0.02 to 0.03 0.7 
SAD time 2  0.02 0.004 to 0.05 0.09 
Time from 0 to 2  0.24 -0.43 to 0.91 0.5 
Triglycerides time 0 115 0.52 0.38 to 0.65 <0.01 * 
Systolic BP time 0  0.00 -0.01 to 0.01 0.5 
Systolic BP time 2  0.01 -0.004 to 0.02 0.2 
Time from 0 to 2  0.09 -0.60 to 0.78 0.8 
Triglycerides time 0 115 0.52 0.38 to 0.65 <0.01 * 
Systolic z BP time 0  -0.03 -0.12 to 0.05 0.5 
Systolic z BP time 2  0.04 -0.05 to 0.13 0.4 
Time from 0 to 2  0.10 -0.60 to 0.80 0.8 
Triglycerides time 0 115 0.52 0.39 to 0.65 <0.01 * 
Diastolic BP time 0  -0.005 -0.01 to 0.005 0.3 
Diastolic BP time 2  0.001 -0.01 to 0.01 0.9 
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Triglycerides Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Time from 0 to 2  0.12 -0.57 to 0.81 0.7 
Triglycerides time 0 115 0.52 0.39 to 0.65 <0.01 * 
Diastolic z BP time 0  -0.03 -0.11 to 0.04 0.4 
Diastolic z BP time 2  0.01 -0.07 to 0.08 0.8 
Time from 0 to 2  0.12 -0.57 to 0.81 0.7 
Triglycerides time 0 103 0.49 0.35 to 0.64 <0.01 * 
C-wake time 0  0.01 -0.004 to 0.01 0.3 
C-wake  time 2  0 -0.01 to 0.01 1.0 
Time from 0 to 2  0.18 -0.54 to 0.9 0.6 
Triglycerides time 0 64 0.54 0.38 to 0.7 <0.01 * 
C-Rate time 0  -0.004 -0.01 to 0.003 0.2 
C-Rate time 2  0.001 -0.01 to 0.01 0.8 
Cholesterol time 0  0.47 -0.67 to 1.62 0.4 
Triglycerides time 0 26 0.08 -0.2 to 0.36 0.6 
Evening cortisol time 0  -0.01 -0.1 to 0.08 0.8 
Evening cortisol time 2  -0.003 -0.04 to 0.04 0.9 
Time from 0 to 2  3.45 -1.6 to 8.5 0.17 
Triglycerides time 0 26 0.06 -0.22 to 0.34 0.6 
C-ratio time 0  0.02 -0.51 to 0.54 1.0 
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Triglycerides Time 2 Multivariable model components 
 n Coefficient  95% CI P 
C-ratio time 2  -0.42 -1.41 to 0.56 0.4 
Time from 0 to 2  3.06 -2.03 to 8.16 0.2 
Triglycerides time 0 64 0.55 0.39 to 0.7 <0.01 * 
CAR-AUC time 0  0.01 -0.01 to 0.03 0.5 
CAR-AUC time 2  0.01 -0.01 to 0.03 0.15 
Time from 0 to 2  0.26 -0.86 to 1.38 0.7 
Triglycerides time 0 26 0.06 -0.23 to 0.35 0.7 
C-DayAUC time 0  0 -0.002 to 0.002 0.8 
C-DayAUC time 2  0.001 -0.001 to 0.003 0.16 
Time from 0 to 2  3.38 -1.75 to 8.51 0.19 
Triglycerides time 0 114 0.51 0.37 to 0.64 <0.01 * 
A-File Total recent life changes 
time 0 
 
-0.01 -0.03 to 0.01 0.3 
A-File Total recent life changes 
time 2 
 
0.01 -0.02 to 0.03 0.5 
Time from 0 to 2  0.16 -0.53 to 0.84 0.6 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening 
response rate of change. CAR-AUC : cortisol awakening response area under the 
curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-
DayAUC : total day cortisol from awakening to evening AUC 
 
206 
Table 6.5 Regression models to predict HDL at time 2 using demographic, adiposity, 
blood pressure, blood risk measures, and stress measures as predictors, adjusted 
for the same variable at time 0, PWV at time 0 and time between measurements 
for time 2 and 0 in years. 
 
HDL Time 2 Multivariable model components 
 n Coefficient  95% CI P 
HDL time 0 113 0.69 0.57 to 0.82 <0.01 * 
Sex  0.03 -0.03 to 0.09 0.3 
Time from 0 to 2  -0.11 -0.35 to 0.14 0.3 
HDL time 0 113 0.68 0.55 to 0.81 <0.01 * 
Ethnicity      
Black versus white  0.06 -0.01 to 0.13 0.1 
Asian versus white  -0.01 -0.09 to 0.08 0.9 
Mixed versus white  0.01 -0.1 to 0.11 0.9 
Time from 0 to 2  -0.1 -0.35 to 0.15 0.4 
HDL time 0 111 0.7 0.56 to 0.83 <0.01 * 
Pubertal stage time 0         
Mid Puberty versus pre/early  -0.01 -0.13 to 0.11 0.8 
Late/post versus pre/early  -0.01 -0.21 to 0.18 0.9 
Pubertal stage time 2     
Mid Puberty versus pre/early  0.05 -0.14 to 0.25 0.6 
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HDL Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Late/post versus pre/early  0.09 -0.16 to 0.34 0.5 
     
Time from 0 to 2  -0.14 -0.39 to 0.11 0.3 
HDL time 0 113 0.70 0.57 to 0.83 <0.01 * 
Intervention  0.01 -0.06 to 0.07 0.8 
Time from 0 to 2  -0.12 -0.37 to 0.12 0.3 
HDL time 0 113 0.70 0.57 to 0.83 <0.01 * 
IMD  0.001 -0.002 to 0.003 0.6 
Time from 0 to 2  -0.12 -0.37 to 0.12 0.3 
HDL time 0 110 0.70 0.57 to 0.83 <0.01 * 
Eversmoked  -0.002 -0.07 to 0.07 0.9 
Time from 0 to 2  -0.12 -0.37 to 0.12 0.3 
HDL time 0 113 0.67 0.54 to 0.80 <0.01* 
BMI time 0  -0.07 -0.23 to 0.10 0.4 
BMI time 2  0.02 -0.13 to 0.16 0.8 
Time from 0 to 2  -0.14 -0.38 to 0.11 0.3 
HDL time 0 110 0.69 0.56 to 0.83 <0.01 * 
Fat mass index time 0  0.00 -0.03 to 0.02 0.7 
Fat mass index time 2  0.00 -0.02 to 0.03 0.8 
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HDL Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Time from 0 to 2  -0.14 -0.39 to 0.11 0.3 
HDL time 0 113 0.65 0.52 to 0.77 <0.01 * 
waist time 0  -0.01 -0.01 to -0.001 0.02* 
waist time 2  0.003 0.002 to 0.01 0.2 
Time from 0 to 2  -0.15 -0.38 to 0.09 0.2 
HDL time 0 100 0.60 0.48 to 0.73 <0.01 * 
SAD time 0  -0.01 -0.02 to 0.004 0.2 
SAD time 2  0.00 -0.01 to 0.01 0.8 
Time from 0 to 2  -0.10 -0.33 to 0.12 0.4 
HDL time 0 112 0.70 0.58 to 0.83 <0.01 * 
Systolic BP time 0  0.001 -0.002 to 0.004 0.5 
Systolic BP time 2  -0.002 -0.01 to 0.001 0.2 
Time from 0 to 2  -0.10 -0.35 to 0.14 0.4 
HDL time 0 112 0.70 0.58 to 0.83 <0.01 * 
Systolic z BP time 0  0.01 -0.02 to 0.04 0.5 
Systolic z BP time 2  -0.02 -0.05 to 0.01 0.2 
Time from 0 to 2  -0.11 -0.36 to 0.13 0.3 
HDL time 0 112 0.7 0.57 to 0.83 <0.01 * 
Diastolic BP time 0  0 -0.004 to 0.003 0.8 
 
209 
HDL Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Diastolic BP time 2  0 -0.003 to 0.004 0.8 
Time from 0 to 2  -0.13 -0.38 to 0.12 0.3 
HDL time 0 112 0.7 0.57 to 0.83 <0.01 * 
Diastolic z BP time 0  -0.01 -0.03 to 0.02 0.6 
Diastolic z BP time 2  0 -0.03 to 0.03 1.0 
Time from 0 to 2  -0.12 -0.37 to 0.13 0.3 
HDL time 0 100 0.71 0.57 to 0.85 <0.01 * 
C-wake 0  -0.003 -0.01 to 0 0.04* 
C-wake  time 2  -0.001 -0.004 to 0.003 0.7 
Time from 0 to 2  -0.12 -0.36 to 0.13 0.4 
HDL time 0 62 0.7 0.53 to 0.87 <0.01 * 
CAR-Rate time 0  -0.001 -0.003 to 0.002 0.6 
CAR-Rate time 2  -0.001 -0.004 to 0.002 0.7 
Cholesterol time 0  0.13 -0.36 to 0.62 0.6 
HDL time 0 25 0.73 0.42 to 1.05 <0.01 * 
C-evening time 0  0.01 -0.03 to 0.05 0.6 
C-evening time 2  0.01 -0.01 to 0.03 0.18 
Time from 0 to 2  0.86 -1.54 to 3.26 0.4 
HDL time 0 25 0.77 0.45 to 1.09 <0.01 * 
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HDL Time 2 Multivariable model components 
 n Coefficient  95% CI P 
C-ratio 0  0.12 -0.14 to 0.38 0.3 
C-ratio time 2  0.09 -0.47 to 0.66 0.7 
Time from 0 to 2  0.81 -1.69 to 3.3 0.5 
HDL time 0 62 0.71 0.53 to 0.88 <0.01 * 
CAR-AUC time 0  -0.01 -0.02 to 0.002 0.11 
CAR-AUC time 2  0.001 -0.01 to 0.01 0.8 
Time from 0 to 2  0.19 -0.29 to 0.66 0.4 
HDL time 0 25 0.69 0.36 to 1.03 <0.01 * 
C-DayAUC time 0  -0.001 -0.002 to 0 0.16 
C-DayAUC time 2  0.001 0 to 0.002 0.2 
Time from 0 to 2  0.67 -1.92 to 3.25 0.5 
HDL time 0 112 0.71 0.57 to 0.84 <0.01 * 
A-File Total recent life changes 
time 0 
 
0.003 -0.01 to 0.01 0.5 
A-File Total recent life changes 
time 2 
 
-0.003 -0.01 to 0.01 0.5 
Time from 0 to 2  -0.12 -0.37 to 0.13 0.3 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening 
response rate of change. CAR-AUC : cortisol awakening response area under the 
curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-
DayAUC : total day cortisol from awakening to evening AUC 
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Table 6.6 Regression models to predict fasting insulin at time 2 using demographic, 
adiposity, blood pressure, blood risk measures, and stress measures as predictors, 
adjusted for the same variable at time 0, PWV at time 0 and time between 
measurements for time 2 and 0 in years. 
 
Fasting insulin Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Fasting insulin time 0 117 0.73 0.59 to 0.87 <0.01 * 
Sex  1.67 -1.81 to 5.15 0.3 
Time from 0 to 2  -1.81 -15.24 to 11.62 0.8 
Fasting insulin time 0 117 0.7 0.56 to 0.84 <0.01 * 
Ethnicity      
Black versus white  1.09 -2.86 to 5.04 0.5 
Asian versus white  5.05 0.51 to 9.6 0.03* 
Mixed versus white  3.23 -2.47 to 8.92 0.2 
Time from 0 to 2  -4.08 -17.82 to 9.67 0.5 
Fasting insulin time 0 115 0.74 0.6 to 0.88 <0.01 * 
Pubertal stage time 0         
Mid Puberty versus pre/early  5.43 -1.15 to 12.01 0.11 
Late/post versus pre/early  5.98 -4.63 to 16.59 0.3 
Pubertal stage time 2     
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Fasting insulin Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Mid Puberty versus pre/early  0.38 -9.1 to 9.86 0.9 
Late/post versus pre/early  -1.38 -14.52 to 11.76 0.8 
     
Time from 0 to 2  -4.61 -18.22 to 8.99 0.5 
Fasting insulin time 0 117 0.73 0.58 to 0.87 <0.01 * 
Intervention  0.10 -3.22 to 3.43 0.9 
Time from 0 to 2  -2.70 -16.07 to 10.66 0.6 
Fasting insulin time 0 117 0.72 0.59 to 0.86 < 0.01 * 
IMD  0.02 -0.10 to 0.15 0.7 
Time from 0 to 2  -2.77 -16.12 to 10.59 0.7 
Fasting insulin time 0 114 0.71 0.57 to 0.85 < 0.01 * 
Eversmoked  0.31 -3.58 to 4.20 0.8 
Time from 0 to 2  -2.63 -16.05 to 10.79 0.7 
Fasting insulin time 0 117 0.69 0.54 to 0.83 <0.01 * 
BMI time 0  -1.65 -10.50 to 7.20 0.7 
BMI time 2  4.59 -3.28 to 12.46 0.3 
Time from 0 to 2  -3.51 -16.64 to 9.62 0.6 
Fasting insulin time 0 113 0.72 0.58 to 0.86 <0.01 * 
Fat mass index time 0  -0.64 -1.93 to 0.66 0.3 
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Fasting insulin Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Fat mass index time 2  0.92 -0.32 to 2.17 0.14 
Time from 0 to 2  -3.43 -16.77 to 9.91 0.6 
Fasting insulin time 0 117 0.68 0.53 to 0.82 <0.01 * 
waist time 0  0.12 -0.18 to 0.42 0.4 
waist time 2  0.05 -0.22 to 0.31 0.7 
Time from 0 to 2  -3.66 -16.87 to 9.56 0.5 
Fasting insulin time 0 104 0.68 0.53 to 0.83 <0.01 * 
SAD time 0  0.02 -0.54 to 0.58 0.9 
SAD time 2  0.51 -0.04 to 1.05 0.07 
Time from 0 to 2  -4.67 -18.17 to 8.83 0.4 
Fasting insulin time 0 116 0.71 0.57 to 0.85 <0.01 * 
Systolic BP time 0  <0.001 * -0.17 to 0.17 1.0 
Systolic BP time 2  0.23 0.04 to 0.41 0.02* 
Time from 0 to 2  -3.60 -16.88 to 9.68 0.6 
Fasting insulin time 0 116 0.71 0.57 to 0.85 <0.01 * 
Systolic z BP time 0  -0.12 -1.77 to 1.52 0.9 
Systolic z BP time 2  1.93 0.20 to 3.66 0.03* 
Time from 0 to 2  -2.29 -15.76 to 11.17 0.7 
Fasting insulin time 0 166 0.72 0.58 to 0.86 <0.01 * 
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Fasting insulin Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Diastolic BP time 0  0.11 -0.08 to 0.29 0.3 
Diastolic BP time 2  0.02 -0.15 to 0.2 0.8 
Time from 0 to 2  -2.85 -16.37 to 10.67 0.7 
Fasting insulin time 0 116 0.72 0.58 to 0.86 <0.01 * 
Diastolic z BP time 0  0.77 -0.71 to 2.24 0.3 
Diastolic z BP time 2  0.17 -1.28 to 1.63 0.8 
Time from 0 to 2  -2.85 -16.4 to 10.69 0.6 
Fasting insulin time 0 103 0.71 0.55 to 0.87 <0.01 * 
C-wake  time 0  0.08 -0.1 to 0.27 0.4 
C-wake  time 2  -0.02 -0.23 to 0.19 0.9 
Time from 0 to 2  -2.39 -16.67 to 11.9 0.7 
Fasting insulin time 0 64 1.01 0.76 to 1.26 <0.01 * 
CAR-Rate time 0  0.004 -0.14 to 0.15 0.9 
CAR-Rate time 2  -0.04 -0.2 to 0.12 0.6 
Cholesterol time 0  8.9 -17.26 to 35.06 0.5 
Fasting insulin time 0 26 1.3 0.93 to 1.67 <0.01 * 
C-evening 0  -0.67 -2.06 to 0.71 0.3 
C-evening 2  -0.13 -0.76 to 0.5 0.6 
Time from 0 to 2  11.52 -56.8 to 79.84 0.7 
 
215 
Fasting insulin Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Fasting insulin time 0 26 1.21 0.83 to 1.59 <0.01 * 
C-Ratio 0  -4.79 -13.18 to 3.61 0.3 
C-Ratio time 2  -5.7 -21.11 to 9.72 0.4 
Time from 0 to 2  21.76 -54.67 to 98.19 0.5 
Fasting insulin time 0 64 1 0.75 to 1.26 <0.01 * 
CAR-AUC time 0  0.34 -0.16 to 0.84 0.18 
CAR-AUC time 2  -0.09 -0.55 to 0.38 0.7 
Time from 0 to 2  3.79 -21.97 to 29.55 0.7 
Fasting insulin time 0 26 1.23 0.76 to 1.7 <0.01 * 
C-DayAUC time 0  0.004 -0.04 to 0.04 0.8 
C-DayAUC time 2  0.01 -0.02 to 0.04 0.6 
Time from 0 to 2  6.58 -70.22 to 83.38 0.8 
Fasting insulin time 0 115 0.73 0.59 to 0.87 <0.01 * 
A-File Total recent life changes 
time 0 
 
0.11 -0.31 to 0.52 0.6 
A-File Total recent life changes 
time 2 
 
0.09 -0.38 to 0.56 0.7 
Time from 0 to 2  -3.57 -17.14 to 10 0.6 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening 
response rate of change. CAR-AUC : cortisol awakening response area under the 
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curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-
DayAUC : total day cortisol from awakening to evening AUC 
 
Table 6.7 Regression models to predict HOMA-IR at time 2 using demographic, 
adiposity, blood pressure, blood risk measures, and stress measures as predictors, 
adjusted for the same variable at time 0, PWV at time 0 and time between 
measurements for time 2 and 0 in years. 
 
HOMA-IR Time 2 Multivariable model components 
 n Coefficient  95% CI P 
HOMA-IR time 0 116 0.64 0.51 to 0.78 <0.01 * 
Sex  0.32 -0.45 to 1.09 0.4 
Time from 0 to 2  -0.47 -3.41 to 2.47 0.7 
HOMA-IR time 0 116 0.61 0.47 to 0.74 <0.01 * 
Ethnicity      
Black versus white  0.13 -0.74 to 0.99 0.7 
Asian versus white  1.09 0.09 to 2.08 0.03* 
Mixed versus white  0.64 -0.61 to 1.88 0.3 
Time from 0 to 2  -0.97 -3.97 to 2.03 0.5 
HOMA-IR time 0 114 0.64 0.5 to 0.77 <0.01 * 
Pubertal stage time 0         
Mid Puberty versus pre/early  1.19 -0.29 to 2.66 0.11 
Late/post versus pre/early  0.89 -1.46 to 3.23 0.4 
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HOMA-IR Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Pubertal stage time 2     
Mid Puberty versus pre/early  0.34 -1.76 to 2.44 0.7 
Late/post versus pre/early  0.28 -2.6 to 3.17 0.8 
     
Time from 0 to 2  -1.15 -4.12 to 1.82 0.4 
HOMA-IR time 0 116 0.63 0.50 to 0.76 <0.01 * 
Intervention  0.08 -0.65 to 0.81 0.8 
Time from 0 to 2  -0.66 -3.58 to 2.26 0.4 
HOMA-IR time 0 116 0.63 0.50 to 0.76 <0.01 * 
IMD  0.01 -0.02 to 0.03 0.6 
Time from 0 to 2  -0.67 -3.59 to 2.24 0.6 
HOMA-IR time 0 113 0.62 0.48 to 0.75 <0.01 * 
Eversmoked  0.006 -0.85 to 0.86 1.0 
Time from 0 to 2  -0.63 -3.57 to 2.30 0.6 
HOMA-IR time 0 116 0.60 0.46 to 0.73 <0.01 * 
BMI time 0  -0.11 -2.04 to 1.81 0.9 
BMI time 2  0.87 -0.83 to 2.58 0.3 
Time from 0 to 2  -0.82 -3.67 to 2.03 0.6 
HOMA-IR time 0 112 0.64 0.51 to 0.77 <0.01 * 
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HOMA-IR Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Fat mass index time 0  -0.11 -0.39 to 0.17 0.4 
Fat mass index time 2  0.19 -0.08 to 0.46 0.17 
Time from 0 to 2  -0.73 -3.65 to -2.19 0.6 
HOMA-IR time 0 116 0.58 0.45 to 0.71 <0.01 * 
waist time 0  0.04 -0.03 to 0.10 0.3 
waist time 2  0.01 -0.05 to 0.07 0.7 
Time from 0 to 2  -0.91 -3.76  to 1.95 0.5 
HOMA-IR time 0 103 0.59 0.45 to 0.72 <0.01 * 
SAD time 0  0.01 -0.12 to 0.13 0.9 
SAD time 2  0.15 0.03 to 0.26 0.02* 
Time from 0 to 2  -1.07 -3.98 to 1.83 0.5 
HOMA-IR time 0 115 0.61 0.48 to 0.74 <0.01 * 
Systolic BP time 0  0.002 -0.04 to 0.04 0.9 
Systolic BP time 2  0.05 0.01 to 0.09 0.01 
Time from 0 to 2  -0.84 -3.73 to 2.05 0.6 
HOMA-IR time 0 115 0.62 0.49 to 0.75 <0.01 * 
Systolic z BP time 0  -0.01 -0.37 to 0.35 1.0 
Systolic z BP time 2  0.43 0.05 to 0.81 0.03* 
Time from 0 to 2  -0.55 -3.48 to 2.39 0.7 
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HOMA-IR Time 2 Multivariable model components 
 n Coefficient  95% CI P 
HOMA-IR time 0 115 0.62 0.49 to 0.76 <0.01 * 
Diastolic BP time 0  0.03 -0.01 to 0.07 0.14 
Diastolic BP time 2  0.002 -0.04 to 0.04 0.9 
Time from 0 to 2  -0.63 -3.58 to 2.31 0.6 
HOMA-IR time 0 115 0.62 0.49 to 0.75 <0.01 * 
Diastolic z BP time 0  0.22 -0.1 to 0.54 0.18 
Diastolic z BP time 2  0.01 -0.3 to 0.33 0.9 
Time from 0 to 2  -0.65 -3.59 to 2.3 0.6 
HOMA-IR time 0 102 0.61 0.47 to 0.76 <0.01 * 
C-wake  time 0  0.02 -0.02 to 0.06 0.4 
C-wake  time 2  -0.002 -0.05 to 0.04 0.9 
Time from 0 to 2  -0.7 -3.8 to 2.4 0.6 
HOMA-IR time 0 64 0.96 0.71 to 1.22 <0.01 * 
CAR-Rate time 0  -0.002 -0.03 to 0.03 0.8 
CAR-Rate time 2  -0.01 -0.04 to 0.03 0.7 
Cholesterol time 0  1.91 -3.63 to 7.45 0.4 
HOMA-IR time 0 26 1.21 0.84 to 1.58 <0.01 * 
C-evening time 0  -0.18 -0.48 to 0.12 0.2 
C-evening time 2  -0.03 -0.16 to 0.11 0.6 
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HOMA-IR Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Time from 0 to 2  3.98 -10.74 to 18.7 0.5 
HOMA-IR time 0 26 1.11 0.73 to 1.48 <0.01 * 
C-Ratio time 0  -1.17 -2.95 to 0.62 0.19 
C-Ratio time 2  -1.17 -4.49 to 2.16 0.4 
Time from 0 to 2  6.98 -9.35 to 23.32 0.3 
HOMA-IR time 0 64 0.95 0.7 to 1.21 <0.01 * 
CAR-AUC time 0  0.06 -0.04 to 0.17 0.2 
CAR-AUC time 2  -0.01 -0.11 to 0.09 0.8 
Time from 0 to 2  0.86 -4.61 to 6.33 0.7 
HOMA-IR time 0 26 1.16 0.7 to 1.63 <0.01 * 
C-DayAUC time 0  <0.001 * -0.01 to 0.01 0.9 
C-DayAUC AUC time 2  0.002 -0.005 to 0.01 0.5 
Time from 0 to 2  3.46 -13.3 to 20.21 0.6 
HOMA-IR time 0 114 0.63 0.5 to 0.77 <0.01 * 
A-File Total recent life changes 
time 0 
 
0.01 -0.08 to 0.1 0.8 
A-File Total recent life changes 
time 2 
 
0.01 -0.09 to 0.12 0.8 
Time from 0 to 2  -0.77 -3.74 to 2.21 0.6 
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Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening 
response rate of change. CAR-AUC : cortisol awakening response area under the 
curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-
DayAUC : total day cortisol from awakening to evening AUC 
 
Table 6.8 Regression models to predict HbA1c at time 2 using demographic, 
adiposity, blood pressure, blood risk measures, and stress measures as predictors, 
adjusted for the same variable at time 0, PWV at time 0 and time between 
measurements for time 2 and 0 in years. 
 
HbA1c Time 2 Multivariable model components 
 n Coefficient  95% CI P 
HbA1c time 0 111 0.33 -0.15 to 0.81 0.17 
Sex  0.21 -0.17 to 0.6 0.3 
Time from 0 to 2  -0.13 -1.6 to 1.34 0.8 
HbA1c time 0 111 0.45 -0.07 to 0.97 0.09 
Ethnicity      
Black versus white  0.1 -0.35 to 0.56 0.6 
Asian versus white  -0.2 -0.73 to 0.34 0.5 
Mixed versus white  0.48 -0.17 to 1.14 0.15 
Time from 0 to 2  -0.52 -2.06 to 1.01 0.5 
HbA1c time 0 109 0.29 -0.2 to 0.78 0.2 
Pubertal stage time 0         
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HbA1c Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Mid Puberty versus pre/early  0.85 0.13 to 1.57 0.02 
Late/post versus pre/early  0.81 -0.34 to 1.96 0.16 
Pubertal stage time 2     
Mid Puberty versus pre/early  -0.92 -1.95 to 0.11 0.08 
Late/post versus pre/early  -0.93 -2.35 to 0.49 0.2 
     
Time from 0 to 2  -0.43 -1.91 to 1.04 0.5 
HbA1c time 0 111 0.35 -0.13 to 0.83 0.15 
Intervention  -0.28 -0.65 to 0.08 0.13 
Time from 0 to 2  -0.20 -1.65 to 1.25 0.7 
HbA1c time 0 111 0.26 -0.23 to 0.75 0.3 
IMD  0.01 -0.01 to 0.02 0.3 
Time from 0 to 2  -0.23 -1.70 to 1.23 0.7 
HbA1c time 0 108 0.36 -0.14 to 0.87 0.16 
Eversmoked  0.26 -0.20 to 0.72 0.3 
Time from 0 to 2  -0.25 -1.73 to 1.23 0.7 
HbA1c time 0 111 0.32 -0.17 to 0.80 0.20 
BMI time 0  -0.75 -1.75 to 0.25 0.14 
BMI time 2  0.79 -0.11 to 1.68 0.09 
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HbA1c Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Time from 0 to 2  -0.31 -1.77 to 1.15  0.7 
HbA1c time 0 107 0.30 -0.20 to 0.80 0.2 
Fat mass index time 0  -0.01 -0.16 to 0.14 0.8 
Fat mass index time 2  0.04 -0.11 to 0.18 0.6 
Time from 0 to 2  -0.22 -1.75 to 1.31 0.7 
HbA1c time 0 111 0.30 -0.18 to 0.79 0.2 
waist time 0  0.002 -0.03 to 0.03 0.9 
waist time 2  0.004 -0.03 to 0.03 0.8 
Time from 0 to 2  -0.24 -1.72 to 1.24 0.8 
HbA1c time 0 99 0.09 -0.47 to 0.65 0.7 
SAD time 0  0.04 -0.02 to 0.11 0.19 
SAD time 2  0.01 -0.05 to 0.08 0.7 
Time from 0 to 2  -0.27 -1.83 to 1.30 0.7 
HbA1c time 0 110 0.40 -0.09 to 0.89 0.11 
Systolic BP time 0  0.01 -0.01 to 0.02 0.6 
Systolic BP time 2  0.02 -0.003 to 0.04 0.10 
Time from 0 to 2  -0.18 -1.67 to 1.30 0.8 
HbA1c time 0 110 0.37 -0.11 to 0.86 0.13 
Systolic z BP time 0  0.04 -0.15 to 0.22 0.7 
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HbA1c Time 2 Multivariable model components 
 n Coefficient  95% CI P 
Systolic z BP time 2  0.15 -0.04 to 0.35 0.13 
Time from 0 to 2  -0.08 -1.58 to 1.42 0.9 
HbA1c time 0 110 0.33 -0.17 to 0.82 0.19 
Diastolic BP time 0  0.01 -0.01 to 0.03 0.5 
Diastolic BP time 2  -0.004 -0.02 to 0.02 0.7 
Time from 0 to 2  -0.16 -1.66 to 1.34 0.8 
HbA1c time 0 110 0.32 -0.17 to 0.81 0.2 
Diastolic z BP time 0  0.05 -0.12 to 0.21 0.5 
Diastolic z BP time 2  -0.04 -0.2 to 0.12 0.6 
Time from 0 to 2  -0.15 -1.65 to 1.35 0.8 
HbA1c time 0 97 0.2 -0.35 to 0.75 0.5 
Awakening cortisol  time 0  0.01 -0.01 to 0.04 0.2 
Awakening cortisol  time 2  -0.02 -0.04 to 0.01 0.16 
Time from 0 to 2  -0.12 -1.7 to 1.46 0.8 
HbA1c time 0 61 0.03 -0.89 to 0.95 0.9 
Rate of change awakening 
cortisol rate time 0 
 
-0.01 -0.03 to 0.01 0.2 
Rate of change awakening 
cortisol rate time 2 
 
0.003 -0.02 to 0.03 0.7 
Cholesterol time 0  0.08 -3.56 to 3.73 0.9 
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HbA1c Time 2 Multivariable model components 
 n Coefficient  95% CI P 
HbA1c time 0 26 1.05 0.79 to 1.31 <0.01 * 
Evening cortisol time 0  -0.01 -0.05 to 0.03 0.6 
Evening cortisol time 2  -0.01 -0.03 to 0.01 0.17 
Time from 0 to 2  -0.58 -2.61 to 1.45 0.5 
HbA1c time 0 26 1.07 0.81 to 1.33 <0.01 * 
Ratio awakening to evening 
cortisol time 0 
 
-0.19 -0.44 to 0.05 0.11 
Ratio awakening to evening 
cortisol time 2 
 
-0.17 -0.61 to 0.28 0.4 
Time from 0 to 2  -0.32 -2.54 to 1.9 0.7 
HbA1c time 0 61 0.1 -0.86 to 1.06 0.8 
Awakening cortisol AUC time 0  0.02 -0.05 to 0.1 0.5 
Awakening cortisol AUC time 2  -0.03 -0.1 to 0.04 0.3 
Time from 0 to 2  -0.88 -4.53 to 2.78 0.6 
HbA1c time 0 26 1.06 0.78 to 1.34 <0.01 * 
Day cortisol AUC time 0  <0.001 * -0.001 to 0.001 0.5 
Day cortisol AUC time 2  <0.001 * -0.001 to 0.001 0.7 
Time from 0 to 2  -0.86 -3.13 to 1.4 0.4 
HbA1c time 0 109 0.31 -0.18 to 0.8 0.2 
A-File Total recent life changes  0.002 -0.05 to 0.05 0.9 
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HbA1c Time 2 Multivariable model components 
 n Coefficient  95% CI P 
time 0 
A-File Total recent life changes 
time 2 
 
0.02 -0.03 to 0.08 0.4 
Time from 0 to 2  -0.29 -1.78 to 1.21 0.7 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening 
response rate of change. CAR-AUC : cortisol awakening response area under the 
curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-
DayAUC : total day cortisol from awakening to evening AUC 
 
Table 6.9 Logistic regression models to predict abnormal fasting insulin at time 2 
using demographic, adiposity, blood pressure, blood risk measures, and stress 
measures as predictors, adjusted for the same variable at time 0, PWV at time 0 
and time between measurements for time 2 and 0 in years. 
 
Abnormal insulin Time 2 Multivariable model components 
 n Odds ratio 95% CI p 
Abnormal insulin time 0 115 12.56 4.23 to 37.27 <0.01 * 
Sex  1.21 0.46 to 3.2 0.7 
Time from 0 to 2  0.34 0.003 to 34.42 0.6 
Abnormal insulin time 0 115 14.82 4.47 to 49.09 <0.01 * 
Ethnicity      
Black versus white  2.03 0.59 to 0.76 0.2 
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Abnormal insulin Time 2 Multivariable model components 
 n Odds ratio 95% CI p 
Asian versus white  2.68 0.71 to 10.09 0.15 
Mixed versus white  7.42 1.59 to 34.65 0.01* 
Time from 0 to 2  0.12 0.001 to 11.51 0.3 
Abnormal insulin time 0 115 32.66 6.77 to 157.51 <0.01 * 
Pubertal stage time 0         
Mid Puberty versus pre/early  21.5 1.85 to 250.48 0.01* 
Late/post versus pre/early  3.81 0.17 to 85.29 0.4 
Pubertal stage time 2     
Mid Puberty versus pre/early  0.01 <0.001 * to 0.16 <0.01 * 
Late/post versus pre/early  0.03 0.001 to 1.45 0.08 
     
Time from 0 to 2  0.09 <0.001 * to 37.02 0.4 
Abnormal insulin time 0 115 13.27 4.40 to 39.99 <0.001 * 
Intervention  0.69 0.27 to 1.76 0.4 
Time from 0 to 2  0.35 0.01 to 29.29 0.6 
Abnormal insulin time 0 115 12.01 4.16 to 35.18 <0.01 * 
IMD  1.00 0.97 to 1.03 1.00 
Time from 0 to 2  0.31 0.003 to 30.14 0.6 
Abnormal insulin time 0 112 11.19 3.82 to 32.79 <0.001 * 
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Abnormal insulin Time 2 Multivariable model components 
 n Odds ratio 95% CI p 
Eversmoked  1.05 0.36 to 3.02 0.9 
Time from 0 to 2  0.30 0.003 to 28.96 0.6 
Abnormal insulin time 0 115 10.13 3.30 to 31.03  <0.001 * 
BMI time 0  0.60 0.04 to 8.63 0.7 
BMI time 2  2.39 0.21 to 27.19 0.5 
Time from 0 to 2  0.23 0.00 to 28.35 0.5 
Abnormal insulin time 0 111 14.62 4.48 to 47.73 <0.01 * 
Fat mass index time 0  0.93 0.64 to 1.34 0.7 
Fat mass index time 2  1.06 0.74 to 1.52 0.7 
Time from 0 to 2  0.29 0.00 to 30.16 0.6 
Abnormal insulin time 0 115 11.11 3.45 to 35.72 <0.01 * 
waist time 0  1.00 0.91 to 1.09 0.9 
waist time 2  1.01 0.94 to 1.09 0.7 
Time from 0 to 2  0.27 0.003 to 28.04 0.5 
Abnormal insulin time 0 102 11.88 3.46 to 40.80 <0.01 * 
SAD time 0  0.96 0.82 to 1.12 0.6 
SAD time 2  1.06 0.91 to 1.23 0.5 
Time from 0 to 2  0.21 0.002 to 29.68 0.5 
Abnormal insulin time 0 114 11.79 4.01 to 34.69 <0.01 * 
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Abnormal insulin Time 2 Multivariable model components 
 n Odds ratio 95% CI p 
Systolic BP time 0  1.01 0.96 to 1.06 0.7 
Systolic BP time 2  1.03 0.98 to 1.08 0.3 
Time from 0 to 2  0.29 0.003 to 32.37 0.6 
Abnormal insulin time 0 114 11.46 3.93 to 33.44 <0.01 * 
Systolic z BP time 0  1.02 0.65 to 1.59 0.9 
Systolic z BP time 2  1.18 0.73 to 1.91 0.5 
Time from 0 to 2  0.31 0.003 to 33.50 0.6 
Abnormal insulin time 0 114 12.41 4.21 to 36.59 <0.01 * 
Diastolic BP time 0  1.02 0.97 to 1.08 0.3 
Diastolic BP time 2  1 0.95 to 1.04 0.8 
Time from 0 to 2  0.31 0.003 to 34.96 0.6 
Abnormal insulin time 0 114 12.15 4.15 to 35.54 <0.01 * 
Diastolic z BP time 0  1.18 0.79 to 1.76 0.4 
Diastolic z BP time 2  0.97 0.66 to 1.43 0.8 
Time from 0 to 2  0.31 0.003 to 33.57 0.6 
Abnormal insulin time 0 101 9.11 2.97 to 27.96 <0.01 * 
Awakening cortisol  time 0  1 0.96 to 1.05 0.9 
Awakening cortisol  time 2  0.97 0.91 to 1.02 0.2 
Time from 0 to 2  0.22 0.001 to 36.24 0.5 
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Abnormal insulin Time 2 Multivariable model components 
 n Odds ratio 95% CI p 
Abnormal insulin time 0 63 9.65 2.2 to 42.27 0.03* 
Rate of change awakening 
cortisol rate time 0 
 
0.98 0.94 to 1.02 0.4 
Rate of change awakening 
cortisol rate time 2 
 
1.01 0.97 to 1.05 0.6 
Cholesterol time 0  0.89 0.001 to 859.21 1.0 
Abnormal insulin time 0 25 11.07 1.17 to 104.45 0.04* 
Evening cortisol time 0  1.04 0.67 to 1.63 0.8 
Evening cortisol time 2  0.98 0.79 to 1.22 0.8 
Time from 0 to 2  54600000 0.004 to 7.01E+17 0.13 
Abnormal insulin time 0 25 9.91 0.89 to 109.93 0.06 
Ratio awakening to evening 
cortisol time 0 
 
0.25 0.002 to 30.37 0.5 
Ratio awakening to evening 
cortisol time 2 
 
0.06 <0.001 * to 18.39 0.3 
Time from 0 to 2  1.23E+10 0.001 to 1.68E+23 0.13 
Abnormal insulin time 0 63 6.88 1.67 to 28.28 0.01 
Awakening cortisol AUC time 0  1.02 0.91 to 1.16 0.7 
Awakening cortisol AUC time 2  1.02 0.91 to 1.14 0.7 
Time from 0 to 2  0.3 <0.001 * to 331.06 0.7 
Abnormal insulin time 0 25 23.02 0.62 to 853.96 0.09 
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Abnormal insulin Time 2 Multivariable model components 
 n Odds ratio 95% CI p 
Day cortisol AUC time 0  1 0.98 to 1.01 0.7 
Day cortisol AUC time 2  1.01 0.99 to 1.02 0.3 
Time from 0 to 2  1.17E+12 0.002 to 5.67E+26 0.11 
Abnormal insulin time 0 113 15.9 4.97 to 50.82 <0.01 * 
A-File Total recent life changes 
time 0 
 
1.1 0.98 to 1.23 0.12 
A-File Total recent life changes 
time 2 
 
0.93 0.81 to 1.07 0.3 
Time from 0 to 2  0.21 0.001 to 29.18 0.5 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening 
response rate of change. CAR-AUC : cortisol awakening response area under the 
curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-
DayAUC : total day cortisol from awakening to evening AUC 
 
Table 6.10 Logistic regression models to predict abnormal HOMA-IR at time 2 using 
demographic, adiposity, blood pressure, blood risk measures, and stress measures 
as predictors, adjusted for the same variable at time 0, PWV at time 0 and time 
between measurements for time 2 and 0 in years. 
 
 
Abnormal HOMA-IR Time 2 Multivariable model components 
 n Odds ratio 95% CI P 
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Abnormal HOMA-IR Time 2 Multivariable model components 
 n Odds ratio 95% CI P 
Abnormal HOMA-IR time 0 117 12.52 4.32 to 36.23 <0.001 * 
Sex  1.89 0.67 to 5.28 0.2 
Time from 0 to 2  2.4 0.06 to 90.9 0.6 
Abnormal HOMA-IR time 0 117 10.28 3.61 to 29.23 <0.01 * 
Ethnicity      
Black versus white  1.08 0.34 to 3.48 0.8 
Asian versus white  2.06 0.6 to 7.06 0.2 
Mixed versus white  2.24 0.48 to 10.36 0.3 
Time from 0 to 2  1.04 0.03 to 40.76 0.9 
Abnormal HOMA-IR time 0 110 15.75 4.74 to 52.36 <0.01 * 
Pubertal stage time 0         
Mid Puberty versus pre/early  2.81 0.34 to 22.91 0.3 
Late/post versus pre/early  2.08 0.09 to 47.8 0.6 
Pubertal stage time 2     
Mid Puberty versus pre/early  0.77 0.06 to 9.43 0.8 
Late/post versus pre/early     
     
Time from 0 to 2  0.91 0.02 to 44.24 0.9 
Abnormal HOMA-IR time 0 117 10.31 3.75 to 28.36 <0.01 * 
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Abnormal HOMA-IR Time 2 Multivariable model components 
 n Odds ratio 95% CI P 
Intervention  1.38 0.55 to 3.46 0.5 
Time from 0 to 2  1.64 0.05 to 60.10 0.7 
Abnormal HOMA-IR time 0 117 11.12 4.02 to 30.74 <0.01 * 
IMD  1.02 0.98 to 1.05 0.3 
Time from 0 to 2  1.65 0.05 to 57.42 0.7 
Abnormal HOMA-IR time 0 114 9.43 3.40 to 26.19 <0.01* 
Eversmoked  0.64 0.21 to 1.96  0.4 
Time from 0 to 2  1.81 0.06 to 58.53 0.7 
Abnormal HOMA-IR time 0 117 8.71 3.08 to 24.63 <0.01 * 
BMI time 0  1.18 0.09 to 15.16 0.9 
BMI time 2  2.40 0.24 to 23.88 0.4 
Time from 0 to 2  1.65 0.04 to 69.41 0.7 
Abnormal HOMA-IR time 0 113 13.51 4.60 to 39.65 4.6 
Fat mass index time 0  0.97 0.67 to 1.41 0.6 
Fat mass index time 2  1.12 0.78 to 1.60 0.7 
Time from 0 to 2  2.34 0.06 to 97.98 0.06 
Abnormal HOMA-IR time 0 117 8.64 3.08 to 24.21 <0.01 * 
waist time 0  1.03 0.95 to 1.12 0.4 
waist time 2  1.01 0.94 to 1.08 0.8 
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Abnormal HOMA-IR Time 2 Multivariable model components 
 n Odds ratio 95% CI P 
Time from 0 to 2  1.38 0.04 to 53.06 0.8 
Abnormal HOMA-IR time 0 104 10.02 3.35 to 29.97 <0.01 * 
SAD time 0  1.03 0.88 to 1.20 0.7 
SAD time 2  1.04 0.89 to 1.21 0.6 
Time from 0 to 2  1.15 0.03 to 51.49 0.9 
Abnormal HOMA-IR time 0 116 10.81 3.84 to 30.42 <0.01 * 
Systolic BP time 0  1.00 0.95 to  1.05 0.9 
Systolic BP time 2  1.05 1.00  to 1.11 0.07 
Time from 0 to 2  1.48 0.04 to 56.78 0.8 
Abnormal HOMA-IR time 0 116 10.85 3.87 to 30.43 <0.01 * 
Systolic z BP time 0  0.99 0.62 to 1.57 0.9 
Systolic z BP time 2  1.50 0.91 to 2.47 0.11 
Time from 0 to 2  1.97 0.05 to 77.98 0.7 
Abnormal HOMA-IR time 0 116 11.8 4.16 to 33.49 <0.01 * 
Diastolic BP time 0  1.03 0.98 to 1.09 0.2 
Diastolic BP time 2  1.01 0.96 to 1.06 0.7 
Time from 0 to 2  1.65 0.04 to 62.77 0.7 
Abnormal HOMA-IR time 0 116 11.44 4.07 to 32.15 <0.01 * 
Diastolic z BP time 0  1.25 0.83 to 1.89 0.3 
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Abnormal HOMA-IR Time 2 Multivariable model components 
 n Odds ratio 95% CI P 
Diastolic z BP time 2  1.07 0.72 to 1.59 0.7 
Time from 0 to 2  1.64 0.04 to 60.39 0.7 
Abnormal HOMA-IR time 0 103 9.52 3.26 to 27.8 <0.01 * 
C-wake  time 0  1 0.95 to 1.05 1.0 
C-wake  time 2  1 0.95 to 1.06 0.8 
Time from 0 to 2  1.15 0.03 to 47.88 0.9 
Abnormal HOMA-IR time 0 64 8.47 2.21 to 32.43 <0.01 * 
CAR-Rate time 0  1 0.96 to 1.04 0.9 
CAR-Rate time 2  0.98 0.94 to 1.02 0.3 
Cholesterol time 0  1.87 0.002 to 2002.08 0.8 
Abnormal HOMA-IR time 0 26 7.24 1 to 52.47 0.05 
C-evening time 0  0.88 0.5 to 1.55 0.6 
C-evening time 2  1 0.8 to 1.24 1.0 
Time from 0 to 2  
5749213 
<0.001 * to 
2.37E+17 0.21 
Abnormal HOMA-IR time 0 26 4.28 0.52 to 35.07 0.18 
C-Ratio 0  0.003 <0.001 * to 1132.45 0.4 
C-Ratio time 2  0.02 <0.001 * to 18 0.3 
Time from 0 to 2  
1400000000 
<0.001 * to 
5.45E+22 0.19 
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Abnormal HOMA-IR Time 2 Multivariable model components 
 n Odds ratio 95% CI P 
Abnormal HOMA-IR time 0 64 8.1 2.13 to 30.82 <0.01 * 
CAR-AUC time 0  1.01 0.89 to 1.15 0.8 
CAR-AUC time 2  1.05 0.93 to 1.17 0.4 
Time from 0 to 2  1.18 0.001 to 1182.34 1.0 
Abnormal HOMA-IR time 0 26 10.73 0.98 to 116.94 0.05 
C-DayAUC time 0  1 0.99 to 1.01 0.5 
C-DayAUC time 2  1.01 0.99 to 1.02 0.3 
Time from 0 to 2  
54900000 
<0.001 * to 
9.23E+21 0.29 
Abnormal HOMA-IR time 0 115 10.59 3.73 to 30.04 <0.01 * 
A-File Total recent life changes 
time 0 
 
1.11 0.99 to 1.24 0.07 
A-File Total recent life changes 
time 2 
 
0.94 0.82 to 1.07 0.3 
Time from 0 to 2  1.36 0.03 to 53.85 0.8 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening 
response rate of change. CAR-AUC : cortisol awakening response area under the 
curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-
DayAUC : total day cortisol from awakening to evening AUC 
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6.3 Multilevel modelling of anthropometry, blood pressure and cortisol 
measures over times t0-t4 
6.3.1. Summaries of longitudinal data across time points 
Where variables were measured three or more times during the trial, multi-level 
models were applied to examine change over time and relationships between 
variables over time. Summaries of sample sizes for adiposity and blood pressure at 
each time point (t0-3) are shown in table 6.11; and for cortisol measures in 6.12. 
Note that the A-FILE was only recorded at time 0 and 2 and is thus not included in 
these analyses. Data was incomplete for all adiposity, blood pressure and cortisol 
measures at time points 1, 2 and 3 with increasing levels of incomplete data as time 
progressed. BMI was the most consistently measured over time, and was measured 
for all participants who were repeatedly measured during the trial at all time points, 
with 66% complete at time 3 compared to time 0. At time 2, 10 participants had 
withdrawn from the HELP trial, and 19 had been lost to follow up; by time 3, 25 
participants had withdrawn and 34 were lost to follow up. Note that for a small 
number of participants, data for time point 3 were chased some time after 1 year, 
but for most time point 3 was close to 1 year, and this is highlighted on the 
trajectory graphs for each measure shown below. 
Table 6.11 Adiposity and blood pressure markers at each time point 
 
Variable N at time 0 N at time 1 N at time 2 N at time 3 TOTAL 
BMI 174 136 145 115 570 
Fat mass index 171 130 117 102 520 
SAD 159 126 140 110 535 
Waist 174 134 125 115 548 
Systolic BP 172 134 143 113 562 
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Variable N at time 0 N at time 1 N at time 2 N at time 3 TOTAL 
Systolic z BP 172 134 143 111 560 
Diastolic BP 172 134 143 113 562 
Diastolic z BP 172 134 143 111 560 
 
Table 6.12 Cortisol measures at each time point 
Variable N at time 0 N at time 1 N at time 2 N at time 3 TOTAL 
C-wake 163 - 131 93 387 
CAR-Rate 131 - 91 53 275 
C-evening 53 - 73 53 179 
C-Ratio  53 - 73 53 179 
CAR-AUC 131 - 91 53 275 
C-DayAUC 53 - 73 53 179 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening 
response rate of change. CAR-AUC : cortisol awakening response area under the 
curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-
DayAUC : total day cortisol from awakening to evening AUC 
 
6.3.2 Change in adiposity measures over time 
Figures 6.2-6.4 show the individual trajectories for adiposity measures for each 
participant over time plotted together, with time in years. Note that for a small 
number of participants, data for time point 3 were chased some time after 1 year, 
but for most time point 3 was close to 1 year. Multi-level models for each adiposity 
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measure predicted by time are then shown in table 6.13. There was a significant, 
positive change in both BMI and fat mass index over time during the time of study. 
BMI increased by 0.59 kg/m2 per year (95% CI 0.21 – 0.96) from a baseline average 
of 32.38 (95% CI 31.73 to 33.02). Fat mass increased by 0.43 kg/m2 per year (95% CI  
0.07 -0.78). There was no relationship for waist or SAD with time. A considerable 
proportion of variation from the fixed components of the model was explained by 
non-time dependent, unaccounted for inter-participant variation, at 93% and 94% 
for fat mass index.  For each individual adiposity model, models using t2 and t3 were 
created. In all cases non-linear models were not significant.  
 
Figure 6.2 Graph of change in BMI for the participants over time (time in years) 
with all participant trajectories over time joined by a single line per participant. 
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Figure 6.3 Graph of change in fat mass index for the participants over time (time in 
years) with all participant trajectories over time joined by a single line per 
participant 
 
Figure 6.4 Graph of change in waist circumference for the participants over 
time(time in years) with all participant trajectories over time joined by a single line 
per participant 
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Figure 6.5 Graph of change in waist SAD for the participants over time (time in 
years) with all participant trajectories over time joined by a single line per 
participant. 
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Table 6.13. Multi-level models (random intercepts) of each adiposity model with time. 
 Fixed effects  Random effect components 
of models 
Adiposity Total number 
of 
observations 
Number 
of 
subjects 
Coefficien
t 
95%CI p Constant 95% CI 
constant 
SD 
constant  
SD residuals 
BMI 570 174 0.59 0.21 to 
0.96 
<0.01* 32.38 31.73 to 
33.02 
4.23 1.08 
Fat mass 
index 
520 173 0.43 0.09 to 
0.78 
0.01 * 14.10 13.53 to 
14.68 
3.75 0.93 
SAD 535 170  0.08 -0.56 to 
0.72 
0.8 22.49 22.01 to 
22.97 
2.06 2.89 
Waist 548 174 -1.07 -2.63 to 
0.15 
0.09 100.20 98.58 to 
101.82 
10.10 4.92 
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6.3.3 Change in blood pressure measures over time. 
As stated in chapter 4, at baseline no participants had systolic hypertension, and 4 
had diastolic hypertension. At t3, 1 participant had developed systolic hypertension. 
At t3, only 2 participants had diastolic hypertension, however 2 of the baseline 
participants with diastolic hypertension were lost to follow-up.   
Figures 6.5-6.8 show the individual trajectories for blood pressure measures for each 
participant over time, for systolic, systolic-z score, diastolic, and diastolic z-score, 
plotted together. Note that as for adiposity, for a small number of participants, data 
for time point 3 were chased some time after 1 year, but for most time point 3 was 
close to 1 year. Multi-level models for each blood pressure measure predicted by 
time are then shown in table 6.14. There was a significant, positive change in all 
blood pressure measurements over time during the time of study. Raw systolic BP 
increased by 4mm Hg per year (95% CI 2.02 to 5.98), systolic z score by 0.28 per year 
(95% CI 0.08 to 0.48), raw diastolic increased by 3.36 mmHg per year (95% CI 1.39 to 
5.32) and diastolic z  score by 0.31 (95%CI 0.07 to 0.55).  
Random effect outputs from models showed that proportions of variation from the 
fixed models explained by non time-variant within participant factors were 28%, 
25%, 23% and 17% for raw systolic BP, z-systolic, diastolic BP and diastolic z 
respectively.  For each individual blood pressure model, models using t2 and t3 were 
created. In all cases non-linear models were not significant. 
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Figure 6.5 Graph of change in systolic blood pressure for the participants over time 
with all participant trajectories over time joined by a single line per participant. 
 
Figure 6.6 Graph of change in systolic z-score blood pressure for the participants 
over time with all participant trajectories over time joined by a single line per 
participant. 
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Figure 6.7 Graph of change in diastolic blood pressure for the participants over 
time with all participant trajectories over time joined by a single line per 
participant. 
 
 Figure 6.8 Graph of change in diastolic z-score blood pressure for the participants 
over time with all participant trajectories over time joined by a single line per 
participant   
.   
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Table 6.14. Multi-level models (random intercepts) of each blood pressure model with time. 
 
 Fixed effects components Random effect 
components of models 
Blood 
pressure 
Total number 
of 
observations 
Number of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Systolic 562 174 4.00 2.02 to 5.98 <0.01* 108.97 107.52 to 
110.40 
5.87 9.34 
Systolic z 560 174 0.28 0.08 to 0.48 <0.01* -0.86 -1.01 to -
0.72 
0.55 0.94 
Diastolic 562 174 3.36 1.39 to 5.32 <0.01* 55.12 53.77 to 
56.47 
5.04 9.20 
Diastolic z 560 174 0.31 0.07 to 0.55 <0.01* -0.45 -0.61 to -
0.30 
0.51 1.12  
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6.3.4 Change in cortisol measures over time 
Figures 6.9-6.14 show the individual trajectories for cortisol measures for each 
participant over time plotted together, with time in years. Multi-level models for 
each cortisol measure predicted by time are then shown in table 6.14. There was a 
significant, positive change in cortisol at awakening value (C-wake) over time during 
the time of study, with an increase of 3.88 nmol/L per year (95% CI 1.67 to 6.08). No 
associations were found in change in other measures of cortisol over time.  
Random effects for C-wake showed that variation from the fixed model accounted 
for by only 4% within individual non time variant factors unaccounted for in the 
multi-level model. This implied that more simple modeling (eg. simple linear 
regression would have been appropriate), and indeed a linear regression of time on 
BMI produced a similar model : coefficient 3.89, 95%CI 1.64 to 6.14, p < 0.001). For 
each individual cortisol model, models using t2 and t3 were created. In all cases non-
linear models were not significant. 
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Figure 6.9 Graph of change in C-wake for the participants over time with all 
participant trajectories over time joined by a single line per participant   
 
Figure 6.10 Graph of CAR-Rate for the participants over time with all participant 
trajectories over time joined by a single line per participant   
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Figure 6.11 Graph of change in C-evening for the participants over time with all 
participant trajectories over time joined by a single line per participant   
 
 
Figure 6.12 Graph of change in C-Ratio for the participants over time with all 
participant trajectories over time joined by a single line per participant   
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Figure 6.13 Graph of CAR-AUC for the participants over time with all participant 
trajectories over time joined by a single line per participant   
 
 
Figure 6.14 Graph of change C-DayAUC for the participants over time with all 
participant trajectories over time joined by a single line per participant   
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Table 6.14. Multi-level models (random intercepts) of each cortisol measure over time 
 
 Fixed effects models Random effect 
components of models 
 Total 
number of 
observatio
ns 
Number of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
C-wake 387 160 3.88 1.67 to 6.08 <0.01* 15.03 13.63 to 
16.42 
1.92 9.42 
CAR-Rate 275 157 -2.41 -7.15 to 2.32 0.3 24.91 22.17 to 
27.65 
3.10 16.50 
C-evening 179 104 0.36 -0.55 to 1.28 0.4 2.21 1.55 to 2.86 1.01 2.50 
C-Ratio 179 104 -0.03 -0.09 to 0.02 0.2 0.17 0.14 to 0.21 0.02 0.15 
CAR-AUC 275 157 -0.13 -1.69 to 1.45 0.8 10.83 9.93 to 
11.73 
0.27 5.48 
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 Fixed effects models Random effect 
components of models 
 Total 
number of 
observatio
ns 
Number of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
C-DayAUC 179 104 -11.41 -43.87 to 
21.05 
0.5 198.64 175.26 to 
222.02 
47.43 84.08 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of change. CAR-AUC : cortisol awakening 
response area under the curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-DayAUC : total day cortisol from 
awakening to evening AUC 
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6.3.5 Relationships between adiposity measures over time and baseline 
characteristics, pubertal change and stress measures 
 
After individual models for adiposity and time were constructed, individual baseline 
characteristics – Sex, ethnicity, deprivation score and intervention status were added 
into models individually with time to predict adiposity measures. Next covariates 
that altered over time – pubertal status and cortisol measures - were added 
individually to models with time to predict adiposity measures. The addition of 
cortisol measures was performed to look for associations between change in cortisol 
measures over time and change in adiposity markers, to test one of the key 
hypotheses of the thesis.  
These models are presented together in tables 6.15-6.18 below. 
There were few associations found. For BMI, late/complete puberty compared to 
early/pre pubertal status was associated with BMI positively over time (and time 
remained significant in the model). There was a negative association between Sex 
and SAD over time (though time was no longer significant in this model).  
There were no statistically significant associations found between any of the cortisol 
measures and any of the adiposity measures.
 
254 
 
Table 6.15 Multi-level models (random intercepts) of individual baseline characteristics, pubertal change over time, and cortisol measures 
over time in models with time to predict BMI. 
 Fixed effects components of models Random effect 
components of model 
 Total number of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time  
 
Sex 
570 174 0.58 0.21 to 
0.96 
<0.01 * 30.68 28.44 to 
32.92 
4.21 1.08 
1.04 -0.28 to 
2.36 
0.12 
Time 
Pubertal stage 
Mid Puberty versus pre/early 
425 174 0.43 0.07 to 
0.80 
0.02* 31.20 30.21 to 
32.19 
4.25 0.75 
0.26 -0.44 to 
0.96 
0.4 
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 Fixed effects components of models Random effect 
components of model 
 Total number of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Late/post versus pre/early 
1.60 0.64 to 
2.56 
<0.01 * 
Time 
Ethnicity  
Black versus white 
 
Asian versus white 
 
Mixed versus white 
570 174 0.59 0.21 to 
0.98 
<0.01 * 32.37 31.33 to 
33.41 
4.23 1.08 
0.46 -1.09 to 
2.01 
0.5 
-0.31 -2.06 to 
1.44 
0.7 
-0.57 -2.83 to 
1.56 
0.6 
Time 570 174 0.56 0.21 to 
0.96 
<0.01 * 32.17 31.26 to 
33.08 
4.23 1.08 
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 Fixed effects components of models Random effect 
components of model 
 Total number of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
Intervention 
0.43 -0.86 to 
1.71 
0.5 
Time 
 
C-wake 
387 173 0.72 0.35 to 
1.09 
<0.01 * 32.28 31.60 to 
32.97  
 
4.44 1.15 
-0.00 -0.02 to 
0.12 
0.9 
Time 
 
CAR-Rate 
275 157 0.60 0.11 to 
1.07 
0.02* 32.32 31.60 to 
33.05 
4.40 1.21 
-0.00 -0.02 to 
0.01 
0.5 
Time 179 104 0.80 0.26 to 
1.34 
<0.01 * 31.38 30.46 to 
32.28 
4.38 0.98 
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 Fixed effects components of models Random effect 
components of model 
 Total number of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
C-evening 
-0.04 -0.11 to 
0.04 
0.2 
Time 
 
C-Ratio 
179 104 0.62 0.09 to 
1.16 
0.02* 31.30 30.41 to 
32.18 
4.41 0.98 
-1.22 -2.72 to 
0.27 
0.11 
Time 
 
CAR-AUC 
275 157 0.60 0.12 to 
1.07 
0.02* 32.23 31.47 to 
33.00 
4.40 1.19 
-0.01 -0.05 to 
0.03 
0.5 
Time 179 104 0.66 0.15 to 
1.17 
0.01* 31.61 30.62 to 
32.61 
4.41 0.96 
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 Fixed effects components of models Random effect 
components of model 
 Total number of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
C-DayAUC 
-0.00 -0.00 to 
0.00 
0.10 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of change. CAR-AUC : cortisol awakening 
response area under the curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-DayAUC : total day cortisol from 
awakening to evening AUC 
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Table 6.16 Multi-level models (random intercepts) of individual baseline characteristics, pubertal change over time, and cortisol measures 
over time in models with time to predict fat mass index. 
 
 
 Fixed effects components of models Random effect 
components of model 
Fat mass index Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time  
 
Sex 
520 173 0.43 0.09 to 
0.78 
0.01* 9.95 8.04 to 
11.85 
3.55 0.93 
2.54 1.42 to 
3.67 
<0.01 * 
Time 
Pubertal stage 
Mid Puberty versus pre/early 
382 173 0.36 -0.00 to 
0.73 
0.06 13.56 12.58 to 
14.53 
3.76 0.84 
0.24 -0.50 to 
0.98 
0.5 
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 Fixed effects components of models Random effect 
components of model 
Fat mass index Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
Late/post versus pre/early 
0.74 -0.26 to 
1.74 
0.15 
Time 
Ethnicity  
Black versus white 
 
Asian versus white 
 
Mixed versus white 
520 173 0.43 0.09 to 
0.78 
0.01* 14.25 13.32 to 
15.18 
3.75 0.93 
-0.18 -1.58 to 
1.21 
0.8 
-0.29 -1.84 to 
1.27 
0.7 
-0.35  -2.30 to 
1.60 
0.7 
Time 520 173 0.43 0.08 to 
0.78 
0.01* 13.80 13.00 to 
14.61 
3.74 0.93 
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 Fixed effects components of models Random effect 
components of model 
Fat mass index Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
Intervention 
0.60 -0.53 to 
1.73 
0.3 
Time 
 
C-wake 
354 172 0.58 0.21 to 
0.97 
<0.01 * 14.00 13.3 to 
14.62 
3.76 1.14 
0.01 -0.01 to 
0.02 
0.3 
Time 
 
CAR-Rate 
255 151 0.42 -0.03 to 
0.87 
0.07 14.17 13.51 to 
14.83 
3.80 1.07 
-0.00 -0.01 to 
0.01 
0.2 
Time 165 100 0.16 -0.43 to 
0.77 
0.5 13.76 12.89 to 
14.62 
3.95 1.08 
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 Fixed effects components of models Random effect 
components of model 
Fat mass index Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
C-evening 
0.03 -0.05 to 
0.13 
0.4 
Time 
 
C-Ratio 
165 100 0.15 -0.50 to 
0.78 
0.7 13.92 13.06 to 
14.77 
3.91 1.12 
-0.76 12.87 
to 1.36 
0.4 
Time 
 
CAR-AUC 
255 151 0.65 -0.21 to 
1.51 
0.14 13.94 13.10 to 
14.79 
3.89 1.05 
0.00 -0.03 to 
0.04 
0.8 
Time 165 100 0.17 -0.46 to 
0.80 
0.6 13.67 12.67 to 
14.68 
3.99 1.12 
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 Fixed effects components of models Random effect 
components of model 
Fat mass index Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
C-DayAUC 
0.00 -0.00 to 
0.00 
0.9 
Table 6.17 Multi-level models (random intercepts) of individual baseline characteristics, pubertal change over time, and cortisol measures 
over time in models with time to predict SAD. 
 
 Fixed effects components of models Random effect 
components of model 
SAD Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time  535 170 0.09 -0.55 to 0.8 24.10 22.66 to 2.00 2.88 
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 Fixed effects components of models Random effect 
components of model 
SAD Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Sex 0.73 25.54 
-0.98 -1.81 to 
-0.15 
0.02* 
Time 
Pubertal stage 
Mid Puberty versus pre/early 
Late/post versus pre/early 
400 169 0.19 -0.66 to 
0.71 
0.9 22.26 20.89 to 
23.63 
2.14 2.78 
0.47 -1.03 to 
1.98 
0.5 
0.30 -1.18 to 
1.78 
0.6 
Time 535 170 0.07 -0.58 to 
0.71 
0.8 22.26 21.56 to 
22.95 
2.03 2.89 
 
265 
 Fixed effects components of models Random effect 
components of model 
SAD Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Ethnicity  
Black versus white 
 
Asian versus white 
 
Mixed versus white 
0.76 -0.21 to 
1.74 
0.12 
-0.10 -1.21 to 
1.01 
0.8 
0.18 -1.17 to 
1.54 
0.8 
Time 
 
Intervention 
535 170 0.08 -0.56 to 
0.72 
0.8 22.60 21.97 to 
23.23 
2.05 2.88 
-0.22 -1.03 to 
0.59 
0.6 
Time 364 168 -0.23 -0.94 to 
0.49 
0.5 22.95 22.24 to 
23.65 
2.03 2.72 
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 Fixed effects components of models Random effect 
components of model 
SAD Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
C-wake 
-0.02 -0.05 to 
0.01 
0.2 
Time 
 
CAR-Rate 
263 155 -0.08 -0.95 to 
0.79 
0.9 22.74 22.05 to 
23.42 
1.99 2.61 
-0.00 -0.03 to 
0.01 
0.4 
Time 
 
C-evening 
174 103 -1.53 -2.65 to 
-0.41 
0.01* 23.51 22.65 to 
24.37 
1.48 2.92 
-0.07 -0.24 to 
0.11 
0.3 
Time 174 103 -1.52 -2.64 to 
-0.41 
0.01* 23.32 22.46 to 
24.18 
1.52 2.84 
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 Fixed effects components of models Random effect 
components of model 
SAD Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
C-Ratio 
-0.74 -4.08 to 
0.80 
0.7 
Time 
 
CAR-AUC 
263 155 -0.07 -0.94 to 
0.80 
0.8 22.49 21.71 to 
23.27 
1.55 2.88 
-0.74 -4.08 to 
2.59 
0.6 
Time 
C-DayAUC 
174 103 -1.52 -2.61 to 
-0.43 
<0.01* 23.73 22.49 to 
24.96 
2.03 2.57 
-0.00 -0.07 to 
0.06 
0.9 
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Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of change. CAR-AUC : cortisol awakening 
response area under the curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day cortisol from 
awakening to evening AUC 
 
 
 
 
Table 6.18 Multi-level models (random intercepts) of individual baseline characteristics, pubertal change over time, and cortisol measures 
over time in models with time to predict waist circumference. 
 
 
 Fixed effects components of models Random effect components of 
model 
Waist Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD residuals 
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 Fixed effects components of models Random effect components of 
model 
Waist Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD residuals 
Time  
 
Sex 
548 174 -1.07 -2.62 to 
0.48 
0.18 10.6.40 100.88 to 
111.92 
9.93  4.93 
-3.81 -7.06 to 
-0.56 
0.02* 
Time 
Pubertal stage 
Mid Puberty versus pre/early 
 
Late/post versus pre/early 
  -0.82 -2.47 to 
0.82 
0.3 99.37 95.78 to 
102.95 
10.23 4.63 
0.37 -2.98 to 
3.73 
0.8 
0.66 -3.22 to 
4.56 
0.7 
Time 548 174 -1.07 -2.62 to 
0.48 
0.18 100.98 98.38 to 
103.57 
10.06 4.93 
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 Fixed effects components of models Random effect components of 
model 
Waist Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD residuals 
Ethnicity  
Black versus white 
 
Asian versus white 
 
Mixed versus white 
-1.04 -4.90 to 
2.81 
0.6 
-0.83 -5.19 to 
3.52 
0.7 
-2.63 -8.08 to 
2.81 
0.3 
Time 
 
Intervention 
405 174 -1.08 -2.63 to 
0.48 
0.17 100.16 97.88 to 
102.43 
10.10 4.92 
0.09 -3.09 to 
3.28 
1.0 
Time 375 173 -0.73 -2.47 to 
1.02 
0.4 100.4 98.41 to 
102.42 
10.47 5.81 
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 Fixed effects components of models Random effect components of 
model 
Waist Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD residuals 
C-wake 
-0.77 -2.31 to 
0.76 
0.3 
Time 
 
CAR-Rate 
271 155 -0.51 -2.89 to 
1.88 
0.7 99.56 97.51 to 
101.63 
10.02 6.21 
-0.01 -0.07 to 
0.05 
0.7 
Time 
 
C-evening 
172 102 -1.44 -4.42 to 
1.54 
0.3 98.28 95.64 to 
100.92 
10.48 5.76 
-0.17 -0.62 to 
0.28 
0.5 
Time 172 102 -1.95 -4.91 to 
1.02 
0.2 98.21 95.60 to 
100.83 
10.40 6.04 
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 Fixed effects components of models Random effect components of 
model 
Waist Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD residuals 
 
C-Ratio  
-2.11 -11.27 
to 7.04 
0.7 
Time 
 
CAR-AUC 
271 155 -0.50 -2.90 to 
1.90 
0.7 99.58 97.24 to 
101.94 
10.09 6.13 
-0.12 -0.30 to 
0.07 
0.2 
Time 
 
C-DayAUC 
172 102 -1.90 -4.81 to 
1.00 
0.2 99.49 95.88 to 
103.10 
10.23 5.93 
-0.01 -0.02 to 
0.01 
0.4 
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6.3.6 Relationships between blood pressure measures over time and 
baseline characteristics, pubertal change and stress measures 
 
After individual models for blood pressure and time were constructed, individual 
baseline characteristics – Sex, ethnicity, deprivation score and intervention status 
were added into models individually with time to predict blood pressure measures. 
Next covariates that altered over time – pubertal status and cortisol measures - were 
added individually to models with time to predict blood pressure measures. The 
addition of cortisol measures was performed to look for associations between 
change in cortisol measures over time and change in blood pressure markers, to test 
one of the key hypotheses of the thesis.  
These models are presented together in tables 7.19-7.22 below. The only association 
found was a positive association between diastolic blood pressure and diastolic 
blood pressure z-score and Asian ethnicity over the time period studied versus white 
ethnicity. There were no statistically significant associations found between any of 
the cortisol measures and any of the blood pressure measures.  
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Table 6.19 Multi-level models (random intercepts) of individual baseline characteristics, pubertal change over time, and cortisol measures 
over time in models with time to predict systolic blood pressure. 
 
 Fixed effects components of models Random effect 
components of model 
Systolic BP Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time  
 
Sex 
562 174 4.02 2.04 to 
6.00 
<0.01* 112.84 108.61 to 
117.10 
5.76 9.33 
-2.38 -4.82 to 
0.06 
0.06 
Time 
Pubertal stage 
Mid Puberty versus pre/early 
419 174 5.96 3.98 to 
7.94 
<0.01* 105.45 101.55 to 
109.35 
5.58 8.65 
1.33 -2.97 to 
5.65 
0.5 
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 Fixed effects components of models Random effect 
components of model 
Systolic BP Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Late/post versus pre/early 
1.45 -2.76 to 
5.67 
0.5 
Time 
Ethnicity  
Black versus white 
 
Asian versus white 
 
Mixed versus white 
562 174 3.96 1.98 to 
5.94 
<0.01* 108.63 106.56 to 
110.71 
5.78 9.34 
1.60 -1.25 to 
4.46 
0.3 
-0.89 -4.14 to 
2.36 
0.6 
0.26 -3.71 to 
4.24 
0.9 
Time 562 174 3.99 2.01 to 
5.97 
<0.01* 109.13 107.26 to 
111.01 
5.87 9.33 
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 Fixed effects components of models Random effect 
components of model 
Systolic BP Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
Intervention 
-0.32 -2.70 to 
2.70 
0.8 
Time 
 
C-wake 
382 172 5.26 3.22 to 
7.30 
<0.01* 106.13 104.11 to 
108.13 
5.29 8.24 
0.05 -0.04 to 
0.14 
0.3 
Time 
 
CAR-Rate 
271 155 5.23 2.73 to 
7.72 
<0.01* 105.85 103.73 to 
107.98 
5.73 8.04 
0.03 -0.04 to 
0.09 
0.5 
Time 174 102 4.62 1.29 to 
7.95 
0.01* 106.75 104.15 to 
109.35 
5.18 8.56 
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 Fixed effects components of models Random effect 
components of model 
Systolic BP Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
C-evening 
-0.34 -0.87 to 
0.21 
0.2 
Time 
 
C-Ratio 
174 102 4.75 1.52 to 
7.99 
<0.01 107.76 105.18 to 
110.34 
5.74 8.04 
-4.75 -14.36 
to 4.86 
0.3 
Time 
 
CAR-AUC 
271 155 5.31 2.79 to 
7.83 
<0.01 106.70 104.42 to 
108.98 
5.82 7.99 
0.05 -0.15 to 
0.25 
0.7 
Time 174 102 4.63 1.25 to 
8.00 
<0.01* 106.7 102.95 to 
110.57 
5.45 8.45 
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 Fixed effects components of models Random effect 
components of model 
Systolic BP Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
C-DayAUC 
-0.00 -0.02 to 
0.02 
1.0 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of change. CAR-AUC : cortisol awakening 
response area under the curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day cortisol from 
awakening to evening AUC 
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Table 6.20 Multi-level models (random intercepts) of individual baseline characteristics, pubertal change over time, and cortisol measures 
over time in models with time to predict systolic blood pressure z-score. 
 
 
 Fixed effects components of models Random effect 
components of model 
Systolic BPz Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time  
 
Sex 
560 174 0.28 0.08 to 
0.48 
<0.01* -0.92 -1.34 to -
0.51 
0.54 0.94 
0.04 -0.21 to 
0.28 
0.7 
Time 
Pubertal stage 
 
417 174 0.50 0.29 to 
0.70 
<0.01* -1.06 -1.46 to -
0.67 
0.53 0.88 
-0.04 -0.47 to 
0.40 
0.8 
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 Fixed effects components of models Random effect 
components of model 
Systolic BPz Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Mid Puberty versus pre/early 
 
Late/post versus pre/early 
-0.04 -0.45 to 
0.38 
0.8 
Time 
Ethnicity  
 
 
Black versus white 
 
Asian versus white 
 
560 174 0.28 0.08 to 
0.48 
<0.01* -0.84 -1.04 to -
0.64 
0.54 0.94 
   
0.06 -0.21 to 
0.34 
0.7 
-0.17 -0.48 to 
0.15 
0.3 
-0.09 -0.48 to 0.6 
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 Fixed effects components of models Random effect 
components of model 
Systolic BPz Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Mixed versus white 0.28 
Time 
 
Intervention 
560 174 0.28 0.08 to 
0.48 
0.01* -0.87 -1.05 to -
0.68 
0.54 0.94 
0.01 -0.22 to 
0.24 
1.0 
Time 
 
C-wake 
382 172 0.43 0.25 to 
0.65 
<0.01* -1.16 -1.37 to -
0.96 
0.55 0.85 
0.01 -0.01 to 
0.02 
0.2 
Time 270 155 0.42 0.17 to 
0.68 
<0.01* -1.16 -1.39 to -
0.94 
0.59 0.82 
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 Fixed effects components of models Random effect 
components of model 
Systolic BPz Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
CAR-Rate 
0.01 -0.01 to 
0.01 
0.2 
Time 
C-evening 
174 102 0.38 0.03 to 
0.72 
0.03* -1.04 -1.31 to -
0.78 
0.51 0.88 
-0.04 -0.09 to 
0.02 
0.2 
Time 
 
C-Ratio 
174 102 0.38 0.05 to 
0.71 
0.02* -0.93 -1.19 to -
0.67 
0.55 0.82 
-0.54 -1.51 to 
0.42 
0.3 
Time 270 155 0.43 0.17 to 
0.69 
<0.01* -1.13 -1.13 to-
0.90 
0.58  0.83 
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 Fixed effects components of models Random effect 
components of model 
Systolic BPz Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
 
CAR-AUC 
0.01 -0.01 to 
0.03 
0.3 
Time 
C-DayAUC 
174 102 0.36 0.02 to 
0.71 
0.04* -1.03 -1.42 to -
0.65 
0.54 0.82 
-0.01 -0.01 to 
0.01 
0.9 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of change. CAR-AUC : cortisol awakening 
response area under the curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day cortisol from 
awakening to evening AUC 
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Table 6.21 Multi-level models (random intercepts) of individual baseline characteristics, pubertal change over time, and cortisol measures 
over time in models with time to predict diastolic blood pressure. 
 
 
 
 
 Fixed effects components of models Random effect 
components of model 
Diastolic BP Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time  
 
Sex 
562 174 3.34 1.37 to 
5.30 
<0.01* 53.22 49.27 to 
57.18 
5.02 9.20 
1.16 -1.11 to 
3.43 
0.3 
Time 419 174 4.33 2.29 to 
6.37 
<0.01* 53.42 49.64 to 
57.19 
4.85 8.70 
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 Fixed effects components of models Random effect 
components of model 
Diastolic BP Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Pubertal stage 
Mid Puberty versus pre/early 
 
Late/post versus pre/early 
-1.27 -5.51 to 
2.96 
0.6 
1.21 -2.88 to 
5.28 
0.5 
Time 
Ethnicity  
Black versus white 
 
Asian versus white 
 
Mixed versus white 
562 174 3.31 1.37 to 
5.26 
<0.01* 53.39 51.48 to 
55.30 
4.86 9.23 
2.49 -0.10 to 
5.08 
0.06 
3.52 0.56 to 
6.49 
0.02* 
2.29 -1.32 to 
5.89 
0.2 
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 Fixed effects components of models Random effect 
components of model 
Diastolic BP Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time 
 
Intervention 
562 174 3.36 1.39 to 
5.32 
<0.01* 54.64 52.90 to 
56.39 
5.02 9.19 
0.93 -1.25 to 
3.11 
0.4 
Time 
 
C-wake 
382 172 3.78 1.62 to 
5.93 
<0.01* 53.45 51.42 to 
55.47 
4.70 8.45 
0.03 -0.07 to 
0.13 
0.5 
Time 
 
CAR-Rate 
273 156 2.96 0.01 to 
5.92 
0.05 54.02 51.88 to 
56.16 
4.29 8.17 
-0.02 -0.09 to 
0.05 
0.5 
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 Fixed effects components of models Random effect 
components of model 
Diastolic BP Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time 
 
C-evening 
174 102 0.24 -2.76 to 
3.25 
0.8 55.86 53.46 to 
58.25 
5.31 7.60 
0.05 -0.44 to 
0.53 
0.8 
Time 
 
C-Ratio 
174 102 0.62 -2.45 to 
3.68 
0.7 56.07 53.67 to 
58.48 
4.82 7.75 
3.83 -5.27 to 
12.93 
0.4 
Time 
 
CAR-AUC 
273 156 3.12 0.20 to 
6.13 
0.04* 55.10 52.73 to 
57.48 
4.27 8.23 
-0.11 -0.33 to 
0.10 
0.2 
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 Fixed effects components of models Random effect 
components of model 
Diastolic BP Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI P Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time 
 
C-DayAUC 
174 102 0.81 -2.27 to 
3.89 
0.6 55.44 51.96 to 
58.92 
4.92 7.74 
0.01 -0.01 to 
0.02 
0.7 
Note table label : C-wake : cortisol on wakening. CAR-Rate : cortisol awakening response rate of change. CAR-AUC : cortisol awakening 
response area under the curve. C-evening : evening cortisol. C-ratio : ratio of evening to awakening cortisol. C-dayAUC : total day cortisol from 
awakening to evening AUC 
 
 
 
   0.88 -0.66 to 
2.43 
0.3     
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Table 6.22 Multi-level models (random intercepts) of individual baseline characteristics, pubertal change over time, and cortisol measures 
over time in models with time to predict diasolic blood pressure. Z-sc0re 
 
 Fixed effects components of models Random effect 
components of model 
Diastolic BP z Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
SD(t) 
SD constant  SD 
residuals 
Time  
 
Sex 
560 174 0.31 0.07 to 
0.55 
0.01* -0.34 0.00-0.00 0.50 1.12 
-0.07 -0.32 to 
0.18 
0.6 
Time 
Pubertal stage 
 
417 174 0.81 -0.40 to 
2.02 
0.19 -0.50 0.00-0.00 0.53 1.07 
-0.52 -1.87 to 
0.83 
0.5 
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 Fixed effects components of models Random effect 
components of model 
Diastolic BP z Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
SD(t) 
SD constant  SD 
residuals 
Mid Puberty versus pre/early 
Late/post versus pre/early 
-0.32 -1.57 to 
0.91 
0.6 
Time 
Ethnicity  
Black versus white 
Asian versus white 
Mixed versus white 
560 174 0.31 0.07 to 
0.55 
0.01* -0.65 0.00-0.00 0.47 1.13  
0.27 -0.02 to 
0.55 
0.07 
0.43 0.10 to 
0.77 
0.01* 
0.23 -0.16 to 
0.64 
0.3 
Time 560 174 0.31 0.07 to 
0.55 
0.01* -0.50 0.00-0.00 0.51 1.12 
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 Fixed effects components of models Random effect 
components of model 
Diastolic BP z Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
SD(t) 
SD constant  SD 
residuals 
 
Intervention 
0.09 0.45 to -
0.15 
0.3 
Time 
 
C-wake 
382 172 0.39 0.13 to 
0.65 
<0.01* -0.66 0.00-0.00 0.48 1.05 
0.01 -0.01 to 
0.01 
0.6 
Time 
CAR-Rate 
272 156 0.30 -0.05 to 
0.65 
0.10 -0.61 0.00-0.00 0.36 1.05 
0.00 -0.01 to 
0.01 
0.8 
Time 174 102 0.01 -0.35 to 
0.38 
0.9 -0.33 0.00-0.00 0.54 0.95 
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 Fixed effects components of models Random effect 
components of model 
Diastolic BP z Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
SD(t) 
SD constant  SD 
residuals 
 
C-evening 
-0.01 -0.05 to 
0.04 
0.7 
Time 
 
C-Ratio 
174 102 0.06 -0.32 to 
0.43 
0.7 -0.31 0.00-0.00 0.46 0.97 
-0.19 -0.71 to 
0.32 
0.5 
Time 
CAR-AUC 
272 156 0.32 -0.03 to 
0.67 
0.08 -0.49 0.00-0.00 1.06 1.06 
-0.01 -0.03 to 
0.10 
0.3 
Time 174 102 0.07 -0.31 to 
0.45 
0.7 -0.31 0.00-0.00 0.46 0.98 
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 Fixed effects components of models Random effect 
components of model 
Diastolic BP z Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
SD(t) 
SD constant  SD 
residuals 
 
C-DayAUC 
-0.00 -0.01 to 
0.01 
0.7 
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6.3.7 Relationships between change in blood pressure measures over 
time and adiposity measures. 
To examine the association of changes in adiposity measures over time and blood 
pressure measures over time, multi-level models were constructed using time and 
adiposity measures as predictors of blood pressure measures. For all adiposity 
measures except for FMI, there was a positive relationship with systolic blood 
pressure, with time remaining significant in all models. With time in models, systolic 
blood pressure increased by 0.28 mmHg per 1 kg/m2 of BMI (0.05 to 0.53), 0.41 
mmHg per 1cm of SAD (0.15 to 0.67), and 0.10 mmHg per 1cm of waist 
circumference (0.02 to 0.2). BMI and SAD were associated with systolic.  
Given the suggestion that there was an association with sex and systolic blood 
pressure in models predicting blood pressure with time, a model of BMI, time and 
sex was constructed to predict systolic BP, which is shown in table 7.27. The positive 
association of BMI over time and systolic BP remained robust to inclusion of sex 
(with girls having lower blood pressures compared to males). A similar model for 
waist and SAD were constructed, and in these models the positive relationship 
between systolic BP and SAD and waist remained robust, though associations with 
female sex did not (data not shown).  
Diastolic blood pressure was not associated with adiposity measures in individual 
models of adiposity measures and time as predictors (tables 6.25 and 6.26).  
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Table 6.23 Multi-level models (random intercepts) of adiposity measures with time in models to predict systolic blood pressure. 
 
 Fixed effects components of models Random effect 
components of model 
Systolic BP  Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time 
 
BMI 
562 174 3.84 1.87 to 
5.82 
<0.01* 99.63 91.53 to 
107.73 
5.80 9.30 
0.28 0.04 to 
0.53 
0.02* 
Time 
 
Fat mass index 
514 172 3.72 1.62 to 
5.81 
<0.01* 106.91 102.50 to 
111.34 
5.97 9,92 
0.13 -0.16 to 
0.42 
0.4 
Time  530 170 4.40 2.37 to <0.01* 99.27 93.18 to 5.81 9.22 
 
296 
 
SAD 
6.41 105.37 
0.41 0.15 to 
0.67 
<0.01* 
Time 
 
Waist 
543 173 3.72 1.71 to 
5.70 
<0.01* 98.21 89.13 to 
107.30 
5.60 9.32 
0.10 0.02 to 
0.20 
0.02* 
 
Table 6.24 Multi-level models (random intercepts) of adiposity measures with time in models to predict systolic blood pressure z-score. 
 
 Fixed effects components of models Random effect 
components of model 
Systolic z Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time 560 174 0.27 0.07 to 0.01* -1.56 -2.35 to - 0.54 0.94 
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BMI 
0.47 0.77 
0.02 -0.01 to 
0.05 
0.08 
Time 
 
Fat mass index 
512 172 0.29 0.04 to 
0.47 
0.02* -1.21 -1.64 to -
0.78 
0.57 0.94 
0.02 -0.01 to 
0.05 
0.11 
Time  
 
SAD 
528 170 0.32 0.11 to 
0.53 
<0.01* -1.59 02.21 to 
-0.97 
0.56 0.93 
0.03 0.00 to 
0.06 
0.02* 
Time 
 
Waist 
541 173 0.26 0.06 to 
0.46 
0.01* -1.53 -2.44 to -
0.62 
0.55 0.94 
0.01 -0.02 to 
0.02 
0.15 
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Table 6.25 Multi-level models (random intercepts) of adiposity measures with time in models to predict diastolic blood pressure. 
 
 
 
 Fixed effects components of models Random effect 
components of model 
Diastolic BP and anthropometry Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time 
 
BMI 
562 174 3.25 1.29 t0 
5.21 
<0.01* 49.39 41.84 to 
56.95 
5.02 9.19 
0.17 -0.05 to 
0.41 
0.13 
Time 
 
Fat mass index 
514 172 2.55 0.53 to 
4.56 
0.01* 52.29 48.23 to 
56.35 
5.27 8.96 
0.17 -0.10 to 
0.44 
0.2 
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Time  
 
SAD 
530 170 3.65 1.62 to 
5.67 
<0.01* 49.76 43.83 to 
55.68 
4.85 9.30 
0.23 -0.02 to 
0.49 
0.07 
Time 
 
Waist 
543 173 2.46 0.54 to 
4.38 
0.01* 52.65 44.11 to 
61.20 
5.09 8.95 
0.02 -0.06 to 
0.12 
0.6 
 
Table 6.26 Multi-level models (random intercepts) of adiposity measures with time in models to predict diastolic blood pressure z-score. 
 
 
 Fixed effects components of models Random effect 
components of model 
Diastolic BPz Total number 
of 
Number 
of 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD residuals 
 
300 
observations subjects 
Time 
 
BMI 
560 174 0.31 0.07 to 
0.54 
0.01* -0.79 -1.64 to 
0.05 
0.51 1.13 
0.01 -0.02 to 
0.04 
0.4 
Time 
 
Fat mass index 
512 172 0.24 -0.01 to 
0.41 
0.06 -0.62 -1.08 to -
0.16 
0.53 1.10 
0.01 -0.02 to 
0.04 
0.6 
Time  
 
SAD 
528 170 0.36 0.11 to 
0.60 
0.01* -1.08 -1.78 to -
0.38 
0.48 1.13 
0.03 -0.01 to 
0.02 
0.08 
Time 
 
Waist 
541 173 0.22 -0.01 to 
0.02 
0.07 -0.7 -1.68 to 
0.28 
0.52 1.09 
0.00 -0.01 to 0.6 
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0.01 
 
Table 6.27 Multi-level models (random intercepts) of BMI with time and Sex in models to predict systolic blood pressure 
 Fixed effects components of models Random effect 
components of model 
Systolic BP  Total number 
of 
observations 
Number 
of 
subjects 
Coefficient 95%CI p Constant 95% CI 
constant 
SD 
constant  
SD 
residuals 
Time 
 
BMI 
 
Sex 
 
 
419 174 5.44 3.45 to 
7.43 
<0.01* 96.75 88.41 to 
105.07 
5.14 8.67 
0.30 0.05 to 
0.54 
0.02*     
-5.27 -8.51 to 
-2.02 
<0.01*     
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Chapter 7 : Discussion 
 
In this last chapter, I will firstly summarize the findings of the thesis, contextualize 
them to the hypotheses of the thesis and existing literature, and also discuss in 
depth the limitations of the thesis. Lastly I will provide some suggestions for further 
research. I will not discuss the findings and limitations of the two systematic reviews 
from chapter 1 and chapter 2 as they are discussed in detail within those chapters 
themselves.  
7.1 Key findings.  
7.1.1 Validity of contemporary risk using PWV 
Adiposity measures and PWV 
At baseline I found a positive association between arterial stiffness and adiposity 
(BMI z, FMI) including central adiposity in the form of standardized waist 
circumference. This association was independent of age and ethnicity. The 
longitudinal measures of PWV showed no change from time 0 to time 2, and change 
in adiposity measures between time 0 and 2 were not associated with PWV at time 
2. It is likely that longer period of time between measurements of PWV are required 
(see limitations section below) to answer the question of how changes in adiposity 
can affect arterial stiffening over time. 
Partitioning subjects by levels of BMI z at baseline showed small differences in mean 
PWV by group, a finding also recently reported elsewhere.185 However it is likely that 
this merely reflects a positive relationship between BMI z and PWV, and there was 
considerable overlap of PWV between groups (seen most clearly in figure 7.1). Thus 
our ability to classify and understand what constitutes “severe obesity” from the 
perspective of contemporary pathological processes remains limited.  
At baseline in our adjusted models, a one SD increase in BMI (i.e a unit increase in 
BMI z) was associated with an increase of 0.5 ms-1 in PWV, equivalent to an 0.4 SD 
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change in PWV. For comparison, in the meta-analysis of adult studies Vlachopoulos 
et al63 discussed in Chapter one, reported that a 1 SD increase in aortic PWV in adults 
led to around a 50% increase in total cardiovascular events and mortality. Similarly, 
Ben-Shlomo et al186 reported hazard ratios of 1.35 and 1.5 for coronary heart disease 
and stroke respectively associated with a 1 SD increase in the log of aortic PWV. To 
be clear here, my data were collected by carotid-radial rather than aortic 
methodology, nonetheless these adult data suggest that the level of increased 
arterial stiffening seen in our sample is concerning, particularly for those with more 
extreme BMI z-scores. Encouragingly, a recent meta-analysis in adults concluded 
that weight loss by lifestyle change appears to reduce PWV187.  
Cardio-metabolic markers 
I found few associations between PWV and conventional markers of cardio-
metabolic risk, in particular standardized blood pressure, and this is discussed in 
more detail in section 8.1.2 below. As discussed above, the lack of change in PWV 
over time limits investigation of change in blood pressure and blood tests. There 
were few associations with any of the blood markers at baseline and no associations 
between change in blood markers and PWV at time 2 (although again, PWV did not 
significantly change). Combined with the evidence that conventional risk markers are 
often unstable across adolescence,147 our findings highlight the need for larger, 
longitudinal studies to  better understand the differential relationships between 
blood markers, blood pressure and arterial stiffening.  However, I think that caution 
must be exercised in interpreting the significance of conventional cardio-metabolic 
markers such as hypertension and dyslipidaemia, especially when considering 
pharmacological treatments for them. 
I also found no association between PWV and stage of puberty, although PWV 
increased with age. This is an important finding, as few of the studies identified in 
the systematic review in chapter one controlled for pubertal stage, and lack of 
knowledge about the effects of puberty on arterial stiffness has been identified as a 
key limitation of many published studies of PWV in children and adolescents with 
obesity.53 188 189 The relationship between puberty, obesity and arterial stiffening also 
needs larger, longitudinal samples, as puberty is associated with the development of 
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sexual dimorphism in cardiovascular risk profiles that is not apparent earlier in 
childhood.  
Lastly I found that South Asian adolescents had greater PWV compared to white, and 
our ability to describe differences in PWV between ethnicities typical of Northern 
European adolescent urban populations is I believe unique in the literature for the 
age group studied. 
Acanthosis nigricans 
AN was common in the study population, with 63 % and 43% found to have AN and 
Severe AN respectively. There was a positive association between BMI z and 
presence of AN (with an increase of 1SD in BMI leading to a doubling in the risk of 
AN) consistent with other published studies of AN in adolescent groups.36-38 
However both presence and severity of AN were poor markers of insulin resistance 
when adjusted for BMI z. There were no associations between PWV and AN, as a 
proxy for arterial stiffening, after adjusting for BMI z. These findings suggests that 
the finding of AN (or severity) in a group of adolescents with obesity does not 
provide additional information about individual cardio-metabolic risk beyond the 
degree of obesity itself. Kobaissi et al39 have similarly reported that presence and 
severity of AN poorly predict insulin resistance in adolescent obesity after adjusting 
for BMI, albeit in an exclusively Hispanic group. However I believe that this is the first 
study to examine a relationship between the presence and severity of AN, and 
contemporary measures of arterial stiffness as a proxy for long-term cardio-
metabolic risk.  
7.1.2 The relationship between blood pressure, adiposity and arterial 
stiffening. 
I will deal with the limitations of the thesis in detail below, however the first thing to 
acknowledge before any discussion about blood pressure here is that the presence 
of hypertension was low in the group of young people studied. This is in contrast to a 
number of publications, which have found greater blood pressure in groups of 
children and adolescents with obesity.190 164 191 192 Whilst it is possible that the group 
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studied are atypical, as the baseline participant descriptions explain, the sample was 
representative of a cross-section of adolescents from an urban community in London 
in terms of ethnicity, age and deprivation level (see limitations below). Blood 
pressures were also averaged from three measures and used the same protocol for 
measurements used in large samples from the UK designed to provide 
representative centile charts.165 The protocol for blood pressure measurement in my 
thesis gave emphasis to relaxation time before measure (and was measured at the 
same time as pulse wave velocity), and it may be that the allowed rest time provided 
a more representative, non-clinical measure of blood pressure. There is however 
evidence that single measures of blood pressures are not representative of the 
overall 24-hour pattern. Aguilar et al have recently published data on adolescents 
with obesity that in a clinic setting were found on spot measurements to be 
normotensive, on 24 hour ambulatory testing demonstrated elevated daytime 
systolic hypertension in around 10 percent and a third had elevated nighttime 
systolic blood pressure; and indeed it was those with the greater degree of obesity in 
this group who demonstrated the highest differences.193  
Most of the published data, and most frequently cited studies on the association 
between blood pressure and obesity in children and adolescents, come from cross 
sectional data comparing large groups of  children and adolescents with obesity 
versus healthy weight controls, or children of different degrees of obesity. For 
example, most recently Skinner et al,190 reported a positive relationship between 
degree of obesity and systolic blood pressure from cross-sectional data on 8579 
children from the NHANES study from the United States. In a large systematic review 
and meta-analysis of 63 studies, including 49, 2220 children, Friedemann et al 
reported around a 7mm Hg difference in systolic blood pressure, and children with 
obesity compared to healthy weight controls.32  These studies, amongst others, have 
led to an agreed consensus that risk for hypertension is greater in children with 
obesity. My data is interesting because rather than cross sectional analyses alone, I 
followed change in BMI and blood pressure longitudinally over a period of time as 
adiposity changed, and I modeled this with multi-level analyses to examine the 
relationship between BMI and systolic blood pressure over time. I showed that in the 
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group of adolescents studied, systolic blood pressure increased by only a small 
amount of 0.28 mmHg per 1kg/m2 per year (and this is all the more modest in the 
context that one standard deviation of systolic blood pressure for the whole group 
was 14mmHg at baseline, and reflected in the change in analyses of systolic z per 1 
Kg/m2 over the same time period was 0.2).  I also found that increase in systolic 
blood pressure was associated with increase in waist circumference rather than fat 
mass index per se, fitting with other studies that have cross-sectionally reported that 
central adiposity is important in the development of hypertension, and its potential 
importance in definitions of the metabolic syndrome.194  195 196 
The finding of a relatively low prevalence of hypertension combined with the finding 
at cross-sectional baseline that there were no associations between systolic blood 
pressure and BMI, highlights the importance of longitudinal studies; but may also 
mean that the participants, as a group, were observed to develop higher blood 
pressure as a result of acquisition of greater BMI and central adiposity and were 
potentially on a life time trajectory which has, for example in one study published 
recently demonstrated that adolescents with obesity are at greater risk in adult life 
of blood pressure related disease such as stroke.197 There have been a number of 
studies published in the last decade which have investigated potential mechanisms 
for how adiposity may drive an increase in blood pressure,198 and these have 
included production of aldosterone by adipose tissue which may directly affect the 
vasculature,199 and also the effects that adiposity can have on the kidneys which in 
turn can effect hypertension.198 It is possible that there are also genetic 
polymorphisms within individuals which lead to some individuals having blood 
pressure that are more sensitive to adipose changes that others,200 and such genetic 
variation could be a reason for the 28% in variation in blood pressure not related to 
time variance and studied variables estimated from the random effect parameters in 
the multi level model constructed for systolic blood pressure and presented in 
chapter 6. Such evidence of genetics is however entirely limited, in the literature, to 
adults and the differential effects of genetics on blood pressure and in the context of 
obesity in children is an area for future study (see below). 
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Given that PWV did not change in the matched repeated measures analysis between 
time 0 and time 2, what I can say about temporal change in arterial stiffening from 
my data is clearly limited. However, I feel that the observation that at baseline PWV 
was associated with adiposity, but not blood pressure, coupled with the longitudinal 
findings of increased blood pressure with increased BMI and waist through the time 
of the study, has some potentially interesting links with two recent published studies 
looking at the temporal relationship of obesity, arterial stiffening and blood pressure 
(albeit not in children or adolescents). Weisbrod et al recently published their study 
of temporal changes in pulse wave velocity and blood pressure in relation to 
adiposity using an animal (mouse) model and experiment.201 They compared blood 
pressure changes and arterial stiffening (using PWV) in a group of mice fed high 
fat/high sugar to a control group of mice on normal diet. They found that, in the 
obese group of mice, as body fat increased, arterial stiffening increased first, and 
was followed by a an increase in systolic blood pressure. They hypothesized that 
arterial stiffening may occur prior to onset of hypertension, and furthermore that 
arterial stiffening may be a mechanism whereby systolic blood pressure increased; 
backed further by the fact that PWV and blood pressure reduced with weight loss in 
the overweight mice. Kaess et al followed an existing cohort of adults (mean age 60 
years, of mixed adiposity classifications) and investigated the temporal relationship 
between arterial stiffness and blood pressure.202 They found that at baseline, there 
was no association between pulse wave velocity and systolic blood pressure, 
however over 7 years, baseline pulse wave velocity was predictive of future systolic 
blood pressure, and incident hypertension. Both of these studies have argued that 
abnormalities in blood pressure may develop secondarily, and further that arterial 
stiffening may be one of a number of mechanisms by which hypertension develops, 
in particular in obesity.203 A number of studies have shown that blood pressure falls 
with weight loss204 205 (with weight reduction being a long established non 
pharmacological recommended intervention to reduce blood pressure in obesity) 
and a recent systematic review showed that weight loss is associated with a 
reduction in arterial stiffening;187 though few have looked at links between the two. I 
am very careful here to be clear that I am not suggesting that my data adds weight 
to this argument, principally because of the lack of change in PWV. However it does 
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highlight the need for more prolonged longitudinal data on blood pressure and 
arterial stiffening such as investigated in my thesis, something I will discuss further in 
areas for further research, below. 
7.1.3 Relationship between stress, adiposity, contemporary risk markers 
and pulse wave velocity. 
There were no associations either cross-sectionally or longitudinally between stress 
measures and adiposity, conventional cardio-metabolic risk markers (for example 
blood pressure) or PWV. However, there was an association between a greater A-
FILE score, i.e. exposure to stressors in the preceding 12 months, and the risk of 
binge eating. The effect size for this association was small, and baseline data, which 
found this association, was cross-sectional. However, the association is interesting 
and may represent a potential mechanism for how exposure to stressful events may 
influence eating behaviour itself, in terms of increased amount of food consumed 
which warrants further research; especially given similar findings in adult women.206 
These findings also fit alongside the recent systematic review by Hill et al,103 which 
was discussed in chapter two, which looked exclusively at types of food consumed 
and eating habits like breakfast consumption, not explicitly evidence of amount of 
food consumed in relation to stress, such as binge eating. Hill et al’s review also 
highlighted the need for investigation of how eating behaviour might be affected 
differentially by sex and pubertal stage. I have demonstrated in this thesis, that in 
the group of adolescents studied, binge eating was neither affected by sex nor 
pubertal stage (or age). From a clinical perspective, my findings highlight the need to 
identify binge eating in clinical settings, especially given how prominent it was 
amongst the group studied (around a quarter). 
It is interesting that no associations were found between any of the cortisol 
measures and adiposity, cardiovascular risk or binge eating. This is in keeping with 
the inconsistency of findings reported in chapter 2. My study does have the 
additional strength of looking at longitudinal changes in cortisol and adiposity, and 
also I was also able to show no associations between cortisol levels and puberty 
 309 
across the time points of study – longitudinal study and interaction of puberty were 
key limitations in the existing data presented in chapter two.  
It is possible that one of the reasons that no associations were found was the limited 
sample size, and this is discussed in more detail below. One other potential reason 
for no association in the group studied is that stress exposure may have been low, 
for example the average A-FILE score was 6.5 out of a maximum of 50. Also 
measuring stress exposure over only one year might not have been enough. Given 
the degree of adiposity in participants, it is likely that obesity developed in a 
significant proportion some years before being enrolled into the trial, and thus 
looking at only 12 months of stressor exposure and the impact on adiposity may 
have been insufficiently long. The other drawback of the A-FILE is that although it 
measures stressors that young people were exposed to, it didn’t measure the 
perceived impact of these stressors. There has also been some limited evidence that 
the response to stress in obesity may flatten over time, or “burn out”137 207 and one 
possibility is that the absence of a cortisol association with obesity was no longer 
evident at the time studied. Against this is the relatively greater degree of salivary 
cortisol values evident in the group I studied compared to those published 
elsewhere. Mean C-wake but not C-evening was greater in my study compared to 
the Rosmalen data130 (see chapter 2 : a study of a large number of children), and 
although the Rosmalen data was on younger children than in my study, our study 
showed no relationship between age, pubertal stage and cortisol levels. I also 
referred back to the normative data on adolescents from the original study on CAR 
by Pruessner et al,208 and average baseline CAR-Rate and CAR-AUC appear 
equivalent to that original data, and CAR-Rate mean and median are consistent with 
the responses seen in other studies of the CAR in adolescents.209 210 
7.2 Strengths and Limitations of data and analyses across the thesis 
In this section I will explore strengths and limitations of the thesis – this will also 
cover the key bias issues in the bias assessment tool presented in table 1.4 in 
Chapter 1. 
 310 
7.2.1 General considerations  
There are a number of characteristics of the study sample making it likely to be 
representative of the background population of adolescents in London, and 
adolescents in urban areas of the United Kingdom in general. Firstly it was drawn 
from community sources rather than many other studies, which have used clinical 
samples. The sample had a representative spread across age groups and was 
ethnically diverse which is helpful for representing the background population and 
for applicability. However, against this, the HELP trial recruited young people and 
their families who were consenting for a trial to test an intervention for weight loss, 
and were therefore motivated (at least at baseline) to attempt to change for weight 
loss. As such the group studied may represent a biased group of community young 
people compared to the total background from which they came from.  
An important consideration is the appropriateness of the HELP trial sample for use 
for the research questions I investigated in this thesis. The HELP trial was not 
originally designed, nor powered to investigate these questions. The benefit of the 
sample was that it allowed a community group of adolescents with obesity to be 
tracked over time. However it clearly did not allow for comparison with a control 
group. The other issue is that the young people studied over time were randomized 
to a control or intervention status. At baseline this would make no difference 
because they were not yet allocated an arm of the trial. For longitudinal data, I am 
reassured that there was no intervention effect in the trial at large, and to account 
for this I included the intervention status in longitudinal analyses (with no statistical 
associations found all such analyses). Issues with sample size are discussed in a 
separate section below. 
7.2.2 Methodological limitations : pulse wave velocity 
PWV was measured by single operator (me) for each participant, following the 
manufacturer’s quality control measures and after training and supervision by the 
vascular physiology department. However there were a number of limitations in the 
measurement of PWV in this study. Firstly, to limit burden on participants to support 
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recruitment and continuation within the main HELP trial, there were two a priori 
decisions made which affect the validity of PWV data collected: 1) That PWV be 
measured by carotid:radial methodology rather than carotid:femoral and 2) That 
PWV be measured only once rather than repeated.  
The location of measurement may be important because, as the systematic review in 
chapter one revealed, the carotid-femoral method appeared to have the most 
consistent findings between those with obesity and without in studies found. Carotid 
femoral is also generally considered to be the gold standard for PWV in adult studies 
used to predict cardiovascular disease outcomes. The reason to measure PWV 
carotid-radial was a pragmatic one as finding the femoral pulse in young people with 
obesity is technically challenging and was also perceived to be potentially 
embarrassing and less compassionate for young people; and this came down to 
ethical decisions about the over investigation and treatment of young people 
recruited into a main trial to support weight loss. My perception was that young 
people did not enjoy having PWV measured and it took time and perseverance; and 
unfortunately had to come last in priority in collecting data for the main HELP trial. I 
feel that this largely explains the 15% missing data at baseline and only 72 matched 
pairs of PWV at time 0 and 2 presented in the thesis.  Since the data was collected 
for this thesis, a newer technology (Vicorder System) has been developed and 
validated which uses inflatable cuffs at the neck and the femoral region which 
measure carotid and femoral pulses to record PWV more quickly and without having 
to hold a tonometer over the actual pulse site.211 The possible use of this in future 
studies is discussed below. The fact that PWV was only measured once per 
participant, again was a pragmatic decision to reduce burden on participants, 
however it would have been preferable to repeat measures at the same time point 
to allow averaging and to also measure repeatability analyses. In defense of the 
methodology and consistency of measurements however, both the fact that the SD 
of PWV at time 0 and time 2 were identical, and moreover the fact that there was no 
statistical difference between PWV at time 0 and 2, I feel are compelling as to the 
consistency of measurement quality. 
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As discussed above, one of the limitations of this thesis in investigating longitudinal 
impact of changes in variables such as adiposity on pulse wave velocity was the lack 
of change found at 6 months. Given the lack of longitudinal data found in the 
systematic review presented in chapter one, it was difficult to know what the correct 
time interval would be for PWV to find change, but the decision to measure it was 
pragmatic as time 0 and 2 were planned to be the timing for the bulk of repeated 
measures for the main HELP trial (with primary and secondary outcomes measured 
at 6 months), so PWV collection was protocolled within the main trial plan in a 
similar way. It would also have been likely challenging to measure PWV at 1 year in 
this group of young people as drop off by this point and need to visit on home visits 
would have made measuring PWV challenging, and indeed numbers at 1 year may 
well have been lower than those at 6 months. 
Another important issue for measuring PWV, and indeed all measurements, was 
blinded status to intervention/control status of young people in the trial to avoid any 
inadvertent influence on measurement. There was careful effort to maintain blinding 
to reduce bias in the trial for both the nurses and myself involved in collecting data 
(including advising and requesting young people and their families to support this by 
preservation of blinding to measurers at repeat visits). That said, it is a recognized 
bias assessment criteria that measurers in observational trials (see table 1.4 in 
chapter 1) are blind to changes in important variables being measured (for example 
BMI and PWV in this thesis) that could have inadvertently influenced measurement 
at consecutive time points. The way that such information could influence measures 
is debatable in any case as measurements using protocols and the same equipment 
(such as the Tanita). Nevertheless, data on measurements at previous time points in 
weight and blood pressure were available at consecutive later measurement time 
points as they were transferred into patient clinic notes (generated for each 
participant as part of the CRF-GOSH standard protocols) and repeated measures put 
into safety protocols to monitor for safe weight loss; and theoretically young people 
and their families could have talked about weight changes during interactions at 
visits, especially given the fact that they were involved in a weight management trial. 
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7.2.3 Methodological issues: other measurements 
I have already discussed limitations around measurement of blood pressure in the 
study above. A number of different nurses worked in the CRF-GOSH through the 
time of the study, and it is possible that this led to some inaccuracies in repeated 
measures of adiposity and blood pressure. In the HELP study, we tried to counter 
and limit this by providing clear training and protocols, however variation was still 
likely due to human error and inter-measurer variability. There were differences in 
the standard deviations of key adiposity measures such as waist circumference and 
SAD for example between distributions of measurements at time 0 and 2. From the 
longitudinal perspective, I think this was likely most evident in the measurement of 
SAD from the appearance of figure  7.5. In contrast to using the same standard scales 
for weight, height, machine for impedance and anatomical landmarks for waist 
circumference, SAD was a difficult measure in practical terms from my own 
observations as it required three-dimensional visualization in the holding of 
equipment, and for young people to exhale fully at the same time. Using averages 
were included in protocols to limit this.  
 
Another limitation was that puberty was self-assessed rather than directly rated, and 
disparities between trained observer and self-report of puberty have been 
reported.212 However we reduced misclassification bias by combining genital/breast 
measures with pubic hair and with menstruation in females. Whilst it would have 
been preferable in terms of accuracy to directly stage puberty by a trained clinician, 
this was not attempted to limit burden on participants, and I think it was the ethical 
thing to do for the young people in the HELP trial. 
  
Because a number of young people appeared to have missed the 30 minute cortisol 
surge (CAR), and had negative cortisol at 30 minutes compared to awakening 
cortisol, I deleted a number of CAR-Rate and CAR-AUC values where this was the 
case. These inaccuracies are well established in obtaining ambulatory salivary 
cortisol in research,119 and also around 25% of individuals have been reported to not 
demonstrate the CAR. There is debate about whether deleting such “non-
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responders” or those with negative results, is appropriate or not.213 214 I decided to 
remove them from CAR analyses because I felt they were likely to introduce bias into 
analyses around CAR, but wanted to maximize power for the C-wake so kept all of 
the wakening sample values for C-wake analyses. Deleting data however does 
reduce the power and sample size as discussed above, which is a limitation. One 
other additional potential area of bias for measurement of cortisol is that 
participants might have been more stressed on days that they were coming to the 
hospital for measurements/assessments which coincided with the days that they 
provided salivary cortisol, even though a fundamental principle of measuring cortisol 
in home settings was to try to eliminate bias from cortisol measures within 
assessments. 
 
In this study I did not investigate the sympathetic nervous system as one of the 
pathways of stress. I had originally planned at the formation of the methodology for 
the thesis to measure catecholamines in urine, however the technology and funding 
was not available for this as things developed. This is an important future area of 
study as there is a lack of published data on this branch of the stress response, as 
highlighted in chapter 2. 
7.2.4 Sample, sample size and power issues 
A key issue for the validity of results is sample size and the impact that this has on 
power in my analyses. In general, adiposity measures and blood pressure 
measurements were complete for most participants in the trial at baseline, but there 
was incomplete data for other key variables, in particular PWV, at baseline (as 
discussed above). As the HELP trial proceeded over time, there was drop out and the 
number of data available for repeated measures was limited. To some extent, the 
use of multi-level modeling for longitudinal analysis was a way of tackling missing 
data over time because of the benefits of this methodology in tackling incomplete 
data for all individuals, but clearly having more repeated measures would have 
improved the study and potentially increased detection of associations with small 
effect sizes (see below). 
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As discussed in the analysis section of chapter 3, the sample size was based on the 
sample size collected from the main HELP trial. The sample size required for this 
thesis should be based on the required sample to avoid a type 2 error by convention 
set at 80% power (allowing a 20% chance of a type II error), and the conventional 
measure of alpha (0.05).  
For cross sectional analyses, the numbers required rely on the effect size. In this 
thesis, I have referred to and presented findings in regression models by co-efficient 
of determination (R2), with size of effect sizes graded as per Cohen as R2 = 0.02 – 
0.13 as small, 0.13 -0.26 as medium and 0.26 or greater as large.215 Miles and Shevlin 
have produced a helpful set of reference tables for cross-sectional regression models 
(a table per number of predictors) plotting sample number to achieved power for 
small, medium and large effect sizes;216 these tables themselves being based on Faul 
et al’s GPower sample size calculator.217 Using these tables, the sample size of 174 
was sufficient to capture associations with large and medium effects in univariable 
analyses; but only had a power of around 0.4 to identify associations with small 
effect sizes. Large numbers > 400 would be needed to detect small effect sizes at 
80% power. It is possible therefore that no associations were found in regression 
analyses between for example the stress measures and adiposity measures because 
of inadequate power – and this likely more important given that most of the 
associations that were found cross sectionally were small in effect; and this is 
perhaps not surprising as complex variables such as BMI are likely to have a number 
of causes. 
Sample size calculation in multi-level models of longitudinal data is more 
complicated than for single level cross-sectional analyses, in particular because these 
models allow for variation at the individual level (in the case of this thesis, individual 
participants). Tables have been produced to look at sample size for level 1 and level 
2 variables, with the sample size in this study appropriate to capture large and 
medium effect sizes, however in multi-level modeling, many hundreds of 
participants are needed for 0.8 beta and 0.05 alpha to detect a small effect size;218 
thus it is possible that in multi-level models, small effects of, for example cortisol 
change on adiposity or blood pressure over time could have been missed in this 
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thesis. Multi-level modeling in this thesis did add the advantage of not being limited 
by missing data, and allowed an understanding of the individual participants, with 
calculation of the intra-class correlation to highlight what proportion of variation 
was due to non time variant included variables. 184 
7.3 Suggestions for future research 
The experience of this thesis, the findings and, in particular, the limitations allow me 
to make some suggestions for further research which I will present here as a final 
section of this thesis.  
7.3.1 General principles for further study 
A key learning point for me in the HELP trial was how important recruitment and 
retention was, and this was a critical issue for data collection for the HELP trial at 
large, but also of course for the data in my thesis. In planning future research studies 
in obesity, concerted and multiple strategies must be applied to maximize 
recruitment – this was a key to success in finally reaching power for the HELP trial, as 
were strategies to avoid attrition (home visits, incentives). Following on from this 
thesis and the HELP trial I have supervised two other researchers to perform a 
systematic review of the literature for effective ways to increase recruitment and 
retention in trials of children and adolescents with obesity. We expect this to be 
valuable to others conducting research with young people and obesity, and of course 
for my own involvement in such research. 
Another key learning point in this thesis was sample size and power. Larger numbers 
are needed to study the trajectories of young people with obesity than were 
recruited to the HELP trial (and as discussed above this represents the limitations of 
conducting research within another research study designed for a different reason). 
Finding large numbers can be challenging, but one way of doing this is to include 
PWV in existing or emerging large-scale population studies, such as they were cross-
sectionally in the Avon Longitudinal Study.74 This is likely to be expensive, with 
potential burden implications for participants and for planning studies with ethics 
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committees, and so the newer technologies discussed above for measuring PWV 
would be useful. 
7.3.2 The group studied in the HELP trial 
A future area of research that I am interested in is to follow up the group of young 
people studied in the HELP trial. When consented, consent was taken for permission 
to contact participants at a later stage; and this would allow me to examine the 
more long-term changes in PWV, blood pressure and adiposity. As outlined in 7.1.2, 
the hypothesis that adiposity is an important driver in arterial stiffening in 
adolescence independent of blood pressure is an important one (in particular 
because it assesses how important efforts to limit adiposity can impact on 
cardiovascular risk); and also how adiposity influences blood pressure. The HELP trial 
did not allow sufficient time to study this properly, and I would propose measuring 
BMI, blood pressure and PWV at further repeated time points – for example at 2 
years, 5 years and if possible 10 years. The benefits of using the HELP trial group is 
that we have baseline data on the participants and have been recruited, thus 
designing and conducting research is already open (with appropriate ethics 
assessment). Key challenges here would be that there would likely be reduced 
numbers over time, reducing power and contacting/tracing individuals would likely 
be complex as young people became older and moved location. Additionally, more 
funding would need to be obtained to conduct this research with consideration of 
continuity of the research team and skills. 
7.3.3 Further study of PWV and adiposity in other groups. 
Beyond the original HELP group, as suggested above, larger cohorts could be set up 
particularly to study change in PWV, adiposity and blood pressure over time. A 
study, which followed up children pre-pubertal through puberty and into adulthood, 
measuring over 10 years with annual visits, would be favorable to understand the 
relationships between the two better. This could be made more effective if it formed 
part of cohort studies as discussed in 7.3.1. Such studies would need to analyze data 
with multi-level models as demonstrated in chapter 6, and control for sex, ethnicity 
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and pubertal stage; and should also look for other explanations for interparticipant 
variation such as genetic factors described above. A longer study, which tracked 
PWV, adiposity and blood pressure into adulthood and linked it to actual 
cardiovascular outcomes (e.g. myocardial infarction and stroke) would also be 
helpful to better identify how PWV predicts adult outcomes rather than stiffening 
per se. Because of the challenges discussed above, use of newer technology such as 
the Vicorder technology discussed above would allow measurement of carotid-
femoral PWV quickly and likely of less burden to participants. Ideally such a study 
would use a group with different categories of obesity/non obesity status, which had 
sufficient numbers of each so as to form a case:control. One of the key issues with 
studies identified in the systematic review in chapter one was that there were only 
small proportions of obesity where cross-sectional studies of different weight status 
were used, few were community and few were longitudinal. 
I also have an interest in the impact of underweight on PWV which at the time of 
writing, as far as I am aware, a study of which has never been published. It was not 
possible to investigate this in the thesis. I am interested in longitudinal study of PWV 
which would include underweight (for example in a population with Anorexia 
Nervosa). 
7.3.4 Further study of stress, adiposity and cardiovascular risk. 
My comments on further study of the role of obesity, cardiovascular risk and stress 
mirrors my comments above i.e. larger numbers, over a longer period of time, and 
preferably with control group are needed. In the HELP trial we used the A-FILE as a 
measure of stress exposure because we had access to this questionnaire, however in 
future research I would be interested in also using a stress measure that also 
examined perception of stress.219 I would also measure cortisol over several days 
rather than just one day to get a more representative sample. Efforts to remind 
participants to take samples at the correct time (for example by text messaging)220 
should also be used to increase the validity of the awakening response which have 
been used elsewhere but where not available in the HELP trial.  
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7.4 Final conclusions 
Despite the lack of long-term findings of PWV in this thesis, the cross-sectional 
findings are important and suggest that obesity as a public health issue is important, 
and there are important potential future implications for individuals and societies in 
terms of long-term cardiovascular health. The evidence for the validity of blood 
pressure, partitioning  adolescents with obesity into groups and blood testing to 
indicate risk in adolescents with obesity still remains unclear and the evidence from 
this thesis questions their validity. There should remain a focus on managing obesity 
in children and adolescents; and research to understand how to support weight 
management in young people must be a priority, including the areas for further 
research I have identified above. 
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